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The effects of exercise on body mass and body composition in 
postmenopausal breast cancer survivors: a systematic review. 
Abstract 
Purpose: The aim of this systematic review was to determine the effects of 
exercise on the body mass (BM), body mass index (BMI), waist circumference 
(WC), lean body mass (LBM), fat mass (FM), body fat percentage (BF%), bone 
mineral content (BMC) and bone mineral density (BMD) of postmenopausal 
breast cancer survivors (BCSs). 
Method: Records were located via; electronic searches of MEDLINE, 
Cochrane Library, CINAHL, ProQuest, Sport Discus, PEDro, ZETOC and 
SCIRUS and handsearches of key journals and book chapters. All searches 
covered the period from the start of 1989 to the end of June 2012.  All identified 
records were screened against predetermined eligibility criteria.  Records that 
met the full eligibility criteria were included in the final review, and assessed for 
methodological quality using the Downs and Black Checklist (1998). 
Results: A total of 5714 records (excluding duplicates) were located; five 
studies and six groups of exercising postmenopausal BCSs were included in 
the final review. The differences in the mean change between exercising and 
control postmenopausal BCSs ranged from 0.70kg to -2.42kg for BM;                
-0.28kg/m2 to -0.86kg/m2 for BMI; -0.54cm to -3.00cm for WC; 0.1kg to 1.0kg for 
LBM; 0.5kg to -2.0kg for FM; 0.2% to -2.0% for BF%; -46g/cm to 68g/cm for 
BMC; 0.000g/cm2 to 0.033g/cm2 for total BMD and 0.004g/cm2 to 0.260g/cm2 
for lumbar spine BMD.    
Conclusion: The findings from individual studies were mixed, however overall 
exercise had a small favourable effect on the body composition of 
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postmenopausal BCSs (↓BM, ↓BMI, ↓WC, ↑LBM, ↓FM, ↓BF%, ↑BMC and 
↑BMD).  Further research into the effects of combined aerobic and resistance 
exercise over longer total exercise durations of 6 to 12 months are warranted.  
Future studies should include larger sample sizes so that results can be 
stratified by important confounding factors, without statistical power being 
compromised. 
 
Keywords: physical activity; body weight; body fat; lean body mass; 
mammary neoplasm; recovery 
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The effects of exercise on body mass and body composition in 
postmenopausal breast cancer survivors: a systematic review. 
1.0. Rationale 
1.1. Rationale for conducting a systematic review on the effects of 
exercise on the body mass and body composition of postmenopausal 
breast cancer survivors 
It was estimated that in 2008 there were 5.5 million breast cancer survivors 
(BCSs) alive worldwide (Boyle & Levin, 2008). The vast majority of BCSs are 
postmenopausal at diagnosis (Cancer Research UK, 2011a; Key, Verkasalo, & 
Banks, 2001). 
Overweight and obesity increase the risk of postmenopausal breast cancer and  
reduce the risk of premenopausal breast cancer (Cancer Research UK, 2011a).  
However, during treatment and recovery, premenopausal BCSs gain a greater 
amount of body mass (BM) and experience greater adverse body composition 
changes than postmenopausal BCSs (Vance, Mourtzakis, McCargar, & 
Hanning, 2011).  Therefore the findings from exercise and body composition 
research that includes BCS populations with mixed menopausal statuses may 
not be representative of either group and important effects may be disguised. 
Postmenopausal BCSs gain a greater than expected amount of BM during 
treatment and recovery, and this may be of an atypical sarcopenic type (Vance 
et al., 2011).  Sarcopenic BM gain is characterised by increased fat mass (FM) 
and decreased lean body mass (LBM) (Heber et al., 1996).  In addition, some 
treatments for postmenopausal breast cancer can result in reductions in bone 
mineral content (BMC) and bone mineral density (BMD) (Chien & Goss, 2006).  
These adverse body composition changes have been associated with an 
2 
 
increased risk of adverse outcome (Bradshaw et al., 2012; Chen et al., 2009; 
Kroenke, Chen, Rosner, & Holmes, 2005; Nichols et al., 2009).   
Exercise may help overcome some of these adverse body composition 
changes and it has been widely reported that exercise is both safe and 
beneficial for BCSs  (A. Campbell, Stevinson, & Crank, 2011; Hayes, Spence, 
Galvão, & Newton, 2009; Macmillan Cancer Support, 2011; Schmitz et al., 
2010).  However there is a lack of studies specifically addressing the effects of 
exercise in older postmenopausal BCSs (Visovsky, 2006).  The effects of 
specific exercise prescriptions on the BM and body composition of 
postmenopausal BCSs are not known (Schmitz et al., 2010). 
A systematic review can summarise what is known about a particular 
intervention so as to resolve conflicting evidence or to confirm current practice 
(Centre for Reviews and Dissemination, 2009, p. v; Green & Higgins, 2011).  A 
systematic review can also demonstrate where knowledge is lacking, so as to 
highlight areas that require further research (Centre for Reviews and 
Dissemination, 2009, p. v; Green & Higgins, 2011).   Therefore the aim of this 
systematic review was to determine the effects of exercise on the BM, body 
mass index (BMI), waist circumference (WC), LBM, FM,  body fat percentage 
(BF%),  BMD and BMC of postmenopausal BCSs. 
 
For full definitions of terms, refer to the glossary attached in Appendix 1.
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2.0. Introduction 
2.1. Breast cancer incidence, survival and prevalence 
Breast cancer is the most common female cancer in the world, in 2008 it was 
estimated that 1.38 million women were diagnosed with breast cancer (Ferlay 
et al., 2010). The lifetime risk of a woman in the UK developing breast cancer is 
1:8; however the risk is strongly related to age and increases to 1:13 at age 69 
(Table 1) (Cancer Research UK, 2012).  
 
Table 1 
Estimated risk of developing breast cancer by age among women in the 
UK in 2008 
Age Estimated risk of breast cancer 
29 1 in 2000 
39 1 in 215 
49 1 in 50 
59 1 in 22 
69 1 in 13 
Lifetime risk 1 in 8 
(Adapted from Cancer Research UK, 2012) 
 
The average age of the menopause is 50 years (Key, Verkasalo, et al., 2001).  
As 80% of breast cancer cases occur in women aged >50 years the vast 
majority of cases occur in postmenopausal women (Cancer Research UK, 
2011a). 
The incidence of breast cancer in the UK has increased from 23,876 in 1978 to 
46,537 in 2008; a 65% increase in the age-standardised incidence rate (ASIR) 
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(Cancer Research UK, 2011a).  Due to an expanding population, with an 
increasing proportion of elderly persons, the incidence of breast cancer has 
been predicted to increase by 26% between 2007 and 2030 (Mistry, Parkin, 
Ahmad, & Sasieni, 2011). 
Advances in detection and improvements in treatment have resulted in 
improved prognoses for women with breast cancer (Bray, McCarron, & Parkin, 
2004).  Age-standardised five year survival rates in England and Wales have 
increased from 52% in 1975 to 82% in 2006 (Fig.1) (Cancer Research UK, 
2009). The predicted twenty-year survival rate for breast cancer patients 
diagnosed in 2001-2003 was 64% (Cancer Research UK, 2009). 
 
 
Figure 1 
Age-standardised five-year relative survival rate, female breast cancer, 
England and Wales, 1971-2006 (Adapted from Cancer Research UK, 2009) 
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A cancer survivor is anyone who has been diagnosed with cancer, from the 
point of diagnosis up until the end of their life and includes all people who have 
recovered (J. K. Brown et al., 2003).  Increased incidence and improved 
prognoses have created an expanding population of BCSs.  It was estimated 
that in 2008 there were 5.5 million BCSs alive worldwide (Boyle & Levin, 2008). 
Compared to other common cancers breast cancer has a proportionally high 
incidence and proportionally low mortality (Maddams, Møller, & Devane, 2008).  
In 2004 28% of all cancer survivors in the UK were BCSs, making them the 
most prevalent group (Fig.2) (Maddams et al., 2008). 
 
Figure 2  
Proportion of total incidence, mortality and prevalence contributed by 
each of the four major cancers in England, 2004 (Adapted from Maddams et al., 
2008) 
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Even if current survival rates are maintained, the predicted increase in 
incidence means that the numbers of postmenopausal BCSs are predicted to 
increase dramatically.  Therefore the health, well-being and long term care of 
postmenopausal BCSs is set to become an increasing challenge which will be 
of considerable importance to researchers, healthcare providers and policy 
makers.  
 
2.2. Stages in the cancer experience 
The Physical Activity and Cancer Control (PACC) Framework indentifies six 
stages in the cancer experience; two pre-diagnosis stages; pre-screening and 
screening and four post-diagnosis stages; pre-treatment, treatment, 
survivorship and end of life (Fig.3) (Courneya & Friedenreich, 2007). 
 
 
 
 
 
 
 
 
Figure 3 
Physical Activity and Cancer Control Framework 
(Adapted from Courneya & Friedenreich, 2007) 
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The PACC framework improves communication and enables health care 
professionals and researchers to clearly and effectively target specific stages of 
the cancer experience. 
 
2.3.  Types and stages of breast cancer 
There are several different types of breast cancer.  Breast cancers are staged 
using the Tumour, Node, Metastasis (TNM) or the number system of breast 
cancer staging. For readers unfamiliar with the different types of breast cancer 
or the staging systems summaries are provided in Appendices 2, 3 and 4 
respectively.  
 
2.4.  The aetiology of breast cancer  
The aetiology of breast cancer is complex and multi faceted however, many of 
the risk factors are linked to lifetime exposure to oestrogens (Key, Verkasalo, et 
al., 2001). Oestrogens are thought to increase breast cancer risk by increasing 
the proliferation, and inhibiting the apoptosis, of mammary cells (Boyle & Levin, 
2008, pp. 140-141).  This increases the likelihood of mutations occurring and 
being replicated; it is the replication of mutations in mammary cells that leads to 
the development of breast cancer (Key, Allen, Verkasalo, & Banks, 2001). 
In premenopausal women the major source of oestrogens is the ovaries (Key, 
Allen, et al., 2001). The menopause is marked by the ending of menstruation; 
once menstruation has ceased for twelve months a woman is postmenopausal.  
In postmenopausal women the ovaries no longer produce oestrogens and the 
major source of oestrogens is from the aromatisation of androgens in adipose 
tissue (Key, Allen, et al., 2001).   
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BMI is a measure of mass relative to height and BMI is often used to determine 
overweight and obesity (World Health Organisation, 2004).  A BMI of 
18.5kg/m2, 18.6-24.9kg/m2, 25-29.9kg/m2 and >30kg/m2 indicates underweight, 
healthy weight, overweight and obese respectively (World Health Organisation, 
2004). There is clear and consistent evidence that overweight and obesity 
increase the risk of postmenopausal breast cancer and reduce the risk of 
premenopausal breast cancer (Bergstrom, Pisani, Tenet, Wolk, & Adami, 2001; 
Bianchini, Kaaks, & Vainio, 2002; Lahmann et al., 2004; Reeves et al., 2007; 
Renehan, Tyson, Egger, Heller, & Zwahlen, 2008).   
Compared to premenopausal women of a healthy weight (BMI 22.5-24.9kg/m2) 
obese premenopausal women (BMI >30kg/m2) have a 20% reduction in breast 
cancer risk (Cancer Research UK, 2012). Compared to postmenopausal 
women of a healthy weight (BMI 22.5-24.9 kg/m2), moderately overweight (BMI 
25-27.4kg/m2), overweight (BMI 27.5-29.5 kg/m2) and obese (BMI >30kg/m2) 
postmenopausal women have a 10%, 20% and 30% increased risk of breast 
cancer respectively (Cancer Research UK, 2012). 
Overweight and obesity are thought to reduce the risk of premenopausal breast 
cancer by increasing the number of anovulatory menstrual cycles, and 
therefore reducing exposure to oestrogens (Key, Allen, et al., 2001).  
Overweight and obesity are thought to increase the risk of postmenopausal 
breast cancer by increasing the production of oestrogens from the 
aromatisation of androgens in adipose tissue (Key, Allen, et al., 2001).  In 
addition sex hormone-binding globulin (SHBG), which binds to oestrogens and 
determines the concentration of free serum oestrogens, falls with increasing 
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BMI,  resulting in increased levels of free serum oestrogens (Key, Allen, et al., 
2001).   
Given the greater prevalence of postmenopausal breast cancer, and given the 
differing roles of overweight and obesity in the aetiology of premenopausal and 
postmenopausal breast cancer, the remainder of this dissertation will focus on 
postmenopausal BCSs. 
 
2.5. Treatments for breast cancer and their side effects 
Treatments for postmenopausal breast cancer have the potential to cause a 
wide range of short and long term side effects (Schmitz et al., 2010). These 
side effects include increases in BM and reductions in BMD. For readers 
unfamiliar with breast cancer treatments and their side effects a summary is 
provided in Appendix 5.  
 
2.6. BM gain in postmenopausal BCSs during the treatment stage of the 
breast cancer experience 
Significant gains in BM can occur during the treatment stage of the breast 
cancer experience (Chlebowski, Aiello, & McTiernan, 2002; Demark-
Wahnefried, Rimer, & Winer, 1997; Vance et al., 2011).  In healthy women the 
menopause has been associated with BM gains of 0.54kg/yr (Guo, Zeller, 
Chumlea, & Siervogel, 1999) and 0.47kg/yr (Wing, Matthews, Kuller, Meilahn, & 
Plantinga, 1991); greater gains of 1.1kg/yr have been observed among users of 
hormone replacement therapy (Wing et al., 1991).  
However during 6 months of chemotherapy treatment postmenopausal BCSs 
gained a mean of 2.8kg and gains of up to 5.5kg were reported (Del Rio et al., 
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2002). Among BCSs with a age mean of 55.5 years Genton, Kyle, Balmer 
Majno, and Pichard (2006) reported a mean BM gain of 2.2kg (±3.1kg) during 
primary treatment and an additional mean gain of 0.6kg (±1.2kg) during 
radiotherapy.   The mean BM gains among BCSs reported by Del Rio et al. 
(2002) and Genton et al. (2006) were in excess of those reported among 
healthy postmenopausal women. 
 
2.7. BM gain in postmenopausal BCSs during the recovery and 
survivorship stages of the breast cancer experience 
Significant gains in BM are a progressive and persistent problem among BCSs 
(Vance et al., 2011).  However premenopausal BCSs gain significantly more 
BM than postmenopausal BCSs, during the recovery and survivorship stages of 
the breast cancer experience (Freedman et al., 2004; Goodwin et al., 1999; 
Makari-Judson, Judson, & Mertens, 2007; Tredan et al., 2010).  Nevertheless, 
Goodwin et al. (1999) and Tredan et al. (2010) reported respective mean BM 
gains of 1.05kg (95%CI, 0.5 to 1.6kg) and 1.0kg (±4.3kg) among 
postmenopausal BCSs, one year after the commencement of treatment. In the 
Tredan et al. (2010) study, 14% of postmenopausal BCSs gained 5% to 10% of 
their baseline BM, and 7% gained >10% of their baseline BM.    
Evidence from studies with longer follow-up periods suggests that BM gain 
among postmenopausal BCSs is persistent.  After a median follow-up of 3.1 
years, Heideman, Russell, Gundy, Rookus, and Voskuil (2009) observed a 
mean increase in BM of 1.1kg (±.5.0kg) among postmenopausal BCSs; 31.9% 
had gained 2kg to 4kg and a further 17.6% had gained >5kg.  Makari-Judson et 
al. (2007) reported that, one year from diagnosis, postmenopausal BCSs had 
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gained 0.8kg (±0.4kg); two years from diagnosis this had increased to 1.3kg.  
Saquib et al. (2007) reported that only 10% of BCSs who gained >5% of their 
pre-diagnosis BM, returned to their pre-cancer BM during six years of follow-up. 
Data relating to the impact of chemotherapy on BM gain in specific 
postmenopausal BCS samples is lacking. However, although individual data 
was not presented, Irwin, McTiernan, Baumgartner, et al. (2005) observed a 
greater BM gain among postmenopausal BCSs who received chemotherapy, 
than those who did not.  Studies of mixed premenopausal and postmenopausal 
BCSs have consistently reported that BCSs who receive chemotherapy gain 
significantly more BM than those who do not (Goodwin et al., 1999; Heideman 
et al., 2009; Makari-Judson et al., 2007; Saquib et al., 2007).  Therefore it is 
possible that chemotherapy may be associated with greater BM gain in 
postmenopausal BCSs. 
The estimation of BM gain among postmenopausal BCSs is challenging, as this 
population is heterogenic, and includes a wide range of; ages, ethnicities, BMIs, 
types of breast cancer, stages of breast cancer, treatment regimes and stages 
of treatment.  In addition studies may vary by design, sample selection, follow-
up periods and definitions of significant BM gain and this makes comparisons 
between studies difficult (Vance et al., 2011). 
Nevertheless, the evidence suggests that BM gain among postmenopausal 
BCSs is greater than would be expected among healthy women and is a 
progressive and persistent problem throughout the treatment, recovery and 
survivorship stages of the cancer experience. 
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2.8.  Methods of body composition assessment in postmenopausal 
BCSs 
BMI is frequently used to assess overweight and obesity and is a measure of 
mass relative to height (World Health Organisation, 2004).  However, the 
isolated use of BMI is limited when determining body composition, as BMI does 
not distinguish between FM and LBM, and has a poor sensitivity to detect 
excess adiposity (Cornier et al., 2011).  Both the total amount, and the 
distribution of FM, are important when determining the risk of obesity related 
co-morbidities as intra-abdominal fat is associated with a greater risk (Alberti, 
Zimmet, & Shaw, 2006). WC may be better able to predict intra-abdominal fat 
mass than BMI (Klein et al., 2007).  Therefore the combined use of BMI and 
WC has been recommended to assess obesity, due to the simplicity and high 
reproducibility of the method (National Institute for Health and Clinical 
Excellence, 2006, pp. 198-199; World Health Organisation, 2004).  In women 
the risk of obesity related co-morbidities starts to increase when WC is >80cm, 
and significantly increases when WC is >88cm (Alberti et al., 2006; National 
Institute for Health and Clinical Excellence, 2006; World Health Organisation, 
2004).  
When determining body composition it is necessary to distinguish between FM, 
FFM, LBM, BF%, BMD and BMC (Table 2) (Heyward & Wagner, 2004, p. 5).  It 
is not possible to directly determine body composition in living individuals, 
however a range of indirect methods are available, including; anthropometry 
(including circumference measurements and skinfolds [SKF]), hydrostatic 
weighing, air displacement plethysmography (ADP), dual-energy-X-ray-
absorptiometry (DEXA), computed tomography/magnetic resonance imaging 
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(MRI) and bioelectric impedance (BIA) (Cornier et al., 2011; Heyward & 
Wagner, 2004).   
 
Table 2 
Definitions of commonly used body composition terminology 
Term Abbreviation Definition 
Body Mass BM The size of the body. Commonly 
referred to as body weight. 
Body Mass Index BMI A measure of mass relative to height. 
Fat mass FM The absolute amount of body fat; 
includes all extractable lipids from 
adipose tissue and all other tissues in 
the body. 
Fat free mass FFM All residual lipid-free tissues and 
chemicals the body including; water, 
muscle, bone, connective tissue and 
internal organs.   
Lean body mass LBM Is similar to, but distinct from, FFM. 
LBM is FFM plus a small amount of 
essential lipids. 
Essential lipids  Phospholipids required for cell 
membrane function. 
Body fat percentage  
Percentage body fat 
BF% 
%BF 
Levels of FM expressed as a 
percentage of the total body mass.  
%BF = FM/BM x 100. 
The terms BF% and %BF are 
interchangeable. 
Bone Mineral Content BMC 
 
The absolute amount of bone mineral 
content. 
Bone Mineral Density BMD The amount of bone mineral content 
expressed relative to the cross sectional 
area of the bone. 
(Adapted from Heyward & Wagner, 2004) 
 
DEXA has been shown to be valid and reliable and is considered to be one of 
the reference methods for body composition analysis (Heyward & Wagner, 
2004, pp. 40-44). However, body composition assessment methods that are 
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valid in the general population may not be valid in BCS populations (Battaglini 
et al., 2011; Freedman et al., 2004).  BIA has been shown to overestimate BF% 
compared to three-site SKF, seven-site SKF, and ADP in a small sample of 14 
BCSs with mixed menopausal statuses (Battaglini et al., 2011).  Freedman et 
al. (2004) used; ADP, BIA and DEXA to assess body composition change 
among a small sample of 20 BCSs (50% postmenopausal).  In this study ADP, 
as opposed to BIA, was shown to overestimate BF%, and mean increases in 
BF% were estimated to be 4.1% by ADP, 0.6% by BIA and 0.9% by DEXA 
(Freedman et al., 2004). Therefore it is important to consider the strengths, 
weaknesses, limitations, validity and reliability of the methods used to assess 
body composition in BCS populations. 
 
2.9. Body composition change in postmenopausal BCSs during the 
treatment and survivorship stages of the breast cancer experience 
 In healthy women BM gain typically includes an increase in both FM and LBM 
and, on average, LBM accounts for 38% of BM gain (Forbes, Brown, Welle, & 
Lipinski, 1986).  In contrast when BCSs gain BM it occurs without the 
associated gains, or even losses in LBM; this is referred to as sarcopenic BM 
gain or sarcopenic obesity (Heber et al., 1996; Vance et al., 2011). Although 
Del Rio et al. (2002) and Genton et al. (2006) reported a typical pattern of BM 
gain in postmenopausal BCSs, sarcopenic BM gains have been reported by 
Cheney, Mahloch, and Freeny (1997); Harvie, Howell, Thatcher, Baildam, and 
Campbell (2005) and Irwin, McTiernan, Baumgartner, et al. (2005). 
In a small study Cheney et al. (1997) reported that, during treatment, three 
postmenopausal BCSs lost a mean BM of 1.1kg, and five BCSs (three 
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postmenopausal and two premenopausal) gained a mean BM of 3.3kg. Among 
those who gained BM, FM increased by a mean 4.4kg whilst LBM declined by 
1.3kg (Cheney et al., 1997). Two of the postmenopausal BCSs who lost BM 
also experienced increases in FM and reductions in LBM (Cheney et al., 1997).  
Harvie et al. (2005) observed sarcopenic BM gains in BCSs with a mean age of 
55.9 years (±.6.5yrs) during chemotherapy treatment; FM increased by 1.5kg 
(95%CI; -1.2 to 4.4kg) and FFM declined by -1.9kg (95%CI; -4.9 to 1.1kg), this 
led to a 2.1% increase in BF% (95%CI; 0.8 to 3.5%; p=<0.05).  Irwin, 
McTiernan, Baumgartner, et al. (2005) reported that between the first to third 
year post-diagnosis, 74% of BCSs (69% postmenopausal) experienced 
increases in BF%; among these BF% gainers the mean increase was 3.6% 
(±.3.0%).  Increases in BF% ranged from 0.1% to 15.0% and some BCSs 
experienced increases in BF% without associated BM gains (Irwin, McTiernan, 
Baumgartner, et al., 2005).  These findings suggest that adverse body 
composition change can occur even among BCSs who lose BM.  Therefore 
body composition assessments must be made alongside measures of BM in 
postmenopausal BCSs. 
Serum oestrogen levels are important for the maintenance of BMC and BMD. 
Some treatments for postmenopausal breast cancer, such as aromatase 
inhibitors (AIs), can result in lowered BMC and BMD (Irwin, Alvarez-Reeves, et 
al., 2009).  In healthy women oestrogens decline after the menopause and 
bone loss occurs at 1% a year; however a greater and more abrupt reduction in 
oestrogens occurs in postmenopausal BCSs who are prescribed AIs; as a 
result bone loss can occur at an accelerated rate of 2.6% a year (Chien & 
Goss, 2006). 
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The number of studies assessing body composition change in postmenopausal 
BCSs is limited.  However, it appears that postmenopausal BCSs can 
experience greater than normal reductions in BMD and can develop an 
atypical, sarcopenic, pattern of body composition change which can occur with 
or without associated BM gain. 
 
2.10. Adverse effects of overweight and obesity among postmenopausal 
BCSs 
Many postmenopausal BCSs have additional obesity related co-morbidities at 
diagnosis; one study reported that 25% to 50% had hypertension, 15% to 27% 
had coronary heart disease, and 5% to 10% had type II diabetes (Yancik et al., 
2001).  Compared to the age and sex-specific mortality rate of the general 
population, BCSs had an increased risk of non cancer death (Hazard Ratio 
[HR] 1.09); this was attributed to the side effects of treatments and the effects 
of co-morbidities (B. W. Brown, Brauner, & Minnotte, 1993). 
Compared to BCSs of a healthy weight, obese BCSs had an increased risk of 
all-cause mortality (HR 1.31; [95%CI; 1.12 to 1.54]) (Dignam et al., 2003). 
Compared to BCSs without type II diabetes, those with pre-existing type II 
diabetes had an increased risk of all-cause mortality (HR 1.61; [95%CI: 1.46 
to 1.78]) (Barone et al., 2008).  Tammemagi, Nerenz, Neslund-Dudas, 
Feldkamp, and Nathanson (2005) reported that among BCSs, type II diabetes, 
hypertension and cardiovascular disease (CVD) were all associated with an 
increased risk of all-cause mortality with respective HRs of 1.85 (95%CI 1.47 to 
2.32), 1.65 (95%CI 1.37 to 1.99) and 1.78 (95%CI 1.35 to 2.35).  The risk of all-
cause mortality increased with increasing BMI; however after adjusting for co-
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morbidities this association disappeared, suggesting that the risks of mortality 
associated with overweight and obesity among BCSs were mediated through 
co-morbid conditions (Tammemagi et al., 2005).  
 
2.11. Adverse effects of post-diagnosis BM gain and body composition 
change in BCSs 
Post-diagnosis BM gain may influence survival and increase the risk of co-
morbid conditions among postmenopausal BCSs (Rock & Demark-Wahnefried, 
2002). Bradshaw et al. (2012) reported that, compared to BCSs who remained 
within 5% of their pre-diagnosis BM, those who gained >10% of their pre-
diagnosis BM were 2.7 times less likely to survive (HR 2.67; [95%CI = 1.37 to 
5.05]).  Among never smoking BCSs, and compared to those who maintained 
their BMI after diagnosis, BCSs whose BMI increased by 0.5-2.0kg/m2 and 
>2.0kg/m2 had an increased relative risk (RR) of all cause mortality of 1.35 
(95%CI; 1.00 to 1.82) and 1.59 (95%CI; 1.12 to 2.27) respectively (p for linear 
trend =0.01) (Kroenke et al., 2005).  Each 5kg post-diagnosis BM gain has 
been associated with a 12% increase in all-cause mortality (p=0.004), a 13% 
increase in breast cancer mortality (p=0.01) and a 19% increase in CVD 
mortality (p=0.04) (Nichols et al., 2009). However, not all studies have found an 
association between BM gain and breast cancer recurrence, breast cancer 
mortality or all-cause mortality (Caan et al., 2006; Caan et al., 2008; Camoriano 
et al., 1990; Makari-Judson et al., 2007). 
Postmenopausal BCSs may have an increased risk of bone fracture.  After 
following a prospective cohort of postmenopausal women for nine years Chen 
et al. (2009) reported that the risk of hip and spinal fractures increased by 55% 
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and 26% respectively after breast cancer diagnosis.  This is significant as, even 
after adjustment for key confounders, non-traumatic fractures of the hip and 
spine have been associated with an increased risk of mortality in women aged 
>50 years (Morin et al., 2011). 
Post-diagnosis BM gain and body composition changes may exacerbate 
existing obesity related co-morbidities, increase the likelihood of new co-
morbidities developing and are associated with an increased risk of adverse 
outcome among postmenopausal BCSs.  It is clear that postmenopausal BCSs 
may benefit from interventions designed to prevent and/or treat the gains in 
BM, FM and BF% and the reductions in LBM, BMC and BMD, that may occur 
during the treatment and recovery stages of the breast cancer experience. 
 
2.12.  Aetiology of BM gain in BCSs 
The aetiology of sarcopenic BM gain in postmenopausal BCSs has not been 
extensively studied.  Although the underlying causes are complex, a person 
gains BM when the energy balance (EB) equation is unbalanced, and energy 
intake (EI) exceeds energy expenditure (EE) (British Nutrition Foundation, 
1999). 
It has been proposed that chemotherapy has a depressive effect upon 
metabolism (Irwin, McTiernan, Baumgartner, et al., 2005; Kroenke et al., 2005; 
Vance et al., 2011).  However, Harvie et al. (2005), Harvie, Campbell, Baildam, 
and Howell (2004) and Demark-Wahnefried, Hars, et al. (1997) all reported that 
that resting energy expenditure (REE) did not change significantly among BCSs 
during the period of chemotherapy treatment.  Del Rio et al. (2002) reported 
that when BCSs were treated with chemotherapy BM gains were accompanied 
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by parallel increases in REE.  These findings suggest that chemotherapy does 
not have a depressive effect on metabolism. 
Another theory is that increased EI, decreased EE, or a combination of both is 
responsible for the BM gains observed in postmenopausal BCSs (Irwin, 
McTiernan, Baumgartner, et al., 2005; Kroenke et al., 2005; Vance et al., 
2011).  However, although small increases in EI have been reported among 
postmenopausal BCSs during treatment by Harvie et al. (2005) and Del Rio et 
al. (2002) these increases were not significant.   The findings from a larger 
study of 260 BCSs with a mean age of 57.5 years, indicated that compared to 
pre-diagnosis EI, by two years post-diagnosis EI had declined by 137kcal/d 
(±441; p=<0.001)  (Wayne et al., 2004).  A mean reduction in EI of 129.6kcal/d 
was reported even among BCSs who gained >3kg (Wayne et al., 2004).  
Although EE was not assessed in this study, 36% of BCSs had reduced their 
exercise levels from pre to post diagnosis (Wayne et al., 2004).   
Data from a large cross sectional study indicated that habitual physical activity 
(PA) was the strongest predictor of BM stability among BCSs (Rock et al., 
1999). Yaw et al. (2011) reported that, although no differences in EI were 
observed between BCSs who lost or gained BM during recovery, those who 
gained BM reported lower levels of PA, than those who lost BM.  Similarly, 
Irwin, McTiernan, Baumgartner, et al. (2005) reported that lower levels of post-
diagnosis recreational PA were associated with greater increases in BF% 
among BCSs (p for trend <0.05). However, no association was observed 
between change in EI and increases in BF% (Irwin, McTiernan, Baumgartner, 
et al., 2005).  These findings suggest that reductions in PA and EE may be a 
stronger predictor of BM gain, than increased EI, among BCSs.  
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Figure 4 
Levels of median leisure-time PA among German postmenopausal BCSs 
across the stages of the cancer experience (Adapted from Huy et al., 2012) 
 
Littman, Tang, and Rossing (2010) observed a similar pattern among 315 
BCSs; pre-diagnosis mean recreational PA was 18.8MET·h/week, one year 
post-diagnosis this fell to 9.2MET·h/week (p=<0.05); although PA increased to 
15.02MET·h/week two and half years post-diagnosis, PA did not return to pre-
diagnosis levels, and remained suppressed, by an average of 3MET·h/week 
over the recovery stage of the breast cancer experience. 
Reductions in EE and PA appear to be the most important factor related to BM 
gain among postmenopausal BCSs.  PA is reduced over the treatment and 
recovery stages of the cancer experience and does not return to pre-diagnosis 
levels over the longer term survivorship stage. Interventions designed to 
increase exercise and PA among postmenopausal BCSs may have an 
important role in weight management. 
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2.13. Exercise and PA guidelines for postmenopausal BCSs 
PA has been defined as any bodily movement, produced by the contraction of 
skeletal muscle, which results in substantially increased EE; exercise is a 
subset of PA that is planned, structured and performed to improve physical 
fitness (Caspersen, Powell, & Christenson, 1985).   
According to reports from the American College of Sports Medicine (ACSM) 
(Schmitz et al., 2010), the Australian Association for Exercise and Sport 
Science (Hayes et al., 2009), the British Association of Sport and Exercise 
Sciences (A. Campbell et al., 2011) and Macmillian Cancer Support (Macmillan 
Cancer Support, 2011) exercise is safe and beneficial for cancer survivors.  It 
has been recommended that cancer survivors should avoid inactivity and, 
unless otherwise advised, should aim to follow the standard age appropriate PA 
guidelines for the general population (A. Campbell et al., 2011; Schmitz et al., 
2010).  The current UK PA guidelines for the promotion and maintenance of 
health in adults are outlined in Table 3 (Department of Health, 2011, pp. 32-41). 
Although it would seem plausible that cancer survivors who follow the general 
PA guidelines would acquire similar health benefits to the general population, 
there is little research to support this (Doyle et al., 2006; Schmitz et al., 2010). 
Treatments for postmenopausal breast cancer can disrupt metabolic and 
physiologic processes, and some postmenopausal BCSs appear to be at an 
increased risk of BM gain, sarcopenia and bone loss (Schmitz et al., 2010; 
Vance et al., 2011).  Therefore postmenopausal BCSs may require higher 
levels of PA than the general population. 
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Table 3 
Physical activity recommendations for the promotion and maintenance of 
health in adults 
Recommendation Description Example 
Physical activity recommendations for adults (19-64 years) and older adults (>65 years) 
At least 150 min (2½ hours) of 
moderate intensity activity in 
bouts of 10 minutes or more 
e.g. 30 minutes on at least 5 
days a week.  
Moderate intensity physical activities 
will cause adults to get warmer and 
breathe harder and their hearts to 
beat faster, but they should still be 
able to carry on a conversation 
• Brisk walking  
• Cycling  
• Ballroom dancing  
 
OR 
For those who are regularly 
active at moderate intensity; 
75 min (1 ¼ hours) of vigorous 
intensity activity spread across 
the week 
Vigorous intensity physical activities 
will cause adults to get warmer and 
breathe much harder and their hearts 
to beat rapidly, making it more 
difficult to carry on a conversation. 
• Swimming 
• Football 
• Climbing stairs  
• Running  
 
OR A combination of moderate and vigorous intensity activity 
AND 
Physical activity to improve 
muscle strength on at least two 
days a week.  
 
Physical activities that strengthen 
muscles involve using body weight or 
working against a resistance. This 
should involve using all the major 
muscle groups 
• Exercising with weights 
• Carrying or moving 
heavy loads such as 
groceries  
• Activities that involve 
stepping and jumping 
• Chair aerobics  
AND   
Minimise the amount of time 
spent being sedentary for 
extended periods. 
Reduce the amount of time spent 
sitting 
• Reducing time spent 
watching TV, using the 
computer or playing 
video games  
• Taking regular breaks 
at work  
• Taking regular walk 
breaks around the 
garden or street 
• Breaking up sedentary 
time such as swapping 
a long bus or car 
journey for walking part 
of the way  
Additional recommendations for older adults (>65 years) 
Older adults at risk of falls 
should incorporate physical 
activity to improve balance and 
co-ordination on at least two 
days a week 
Physical activities that improve 
balance and coordination should 
improve the stability of muscles and 
the ability of muscles to work 
together smoothly 
• Tai chi  
• Yoga 
 
Older adults who participate in any amount of physical activity gain some health benefits, including 
maintenance of good physical and cognitive function. Some physical activity is better than none, and 
more physical activity provides greater health benefits. 
(Adapted from Department of Health, 2011, pp. 32-41) 
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It is vital that the characteristics of PA and exercise are reported in relation to 
the frequency, intensity, time and type; because manipulation of these 
parameters results in differing physiological and metabolic responses and 
differing health and fitness benefits (American College of Sports Medicine, 
2006).  However, historically the reporting of these characteristics in exercise 
intervention studies among BCSs have been poor (K. L. Campbell, Neil, & 
Winters-Stone, 2011). According to the ACSM Roundtable on Exercise 
Guidelines for Cancer Survivors there is a “need for greater specificity about 
the dose-response effects of specific modes of exercise training on specific end 
points” (Schmitz et al., 2010). And Visovsky (2006) reported that there was a 
lack of studies addressing the effects of exercise in older, postmenopausal, 
BCSs. 
 
2.14.  Exercise, BM and body composition change in BCSs: a summary 
of past reviews 
Several reviews assessing the effect of exercise on BM and body composition 
among general cancer survivor populations have been published. Exercise 
during cancer treatment has been shown to have a small effect on BM 
(weighted mean effect size [WMES] -0.25, p=0.05) and BF% (WMES -0.25; 
p=0.04); and exercise after cancer treatment has been shown to have a small 
effect on BM (WMES -0.18, p=0.004), BF% (WMES –0.18; p=0.006) and BMI 
(WMES -0.14; p=0.002) (Speck, Courneya, Masse, Duval, & Schmitz, 2010).  
Fong et al. (2012) reported that PA after cancer treatment was associated with 
reduced BM (-1.1 kg; [95%CI; -1.6 to -0.6 kg] p<0.001) and BMI (-0.4;  [95%CI; 
-0.6 to -0.2]; p<0.01). Winters-Stone, Schwartz, and Nail (2010) reviewed the 
effects of exercise on bone health in cancer survivors, but concluded that 
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studies were too few and too varied to draw conclusions about the effects of 
exercise on BMD. 
A number of reviews assessing the effect of exercise on BM and body 
composition among specific BCSs populations have been published (Cheema, 
Gaul, Lane, & Fiatarone Singh, 2008; Ingram, Courneya, & Kingston, 2006; 
Kim, Kang, & Park, 2009; Kirshbaum, 2007; Markes, Brockow, & Resch, 2006; 
McNeely et al., 2006; Rooney & Wald, 2007; Stevinson, Lawlor, & Fox, 2004; 
White, McAuley, Estabrooks, & Courneya, 2009). Markes et al. (2006), 
McNeely et al. (2006) and Kim et al. (2009); all concluded that exercise resulted 
in small, non-significant reductions, in BM among BCSs (standardised mean 
difference [SMD] -1.11; [95%CI; -2.44 to 0.22]; weighted mean difference 
[WMD] -0.03kg; [95%CI; -0.44 to 0.38] and SMD -0.223; [95%CI; -0.495 to 
0.049] respectively). 
Exercise has had a greater effect on body composition than BM among BCSs 
(Cheema et al., 2008; Ingram et al., 2006; Kim et al., 2009; Stevinson et al., 
2004; White et al., 2009).  Kim et al. (2009) reported a moderate to large effect 
of aerobic exercise on LBM (SMD 0.721; [95%CI; 0.047 to 1.490]) and a 
statistically significant, moderate to large, effect on BF% (SMD -0.890; [95%CI; 
-1.425 to -0.355]; p=<0.001). Ingram et al. (2006) reported BF% reductions of 
2.6% to 11.7% among exercising BCSs compared to increases in BF% among 
controls.  Cheema et al. (2008) reported that progressive resistance training 
was associated with reduced BF% and increased LBM among BCSs, and that 
these adaptations were independent of BM change.    
However, all these past reviews have included both premenopausal and 
postmenopausal BCSs.  Overweight and obesity increase the risk of 
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postmenopausal breast cancer and reduce the risk of premenopausal breast 
cancer (Cancer Research UK, 2011a). Premenopausal BCSs may gain 
significantly more BM than postmenopausal BCSs during the treatment and 
recovery phases of the breast cancer experience (Vance et al., 2011).  
Therefore, it is possible that, exercise may have different effects on the BM and 
body composition of premenopausal and postmenopausal BCSs.  Therefore 
the findings from these past reviews may not have been representative of either 
group, and important effects may have been disguised.  Of all the reviewers, 
only Markes et al. (2006) included an assessment of the training stimulus 
provided by the included exercise interventions.  No past reviews have required 
that all the information in relation to the frequency intensity, time and type of 
exercise be available.  This is important as little is known about the effects of 
specific exercise prescriptions in BCSs (Schmitz et al., 2010). 
The characteristics of exercise in relation to the frequency, intensity, time and 
type which will produce the optimal BM and body composition benefits in 
postmenopausal BCSs have yet to be established.  At present there is 
insufficient evidence to provide specific exercise prescriptions to 
postmenopausal BCSs. 
 
2.15. Aims, objectives and research questions 
The aim of this systematic review was to determine if exercise interventions are 
effective for the prevention and treatment of BM gain, and adverse body 
composition change, among postmenopausal BCSs. 
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The objectives of this systematic review were to; 
 
• Identify exercise intervention studies that have included measures of BM 
and body composition in postmenopausal BCSs. 
• Describe the specific types of exercise interventions, in relation to the 
frequency, intensity, time, type and total duration that have included 
measures of BM and body composition in postmenopausal BCSs. 
• Determine the effects of exercise interventions on the BM, BMI, WC, 
LBM, FM, BF%, WC, BMC and BMD of postmenopausal BCSs. 
 
The specific research questions this systematic review sought to answer were; 
 
1. Do exercise interventions have a beneficial effect on the BM and 
body composition (↓BM, ↓BMI, ↓WC, ↑LBM, ↓FM, ↓BF%, ↑BMC and 
↑BMD) of postmenopausal BCSs? 
 
2. Which specific types of exercise, in relation to frequency, intensity, 
time, type and total duration, have been used to potentially prevent 
or treat BM gain and adverse body composition change (↑BM, ↑BMI, 
↑WC, ↓LBM, ↑FM, ↑BF%, ↓BMC and ↓BMD) in postmenopausal 
BCSs? 
 
As recommended by the Centre for Research and Dissemination (2009, pp. 7-
9) and the Cochrane Collaboration (O’Connor, Green, & Higgins, 2011) the 
research questions were clearly defined and framed using the Population(s), 
Intervention(s), Comparator(s), Outcome(s) and Study Design (PICOS) 
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structure.  Descriptions of each of the PICOS elements, as they relate to this 
systematic review, are outlined in Table 4.  Refer to the glossary, attached in 
Appendix 1, for detailed definitions of terms. 
 
 
Table 4 
Description of the PICOS elements included in the systematic review of 
the effects of exercise on BM and body composition in postmenopausal 
BCSs 
 
PICOS Description 
Population • Studies of participants, who were female and were classified as postmenopausal BCSs. 
• Studies of participants with mixed cancer diagnoses if outcomes 
were reported separately for postmenopausal BCSs. 
• Studies of participants with mixed menopausal statuses if outcomes 
were reported separately for postmenopausal BCSs. 
Interventions • Any exercise only intervention, of aerobic or resistance exercise, or a combination of aerobic and resistance exercise, that took place 
during or after treatment for postmenopausal breast cancer, and for 
which the frequency, intensity, time, type and total duration were 
reported. 
• Any multi-faceted intervention (e.g. exercise and diet, exercise and 
cognitive behavioural therapy [CBT], exercise and nutritional 
supplements) where the exercise intervention met the above criteria 
and where data for an exercise only group was available. 
Comparators • Postmenopausal BCSs assigned to usual care. • Non-exercising postmenopausal BCS. 
• Postmenopausal BCSs asked to continue with usual level of 
exercise and PA. 
• Postmenopausal BCSs assigned to placebo exercise interventions 
with minimal effects on EE e.g. stretching. 
Outcomes • Any specified body composition outcome. Specified body composition outcomes were WC, LBM, FM, BF%, BMD and BMC.  
• Any specified BM outcome, when reported in combination with any 
specified body composition outcome.  Specified BM outcomes were 
BM and BMI. 
Study designs • Randomised Controlled Trials (RCTs) including parallel group trials, randomised cross-over trials and cluster randomised controlled trials 
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3.0. Methodology 
3.1. Overview of the systematic review process 
In order to be valid a systematic review must be based on the best available 
evidence. Systematic reviews should; use a clearly stated reproducible 
methodology that attempts to minimise bias, use a systematic search strategy 
that attempts to identify all studies that meet pre-defined eligibility criteria, make 
an assessment of the methodological quality of individual studies and 
synthesise and present findings in a systematic way (Centre for Reviews and 
Dissemination, 2009, p. 9; Green et al., 2011).   
This systematic review was developed and reported in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement (Moher, Liberati, Tetzlaff, Altman, & Prisma Group, 2009). 
A completed PRISMA 21 item checklist of systematic review reporting items is 
provided in Appendix 6. 
This systematic review was conducted in fulfilment of an MSc dissertation and 
therefore all review processes were conducted by a single reviewer. 
 
3.2. Minimising the risk of bias at the review level 
Bias occurs when obtained results are systematically different to the true 
effects therefore, the conclusions drawn from biased results may be misleading 
or wrong (Centre for Reviews and Dissemination, 2009, p. 262; Crombie, 1996, 
p. 18).  There are a number of types of reporting bias that can affect the validity 
of a systematic review. For definitions and examples of reporting bias refer to 
Table 5. 
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Table 5 
Definitions and evidence of different types of reporting bias 
Type of Bias Definition Evidence 
 
Publication 
bias 
The publication or 
non-publication of 
research findings, 
depending on the 
nature and direction 
of the results 
• Studies with significant results are more likely to be published than those with null or negative findings. 
• Studies with positive results were more likely to be published as scientific papers than studies with inconclusive 
results (adjusted odds ratio 4.59; 95%CI; 2.21 to 9.54) (Decullier, Lheritier, & Chapuis, 2005). 
• Clinical research studies with statistically significant results were more likely to be published than those with 
null results (odds ratio 2.32; 95%Cl 1.25 to 4.28) (Easterbrook, Berlin, Gopalan, & Matthews, 1991).  
• Clinical trials with positive results were nearly four times more likely to be published than those with negative 
results (odds ratio 3.90; 95%CI; 2.68 to 5.68) (Hopewell, Loudon, Clarke, Oxman, & Dickersin, 2009). 
• Cohort studies with positive results were 2.78 times more likely to be published than those with negative results 
(odds ratio 2.78; 95%CI; 2.10 to 3.69) (Song et al., 2009). 
• Clinical research trials with positive results (p=<0.05) were more likely to be published than those with null or 
negative results (HR 2.32; 95%CI; 1.47 to 3.66 [p=0.0003]) (Stern & Simes, 1997). 
 
Time lag bias The rapid or delayed publication of 
research findings, 
depending on the 
nature and direction 
of the results 
• Studies with significant results have a shorter time to publication. 
• Studies with positive results were published more quickly than studies with inconclusive results (HR 2.48; 
95%CI; 1.36 to 4.55) (Decullier et al., 2005). 
• Clinical trials with statistically significant positive results were published one to three years earlier than those 
with negative or null results (4-5yrs vs 6-8yrs) (Hopewell, Clarke, Stewart, & Tierney, 2007). 
• Randomised efficacy trials with positive results (p=<0.05) had a significantly shorter time to publication than 
those with null or negative results (4.3yrs vs 6.5yrs; HR 3.7; 95%CI; 1.8 to 7.7 [p=0.001]) (Ioannidis, 1998). 
• Clinical research trials with positive results (p=<0.05) had a significantly shorter time to publication than those 
with null or negative results (4.7yrs vs 8.0yrs; HR 3.13; 95% CI 1.76 to 5.58 [p=0.0001]) (Stern & Simes, 1997). 
 
Duplicate 
publication 
bias 
The multiple or 
singular publication 
of research findings, 
depending on the 
nature and direction 
of the results 
• Studies with significant results are more likely to be published repeatedly. 
• Studies with significant results were more likely to lead to a greater number of publications (Easterbrook et al., 
1991). 
• Out of 244 research trials investigating non-steroidal anti-inflammatory drugs in rheumatoid arthritis. 44 (18%) 
were multiple publications; 20 trials were published twice, ten trials three times, and one trial four times 
(Gotzsche, 1989). 
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Table 5; Definitions and evidence of different types of reporting bias /cont. 
 
Type of Bias Definition Evidence 
 
Location bias The publication of research findings in 
journals with different 
ease of access or 
levels of indexing, 
depending on the 
nature and direction 
of results 
• Studies not indexed in MEDLINE, and those found in the grey literature, are more likely to show a greater 
treatment effect  Studies with significant results are more likely to be located in low impact factor journals.  
• Compared to trials published in MEDLINE-indexed journals treatment effect estimates were on average 6% more 
beneficial for trials not indexed in MEDLINE (95%CI; 18% more beneficial to 7% less beneficial; p= 0.35) (Egger, 
Juni, Bartlett, Holenstein, & Sterne, 2003). 
• On average published trials showed a 9% greater all over treatment effect than trials located in the grey literature 
(OR for grey versus published trials 1.09; 95%CI; 1.03 to 1.16) (Hopewell, McDonald, Clarke, & Egger, 2007). 
• Journals with low or no-impact factor are more likely to report studies with significant results than journals with a 
high impact factor (p=<0.05) (Pittler, Abbot, Harkness, & Ernst, 2000). 
 
Citation bias The citation or non-citation of research 
findings, depending 
on the nature and 
direction of the 
results 
• Studies with significant results are more likely to be cited. 
• Trials with positive results were 2.8 times more likely to be summarised (cited)  in the secondary literature than 
trials catalogued in MEDLINE (OR 2.8; 95%Ci; 2.02 to 3.93; p<0.001) (Carter, Griffin, & Carter, 2006). 
• Out of 111  research trials investigating non-steroidal anti-inflammatory drugs in rheumatoid arthritis, 44 (49%) 
had a significant positive citation bias (Gotzsche, 1987). 
• In trials of cholesterol lowering in CHD, studies which had  a positive effect were cited almost six times more often 
than those which demonstrated a null or negative effect (mean annual citations 40 vs. 7.4) (Ravnskov, 1992). 
 
Language 
bias 
The publication of 
research findings in a 
particular language, 
depending on the 
nature and direction 
of the results 
• Studies with significant results are more likely to be published in English. 
• RCT in the German language were more likely to be published in an English-language journal if the results were 
statistically significant (odds ratio 3·75; 95%CI 1·25 to 11·3) (Egger et al., 1997). 
• Compared to English language trials treatment effect estimates were on average 16% more beneficial in non-
English language trials (95% CI; 3% to 26%;[ p = 0.011]) (Egger et al., 2003). 
• Compared to English language clinical trials, non English language trials were more likely to produce significant 
results at the p=<0.05 level (41.7% vs 31.3%; p=0.033) (Juni, Holenstein, Sterne, Bartlett, & Egger, 2002). 
 
Outcome 
reporting 
bias 
The selective 
reporting of some 
outcomes but not 
others, depending on 
the nature and 
direction of the 
results 
• Studies with significant results are more likely to fully report all outcomes. 
• Within a trial, incompletely reported outcomes had a higher odds of being statistically non-significant compared 
with fully reported outcomes (OR 2.0; 95%CI; 1.6 to 2.7) (Chan & Altman, 2005). 
• When compared to trial protocols, 62% of published articles had at least  one primary outcome that was changed 
on publication. Statistically significant outcomes had a higher odds of being fully reported compared with non-
significant outcomes (OR; 2.4; 95%CI; 1.4 to 4.0) (Chan, Hrobjartsson, Haahr, Gotzsche, & Altman, 2004). 
• RCT with statistically significant outcomes had a higher odds of being fully reported compared to those with non-
significant outcomes (range of odds ratios: 2.2 to 4.7) (Dwan et al., 2008). 
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Studies with statistically significant results are more likely to be published than 
those with null or negative findings, leading to publication bias (Centre for 
Reviews and Dissemination, 2009; Egger & Smith, 1998; Sterne, Egger, & 
Moher, 2011). Other forms of reporting bias include; publication bias, time-lag 
bias, duplicate publication bias, location bias, citation bias, language bias and 
outcome reporting bias (Table 5)  (Centre for Reviews and Dissemination, 
2009, pp. 12-13; Sterne et al., 2011).  To minimise the effects of reporting bias 
systematic reviews must adopt a comprehensive search strategy.  This search 
strategy must have been designed to identify and include all relevant studies, 
regardless of publication status, otherwise the findings may be biased towards 
the positive and overestimate the effect of an intervention (Centre for Reviews 
and Dissemination, 2009, pp. 12-13; Egger & Smith, 1998; Hopewell et al., 
2009; Sterne et al., 2011).   
 
3.3. Search strategy 
A search strategy should aim to achieve a high sensitivity, so as to detect all 
relevant articles, however such a strategy may result in low specificity, where 
large numbers of unrelated articles are detected (Lefebvre, Manheimer, & 
Glanville, 2011).  In this instance, as only a single reviewer was available, it was 
necessary to carefully balance sensitivity and specificity to take account of the 
human and material resources available.  
 
3.4. Search terms 
The Cochrane Collaboration recommends limiting the number of concepts used 
in systematic review searches (Lefebvre et al., 2011).  Initial scoping literature 
review revealed that menopausal status and body composition outcomes were 
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often not reported in the title or abstract of studies of exercise interventions 
among BCSs.  Therefore initial basic search terms were limited to the 
population and the interventions of interest. The search terms; cancer, breast 
and exercise were applied in isolation to two general (MEDLINE and 
Cumulative Index to Nursing and Allied Health Literature [CINAHL]) and one 
specific (Sports Discus) electronic bibliographical database (all searches were 
conducted on 25th May 2012).  These initial searches were performed in order 
to gauge if this strategy would return a manageable number of records.  The 
limit for a manageable number of records was set at 2000 (arbitrary figure).  It 
became clear that this strategy would return an unmanageable number of 
records (Table 6).  Therefore the basic search terms were combined with the 
Boolean operator “AND” to limit the search and make it more specific.  It was 
determined that this strategy would return a manageable number of records 
(Table 6) and this strategy formed the structure for the extensive search. 
 
Table 6 
Number of records returned from the initial basic search strategy 
Search Terms 
Number of 
records retrieved 
from MEDLINE 
Number of records 
retrieved from 
CINHAL 
Number of records 
retrieved from 
Sports Discus 
Cancer 2628869 137694 14885 
Breast 308119 60279 4467 
Exercise 237634 76606 171572 
Breast AND Cancer 
AND Exercise 1632 863 469 
 
The Cochrane Collaboration advocate the use of extensive keywords and 
phrases to expand the search in each concept area by the use of the Boolean 
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operator “OR” (Lefebvre et al., 2011).  Therefore two lists of keywords and 
phrases, which related to the populations and interventions of interest, were 
generated from studying relevant reviews and Medical Subject Headings 
(MESH) (Table 7).  
 
Table 7 
Key words and phrases related to BCSs populations and exercise 
interventions  
Key words and phrases related to the 
population: Breast cancer survivors 
Key words and phrases related to the 
intervention: Exercise 
Breast Cancer Exercise 
Breast Neoplasm Exercise Intervention 
Breast Carcinoma Exercise Program 
Breast Tumor Exercise Programme 
Breast Tumour Exercise Training 
Mammary Cancer Exercise Therapy 
Mammary Neoplasm Rehabilitation 
Mammary Carcinoma Physical Activity 
Mammary Tumor Physical Activity Intervention 
Mammary Tumour Physical Therapy 
Ductal Carcinoma in Situ Physical Fitness 
Lobular Carcinoma in Situ Aerobic Exercise 
Invasive Ductal Breast Cancer Aerobic Training 
Ductal Carcinoma Aerobics 
Invasive Lobular Breast Cancer Resistance Exercise 
Lobular Carcinoma Resistance Training 
Invasive Breast Cancer Weight Training 
Breast Cancer Patient Weight Lifting 
Breast Cancer Survivors Muscle Strengthening 
Breast Cancer Survivorship Walking 
Breast Cancer Recovery Running 
Breast Cancer Treatment Jogging 
 Cycling 
 Rowing 
 Racing 
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The keywords and phrases presented in Table 7 were applied to the extensive 
search strategy. 
 
3.5. Electronic bibliographical database searches 
A comprehensive database search is required to minimise bias (Lefebvre et al., 
2011). As the topic of exercise and cancer survivorship spans a wide range of 
research disciplines it was necessary to search a wide range of specialist 
databases to locate relevant literature (Stevinson & Lawlor, 2004).  Details of 
the electronic bibliographical databases that were searched are provided in 
Table 8.  These databases were either freely available or were available via 
University of Chester subscriptions. 
Initial literature searches revealed that the earliest published study investigating 
the effects of exercise on body composition in BCSs was performed in 1989 
(Winningham, MacVicar, Bondoc, Anderson, & Minton, 1989). Therefore 
bibliographical databases were searched for studies from 1989 onwards.  
Initially searches were performed up to the end of April 2012 and this was 
updated once, up to the end of June 2012.   
To improve the precision of the searches, and reduce the number of unrelated 
studies returned, wherever possible searches were limited by species 
(humans), gender (female), and age (adults 19+ years).   
Full details of the electronic bibliographical search strategy used, and the 
number of records returned, are provided in Appendices 7 and 8. 
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Table 8 
Descriptions of the bibliographical databases searched 
Database Summary of coverage Access Method Dates Searched 
PubMed - MEDLINE Covers biomedical literature 
Provides citations (sometimes with full text links) to >21 million citations from 
MEDLINE, life science journals, and online books.  
PubMed interface 1989 - End June 2012 
The Cochrane Library 
 
Covers evidence to inform healthcare decision-making 
A collection of six databases (Cochrane Database of Systematic Reviews, 
Database of Abstracts of Reviews of Effects, Cochrane Central Register of 
Controlled Trials [CENTRAL], Cochrane Methodology Register, Health 
Technology Assessment Database NHS Economic Evaluation Database) that 
contain different types of high-quality, independent research  
Freely Available 1989 - End June 2012 
Cumulative Index to 
Nursing and Allied Health 
Literature (CINAHL) 
Covers health and social care 
Includes coverage of >3000 health-related journals and provides full text for 
>560 journals. 
Also includes selected pamphlets, dissertations and foreign language studies 
with English abstracts. 
EBSCO interface 1989 - End June 2012 
ProQuest Nursing & 
Allied Health Source 
Covers nursing, allied health, alternative and complementary medicine  
Provides abstracts for >850 titles, >715 full text titles and >12,000 full text 
dissertations. 
PROQUEST 
interface 1989 - End June 2012 
Sports Discus Covers all sports science disciplines 
Provides references (sometimes with abstracts) to articles from >2,000 journals. 
EBSCO interface 1989 - End June 2012 
Physiotherapy Evidence 
Database (PEDro) 
Covers physiotherapy disciplines 
A database of >21,000 RCT, systematic reviews and clinical practice guidelines. 
Freely Available 1989 - End June 2012 
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3.6. Grey literature searches 
Research reports, policy documents, book chapters, conference abstracts, 
dissertations, personal correspondences and unpublished data are all examples 
of grey literature (Hopewell, McDonald, et al., 2007).  The inclusion of grey 
literature in a systematic review may help to overcome some of the problems of 
publication bias.  Two sources of grey literature are the ZETOC database and 
the SCIRUS search engine. ZETOC is an electronic database of abstract only 
listings of >20,000 current journals and >16,000 conference proceedings held at 
the British Library.  SCIRUS is a science-specific search engine which searches 
>460 million science-specific Web pages. The ZETOC database and the 
SCIRUS search engine were searched to locate sources of grey literature; full 
details these searches are provided in Appendices 9 and 10 respectively.   
A number of relevant book chapters, from the following books, were hand 
searched in order to locate relevant records.  
• Courneya, K. S., & Friedenreich, C. M. (Eds.). (2011). Physical Activity 
and Cancer: Recent Results in Cancer Research (Vol. 186). Heidelberg: 
Springer. 
 
• Irwin, M. L. (Ed.). (2012). ACSM's Guide to Exercise and Cancer 
Survivorship. Champaign; IL: Human Kinetics 
 
• McTiernan, A. (Ed.). (2006). Cancer Prevention and Management 
through Exercise and Weight Control. Boca Raton; FL: CRC Press. 
 
• Saxton, J., & Daley, A. (Eds.). (2010). Exercise and Cancer Survivorship: 
Impact on Health Outcomes and Quality of Life. New York: Springer. 
 
 
Full details of the book chapters searched are provided in Appendix 11.
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3.7. Sources Handsearched  
Handsearching requires a journal to be checked from cover to cover; each item 
(full reports, short reports, editorials, correspondence sections, meeting 
abstracts, supplements and letters) should be read to determine relevance to 
the review (Hopewell, Clarke, Lefebvre, & Scherer, 2007). Handsearching can 
locate records not retrieved by the search terms, or those not indexed in 
electronic bibliographical databases; therefore handsearching can help to 
minimise publication bias (Centre for Reviews and Dissemination, 2009, p. 18; 
Hopewell, Clarke, Lefebvre, et al., 2007).   
 
The online versions of the following journals were handsearched;  
• British Journal of Sports Medicine 
• Journal of Cancer Survivorship 
• Cancer, Epidemiology, Biomarkers and Prevention 
• Medicine & Science in Sport and Exercise 
• Oncology Nursing Forum 
• Psycho-Oncology  
• International Journal of Sports Medicine  
• Journal of Clinical Oncology  
 
The online versions of these journals were accessed from freely accessible 
sources or via subscriptions held by the University of Chester.  All supplements, 
letters and conference proceedings were searched; however, online full-text 
access, to the International Journal of Sports Medicine and the Journal of 
Clinical Oncology were not available, therefore handsearches of titles and 
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abstracts were made.  Journals were searched from inception or from January 
1989, whichever was earlier.  Initial searches were conducted up to the end of 
April 2012 and were updated up to the end of June 2012.  Full details of the 
specific journal handsearches are provided in Appendix 12. 
 
3.8. Data management 
Endnote citation management software (Adept Scientific, 2011) was used to 
document the search process and streamline document management (Centre 
for Reviews and Dissemination, 2009; Lefebvre et al., 2011, p. 21).  All records 
located by the search strategy were exported, or entered manually, into 
Endnote (Adept Scientific, 2011) where records were merged and duplicate 
records were removed. 
 
3.9. Screening records to determine inclusion or exclusion into the 
systematic review 
In order to remove obviously irrelevant reports as efficiently as possible, the 
titles and abstracts of all records were screened against basic initial eligibility 
criteria (Table 9).  A single failed eligibility criterion is sufficient for a study to be 
excluded from a review (Higgins & Deeks, 2011). Therefore eligibility criteria 
were applied in order of importance and the first ‘no’ response was used as the 
primary reason for exclusion. The initial eligibility screening criteria were applied 
cautiously and were generally over-inclusive, so as to avoid inadvertently 
excluding a potentially relevant record. 
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Table 9 
Initial eligibility screening criteria 
 
PICOS concept area Inclusion / exclusion criteria 
Study Design • Was the study primary research? 
• Was the study a RCT? 
Population 
• Did the study include human subjects? 
• Did the study include adult (>18 years) subjects? 
• Did the study include female subjects? 
• Did the study include subjects who were BCS? 
Intervention 
• Was the intervention aerobic or resistance exercise, or a 
combination of aerobic and resistance exercise? 
• Was the exercise intervention applied after the diagnosis of breast 
cancer? 
 
In an attempt to quantify the extent of English language bias the existence of 
non-English language records were documented (Centre for Reviews and 
Dissemination, 2009).  Non-English language records, for which an English 
language title and abstract were available, were screened and excluded in 
accordance with the initial eligibility criteria.  
The full-text versions of any records remaining after initial eligibility screening 
were obtained from; freely available sources, subscriptions held by the 
University of Chester and, when not available from these two sources, from the 
British Library via the University of Chester’s inter-library loan service.  
Full-text articles were screened against the full eligibility criteria outlined in 
Table 10. Refer to the glossary, attached in Appendix 1, for full definitions of 
inclusion or exclusion criteria terms.  
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Table 10 
 
Full eligibility screening criteria 
 
PICOS  Inclusion criteria Exclusion criteria 
Study Design • Was the study published in English language? 
• Was the study published fully? 
• Was the study primary research? 
• Was the study a RCT? 
• Published in languages other 
than English. 
• Abstract only publications 
• Review articles, RCT study 
designs/protocols, proposed 
studies, editorials, news items 
and letters. 
• Study designs other than RCTs. 
Outcome • Did the study include one or more of the specified body composition 
outcomes (WC, LBM, FM, BF%, 
BMC and BMD)?  
• Did the study include one or more 
specified BM outcome (BM, BMI) 
when in combination with one or 
more specified body composition 
outcome? 
• Did the study include body 
composition and BM outcomes 
available for pre and post exercise 
intervention? 
• No specified body composition 
outcome (WC, LBM, FM, BF%, 
BMC and BMD) 
• BM (BM, BMI) only outcomes. 
• Specified outcome data not 
available pre and post 
intervention. 
Population • Did the study include human subjects? 
• Did the study include adult subjects 
(>18yrs)? 
• Did the study include female 
subjects? 
• Did the study include 
postmenopausal subjects?  
• OR if menopausal status was not 
reported; 
• Did the study only include subjects 
>50 years? 
• Did the study include BCSs? 
• Non BCSs populations. 
• Mixed cancer survivor 
populations (unless data for a 
specific breast cancer group 
could be isolated). 
• Mixed premenopausal and 
postmenopausal BCSs 
populations (unless data for a 
specific postmenopausal BCSs 
group could be isolated). 
• If menopausal status was not 
reported; populations containing 
subjects <50yr, (unless data for a 
specific >50yrs group could be 
isolated). 
Comparators • Were the controls postmenopausal BCSs? AND 
• Were controls assigned to usual 
care? OR 
Asked to continue with usual level 
of exercise and PA? OR  
Asked not to exercise? OR 
Assigned to a placebo exercise 
intervention with a minimal effect 
on EE e.g. stretching? 
• Non postmenopausal BCS 
controls 
• Postmenopausal BCS controls 
who were assigned to an 
exercise placebo with a 
>moderate effect on EE. 
 
42 
 
Table 10; Full eligibility screening criteria /cont. 
 
PICOS  Inclusion criteria Exclusion criteria 
Intervention • Was the intervention aerobic exercise or resistance exercise or 
a combination of aerobic and 
resistance exercise? 
• Did the exercise take place after 
diagnoses of breast cancer 
(either during or after completion 
of primary treatment)? 
• Was a full description of the 
exercise in relation to the; 
frequency, intensity, time and 
type reported?  
• Did the exercise intervention 
meet the criteria for a high quality 
training study?   
• (see Appendix 11 for details) 
 
• Exercise interventions with a 
nominal effect on EE (e.g. 
movement therapy, stretching, 
yoga) 
• Exercise inventions which were 
part of a multi-component 
intervention e.g. exercise-diet or 
exercise-CBT (unless data 
relating to an exercise only group 
was available) 
 
Due to feasibility issues relating to translation, non-English language reports 
were excluded at this stage (Centre for Reviews and Dissemination, 2009). 
Initial literature review revealed that abstract only publications would be unlikely 
to provide the level of detail required to determine inclusion or exclusion. 
Therefore abstract only publications were excluded at this stage. In order to 
allow the effects of exercise to be isolated, studies which included exercise as 
part of a complex multi-component intervention (e.g. exercise/diet; 
exercise/nutritional supplement, exercise/CBT, exercise/counselling) were 
excluded.  Many studies of BCSs do not report menopausal status, therefore it 
was decided that studies which included subjects under the age of 50 years, the 
average age of the menopause, would be excluded.   
Exercise interventions should provide an adequate training stimulus that would 
be likely to result in BM and body composition adaptations; an inadequate 
training stimulus may lead to non-significant findings. Therefore an Assessment 
of High Quality Training Studies (HQTS) tool was used to determine if the 
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exercise intervention studies considered for inclusion in this review provided an 
adequate training stimulus (Markes et al., 2006).  Full details of the HQTS tool 
and the HQTS assessment of studies meeting all other eligibility criteria are 
provided in Appendix 13. 
All studies that met the full eligibility criteria were included in the final review. 
 
3.10. Dealing with duplicate publications 
In an attempt to identify duplicate publications; the names of the authors, the 
locations and settings, the specific details of the interventions, the numbers of 
participants, the baseline characteristics of the participants and the dates and 
durations of all studies that met the full eligibility criteria were compared 
(Higgins & Deeks, 2011). Any duplicate publications that were identified were 
treated as a single study, but references were made to all publications in the 
final review (Centre for Reviews and Dissemination, 2009, p. 25). 
 
3.11. Assessing the risk of bias of individual studies 
The terms methodological quality and risk of bias are often used 
interchangeably (Hartling et al., 2009; Higgins, Altman, & Sterne, 2011).  For 
the purposes of this review, risk of bias refers to the internal validity of the study 
(the way in which the study has been designed and conducted), whereas 
methodological quality refers to all other aspects of quality (including the 
adequacy of reporting).   
In order to ensure this systematic review was valid, and based on the best 
quality evidence, only RCTs were considered for inclusion.  However, although 
RCTs are associated with a lower risk of bias than other study designs, not all 
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studies of the same design are equally well designed and conducted (Centre for 
Reviews and Dissemination, 2009; Higgins et al., 2011). There is evidence that 
inadequate sequence generation (Schulz, Chalmers, Hayes, & Altman, 1995), 
inadequate allocation concealment (Egger et al., 2003; Schulz et al., 1995), lack 
of double blinding  (Schulz et al., 1995) and the selective reporting of outcomes 
(Chan & Altman, 2005; Chan et al., 2004) are associated with overestimates of 
treatment effects (Armijo-Olivo, Stiles, Hagen, Biondo, & Cummings, 2010; 
Centre for Reviews and Dissemination, 2009, p. 33; Hartling et al., 2009; 
Higgins et al., 2011).  Therefore, in order to determine if the findings from 
individual studies were valid, assessments of the risk of bias were made for 
each of the studies that were included in this systematic review. 
There are many methods used to assess the methodological quality of studies, 
these include scales and checklists (Higgins et al., 2011). Moher et al. (1995) 
indentified 25 scales and 9 checklists and Armijo-Olivo et al. (2008) indentified 
21 scales that could be used to assess the quality of RCTs.  However despite 
the large number of quality assessment tools, only a minority have been 
rigorously developed and tested for validity and reliability  (Armijo-Olivo et al., 
2008; Deeks et al., 2003; Moher et al., 1995; Moher, Jadad, & Tugwell, 1996).   
There is no validated methodological quality assessment tool specifically 
designed for exercise intervention studies (Armijo-Olivo et al., 2008; Stevinson 
et al., 2004).  True double blinding in exercise intervention studies is often 
impractical or impossible, as participants will know whether or not they are 
performing exercise (Armijo-Olivo et al., 2008; Han et al., 2004; Yeh, 2008; 
Yeh, Wang, Wayne, & Phillips, 2009).  Therefore, many methods that are 
commonly used to assess methodological quality may not be appropriate for 
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exercise intervention studies, due to the focus many of them place on 
participant blinding. 
Past systematic reviews of exercise and body composition in BCSs have used 
a variety of quality assessment tools; Kim et al. (2009) used the Jadad scale 
(Jadad et al., 1996), Cheema et al. (2008) used the Delphi List (Verhagen et al., 
1998), Ingram et al. (2006) used the Effective Public Health Practice Project 
tool (Effective Public Health Practice Project, 2003), Markes et al. (2006) used 
the van Tulder criteria (van Tulder, Assendelft, Koes, & Bouter, 1997) and 
Kirshbaum (2007) and McNeely et al. (2006) developed their own quality 
assessment tools. It is therefore possible to conclude that there is no 
consensus of opinion as to which is the most suitable quality assessment tool to 
use when reviewing exercise and breast cancer survivorship research. 
Higgins et al. (2011) stated that there was a lack of clarity as to what many of 
the scales and checklists currently used to assess methodological quality were 
actually measuring, as many include items relating to the quality of reporting, as 
well as items relating to the risk of bias. In recent years there has been a 
considerable effort to improve the reporting of RCTs; this has primarily been 
driven by the Consolidated Standards of Reporting Trials (CONSORT) 
Statement (Begg et al., 1996; Moher et al., 2010; Schulz, Altman, Moher, & 
Group, 2010).  The CONSORT statement includes a 25 item checklist 
(Appendix 14).   A RCT that does not adhere to the CONSORT statement is not 
completely and transparently reported; as a consequence it may be difficult for 
reviewers to assess the conduct, reliability or validity of the trial (Hopewell, 
Dutton, Yu, Chan, & Altman, 2010; Moher et al., 2010; Schulz et al., 2010). 
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Although the quality of reporting of RCTs has improved in recent years, in 2006 
a significant number of RCTs were still not reporting fully, and the quality of 
reporting remained well below an acceptable level (Hopewell et al., 2010; 
Moher et al., 2010; Plint et al., 2006).  This is of particular importance as RCTs 
of exercise interventions are more complex than many pharmacological RCTs, 
and therefore may require more detailed reporting (Armijo-Olivo et al., 2008).  
As the field of exercise and cancer survivorship is still emerging, it was decided 
that assessments of both the risk of bias, and the quality of reporting, would be 
beneficial and may improve the quality of future research.   
Brouwers et al. (2005) and Juni, Witschi, Bloch, and Egger (1999) reported that 
there was considerable variation in the classification of studies as high or low 
quality as a function of the scale or checklist that was applied. Therefore 
caution should be applied if quality rating scales are used to restrict the number 
of studies included in a systematic review; as the choice of scale will determine 
which studies are eligible (Brouwers et al., 2005; Juni, Altman, & Egger, 2001).  
As studies considered for inclusion into this systematic review were limited to 
RCTs, it was decided not to exclude studies on the basis of methodological 
quality assessment classification; but rather use the assessment of 
methodological quality to determine the quality of research that has been 
conducted and to identify areas of improvement for future research. 
In response to the lack of validity, variations in the classification of quality and 
the lack of clarity as to what is being measured by many methodological quality 
assessment tools, the Cochrane Collaboration no longer advocate the use of 
quality scales and checklists to assess methodological quality (Higgins et al., 
2011). Instead the Cochrane Collaboration Risk of Bias Tool is recommended 
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(CCRBT) (Higgins et al., 2011).  The CCRBT tool is based on six domains: 
sequence generation, allocation concealment, blinding, incomplete outcome 
data, selective outcome reporting, and other sources of bias (Higgins et al., 
2011).  However Armijo-Olivo et al. (2010) and Hartling et al. (2009) reported 
that  certain aspects of the CCRBT were associated with low inter-rater 
reliability, and concluded that this was due to the subjective nature of some of 
the CCRBT domains.  The CCRBT requires thorough training to be used 
effectively and requires users to have experience of making risk of bias 
assessments (Hartling et al., 2009). Therefore the CCRBT was not considered 
appropriate for use in this review, as the single reviewer was inexperienced.  
Of all the methods available, the Downs and Black Checklist (1998) was 
considered the most appropriate tool to use to assess the methodological 
quality of studies included in this systematic review (Appendix 15). This 
checklist was developed by public health specialists, to assess the 
methodological quality of randomised and non-randomised health care 
interventions.  It has been assessed for reliability and validity and scored highly 
for internal consistency (Kuder-Richardson 20 [KR-20] = 0.89), test-retest 
reliability (r = 0.88) and inter-rater reliability (r = 0.75) (Downs & Black, 1998).  
There is clarity of the concepts measured, as five subscales are used; 
reporting, external validity, internal validity-bias, internal validity -selection bias 
and power.  
It has been suggested that methodological quality checklists might need to be 
adapted based on the nature of the review and the type of studies to be 
included (Centre for Reviews and Dissemination, 2009; Deeks et al., 2003).   
Given that it is virtually impossible for exercise intervention studies to blind 
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participants to the intervention they receive, consideration was given to the 
removal of question 14 (that related to participant blinding) from the Downs and 
Black Checklist (1998).  However, lack of double blinding has been associated 
with a 17% exaggeration of the treatment effect, and whilst exercise 
intervention studies may be of the highest methodological quality, the risk of 
bias that results from the participants knowledge of their intervention status still 
exists (Higgins et al., 2011; Schulz et al., 1995).  Therefore, so as to ensure the 
risk of bias was properly assessed, it was decided to leave question 14 in the 
checklist.  Using the Downs and Black Checklist (1998) in an unmodified form 
also allowed validity to be maintained. 
 
3.12. Methodological quality assessment using the Downs and Black 
Checklist (1998) 
All studies that the met the full eligibility criteria were included in the final review 
and were rated for methodological quality using the Downs and Black Checklist 
(1998) (Appendices 15 and 16).  The Downs and Black Checklist (1998) had 27 
questions spread across five subscales; the reporting subscale (10 questions), 
the external validity subscale (3 questions), the internal validity (bias) subscale 
(7 questions), the internal validity (selection bias) subscale (6 questions) and 
the power subscale (1 question).  Each question was scored either 0 or 1, apart 
from question 2 in the reporting subscale, which was scored from 0 to 2, and 
question 27 in the power subscale, which was scored from 0 to 5.  This gave an 
overall score of 32, and subscale scores of 11, 3, 7, 6 and 5 for the reporting, 
external validity, internal validity (bias), internal validity (selection bias) and 
power subscales respectively (Appendix 15).  In order to summarise and 
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compare the methodological quality of studies included in the review, overall 
and subscale percentage scores were calculated for each study.  The higher 
the score, both overall and for each subscale the higher the methodological 
quality.   
 
3.13. Data extraction 
Extraction of data from studies can be a subjective process, therefore to 
minimise bias, a standardised data extraction tool was used (Centre for 
Reviews and Dissemination, 2009, pp. 28-32; Higgins & Deeks, 2011).  A data 
extraction tool should obtain data that relates specifically to the objectives of the 
review (Centre for Reviews and Dissemination, 2009, pp. 28-32; Higgins & 
Deeks, 2011). To this end, a data extraction tool was developed that focused on 
the specific elements of the PICOS that were relevant to the review questions.  
Different studies were likely to present their findings in slightly different ways 
(e.g. mean change or % change) therefore the mean change (from pre to post 
intervention) for the control and exercise groups were recorded (or calculated if 
not available).  The difference in mean change between exercisers and controls 
was calculated for each outcome (BM, BMI, WC, LBM, FM, BF%, BMC and 
BMD).  This was done to standardise data collection across studies and enable 
comparisons of the effect of different exercise prescriptions on body 
composition and BM between studies to be made.  Any statistically significant 
findings reported by individual studies were highlighted in red.  It was not 
possible to provide standard deviations or 95% CIs, as this level of data was not 
reported by all studies. 
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To ensure that he data extraction form functioned well and was efficient i.e. did 
not collect irrelevant information but collected all required information, it was 
piloted on a number of studies generated from the initial search (Centre for 
Reviews and Dissemination, 2009, pp. 28-32; Higgins & Deeks, 2011). 
The data extraction tool was applied to all studies that met the full inclusion 
criteria. A blank copy and an example of a completed data extraction form are 
attached in Appendices 17 and 18. 
Where a study had two or more groups or subsets of exercising 
postmenopausal BCSs, data extraction was performed, and results were 
presented, for each group or subset. 
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4.0. Results  
4.1. Identification of records and study selection 
The flow of records through the systematic review, from detection to final 
inclusion, is presented in Figure 5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5  
Flow of information through the different phases of the systematic review 
6315 records identified 
via database searches 
 
• MEDLINE     =965 
• Cochrane Lib     =926 
• CINHAL     =764 
• ProQuest      =652 
• SportsDiscus     =769 
• Pedro    =1239 
2547 records identified 
via additional sources 
 
• SCIRUS       =229 
• ZECTOC     =1605 
• Book HS      =237 
• Journal HS       =471 
8862  
records identified 
5714 
titles and abstracts screened 
against initial inclusion / exclusion 
criteria 
5457 records excluded  
Did not meet initial eligibility criteria  
257 
Full text articles assessed for 
eligibility against full eligibility 
criteria 
252 records excluded  
• Not English Language            =14 
• Dissertations/thesis               =7 
• Abstract only             =92 
• RCT Protocols              =18 
• No body composition outcome        =87 
• Mixed cancer types               =3 
• Included premenopausal BCSs       =15 
• Included BCSs <50 years                =13 
• Not exercise only interventions         =3 
 
5 
studies included in final review 
3148 duplicate records removed 
 
52 
 
The search strategy identified a total of 8862 records; after duplicate records 
were removed 5714 records remained (Fig. 5). Following application of the 
initial eligibility criteria 5474 records were excluded, and 257 full text articles 
were screened against the full eligibility criteria; 252 were excluded (see Fig. 5 
for reasons). Five studies met the full eligibility criteria and were included in the 
final review (Herrero et al., 2006; Irwin, Alvarez-Reeves, et al., 2009; Rahnama, 
Nouri, Rahmaninia, Damirchi, & Emami, 2010; Saarto et al., 2012; Winters-
Stone et al., 2011).  The search locations and retrieval methods for all of the 
studies included in the final review are given in Appendix 19. 
One included study had two subsets of postmenopausal BCSs; one subset 
exercised for 6 months and the other subset exercised for 12 months (Irwin, 
Alvarez-Reeves, et al., 2009 [6 month and 12 month]).  The results for each of 
these subsets are reported separately; effectively meaning results are 
presented for six studies.  The study of Saarto et al. (2012) included a 
premenopausal and a postmenopausal subset of exercising BCSs; only the 
results from the postmenopausal subset are presented. 
 
4.2. Study characteristics 
Studies took place in Finland, Iran, Spain and USA and were published 
between 2006 and 2012 (Table 11).  Across all studies a total of 278 
postmenopausal BCSs were randomised to exercise interventions and 274 
were randomised to control conditions.  However 25 exercisers and 25 controls 
appear in the analysis twice, as these BCSs formed the 12 month exercise 
subset in the Irwin, Alvarez-Reeves, et al. (2009) study. 
 
53 
 
 
 
 
 
 
 
 
Table 11 
Characteristics of studies and participants 
 
Study Study Location 
Sample 
Size 
(n) 
Attrition 
Rate 
(%) 
Mean Age 
(Years) 
Mean BM  
(kg) 
Mean BMI 
(kg/m2) 
Breast 
cancer 
stage 
Type of 
treatment 
Hormone 
Treatment 
Controls Herrero et 
al. (2006) Spain 
10 20 51 ± 10 67.7 ±  8.9 24 ± 3.2 
I-II SUR + CT + RT na Exercisers 10 20 50 ± 5 66.7 ±  10.5 25.1 ± 3.5 
Controls Irwin et al. 
(2009) 
6 month 
USA 
38 15.8 55.1 ± 7.7 78.4 ±  20.0 29.7 ± 7.3 
In Situ - IIIA 
None 
CT only 
RT only 
CT + RT
None 
AOs 
AIs Exercisers 37 2.7 50 ± 9.5 81.3 ± 17.0 30.6 ± 6.0 
Controls Irwin et al. 
(2009) 
12 month 
USA 
25 8 na 75.9 ± 17.7 na 
In Situ - IIIA 
None 
CT only 
RT only 
CT + RT
None 
AOs 
AIs Exercisers 25 0 na 81.2 ± 18.5 na 
Controls Rahnama 
et al. (2009) Iran 
16 6.25 50-65 70.17 ± 9.0 27.4 ± 3.4 
I-IIIB SUR + CT + RT 
Current 
Hormone 
therapy Use Exercisers 16 12.5 50-65 70.4 ± 12.8 28.0 ± 4.7 
Controls Saarto et 
al. (2012) Finland 
131 9.2 58 (46-68) 70.0 ±  11.9 26.2 ± 4.2 
I-IIIC 
None 
CT only 
RT only 
CT + RT
None 
AOs 
AIs Exercisers 138 8.7 58 (48-68) 79.9 ± 12.5 27.2 ± 4.4 
Controls Winters-
Stone et al. 
(2011) 
USA 
54 42.6 62.3 ± 6.7 74.0 ± 12.3 29.5 ± 5.6 
In Situ - IIIA 
None 
CT only 
RT only 
CT + RT
None 
AOs 
AIs Exercisers 52 30.8 62.2 ± 6.7 75.6 ± 15.5 29.5 ± 5.8 
na = information not available; SUR = Surgery; CT = Chemotherapy, RT = Radiotherapy;  AOs = Anti oestrogens; AIs = Aromatase Inhibitors  
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The attrition rate of exercisers ranged from 0% to 30.8% and the attrition rate of 
controls ranged from 6.25% to 42.6% (Table 11).  Out of the 278 exercisers, 33 
were lost to follow-up, therefore 245 completed exercise interventions and follow-
up measurements.  Out of the 274 controls, 46 were lost to follow-up, therefore 
228 completed follow-up measurements.   
The mean age of the participants ranged from 50 to 62 years (Table 11). The 
mean BM and BMI ranges were 66.7kg to 81.3kg and 24.0kg/m2 to 30.6kg/m2 
respectively (Table 11). Studies included postmenopausal BCSs with in-situ to 
stage IIIC breast cancer (Table 11). Studies included BCSs who received a wide 
range of treatments from no treatment, to surgery, radiotherapy, chemotherapy, 
AIs, AOs or a combination (Table 11).   
 
4.3. Exercise characteristics 
All studies were conducted after the completion of primary treatment (surgery, 
radiotherapy, chemotherapy) and were conducted during the survivorship stage of 
the postmenopausal BCS experience (Table 12).  
Three studies prescribed aerobic exercise in isolation (Irwin, Alvarez-Reeves, et 
al., 2009 [6 month & 12 month]; Saarto et al., 2012), one study prescribed 
resistance exercise in isolation (Winters-Stone et al., 2011) and two studies 
prescribed a combination of aerobic and resistance exercise (Herrero et al., 2006; 
Rahnama et al., 2010) (Table 12). Specific types of exercise included; walking, 
circuit training, cycling, step aerobics, weight lifting with fixed and free weights 
and impact jumping (Table 12).  
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Table 12 
Characteristics of exercise interventions 
Study Timing Type Specific type Frequency (days/week) Time Intensity 
Duration 
(weeks) Setting Supervision Adherence 
Herrero et 
al., (2006) AT 
Aerobic 
and 
Resistance 
Cycling 
Weight lifting 
3 
3x Cycling  
3 x Weights 
Cycling  
20-30 min 
Weights  
11 ex; 1-2 sets; 
 8-15 reps 
70-80% max HR 
8-15 rep max 8 RF S 91% +-7% 
Irwin et al. 
(2009) 
6 month 
AT Aerobic Walking 5 30min 60-80% max HR 26 RF+HM S+UNS 73% 
Irwin et al. 
(2009) 
12 month 
AT Aerobic Walking 5 30min 60-80% max HR 52 RF+HM S+UNS 73% 
Rahnama 
et al. (2009) AT 
Aerobic 
and 
Resistance 
Walking 
Fixed and free 
weights 
4 
2 x Walking  
2 x Weights 
Walking  
25-45 min 
Weights  
9 ex; 3 sets; 
10-14 reps 
55-65% max HR 
10-14 rep max 15 RF S na 
Saarto et al. 
(2012) AT Aerobic 
Step aerobics, 
circuit training, 
Walking 
3-4 30-40min 14-16 RPE 52 RF+HM S+UNS S = 63% US = 107%* 
Winters-
Stone et al. 
(2011) 
AT Resistance 
Free weights 
Resistance 
bands Impact 
jumping 
3 
Weights; 6-8 
ex; 1-2 sets;  8-
14 reps 
Jumping; 1-6 
sets; 10 reps 
Weights 
0-15% BM 
8-14 rep Max 
Jumping 
0-10% BM 
52 UN+HM S+UNS 
57% 
S = 76% 
US = 23% 
na = information not available; AF = After Treatment; RF = Recreational Fitness; HM = Home; UNV = University; S = Supervised; UNS = Unsupervised 
* exercise logs reported an average of 3.2 US exercise sessions a week, this was in excess of the prescribed 3 sessions therefore, adherence was >100%  
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The frequency of prescribed exercise ranged from three to five times a week.  
The time spent performing aerobic exercise ranged from 20 to 45min per 
session (Table 12). Resistance exercise was performed for six to eleven 
exercises, for eight to fifteen repetitions and for one to three sets per session 
(Table 12).  Aerobic exercise intensity ranged from 55 to 80% of heart rate max 
and resistance exercise ranged from eight to fifteen repetition maximum (Table 
12). The total duration of exercise interventions ranged from eight to fifty-two 
weeks (Table 12). 
Five out of the six included studies used recreational fitness facilities as the 
setting (Herrero et al., 2006; Irwin, Alvarez-Reeves, et al., 2009 [6 month & 12 
month]; Rahnama et al., 2010; Saarto et al., 2012); three studies combined this 
with home based exercise (Irwin, Alvarez-Reeves, et al., 2009 [6 month & 12 
month]; Saarto et al., 2012) and one study used a university research facility 
combined with home based exercise (Winters-Stone et al., 2011) (Table 12). 
Two studies included only supervised exercise (Herrero et al., 2006; Rahnama 
et al., 2010) whilst four studies used a combination of supervised and 
unsupervised exercise (Irwin, Alvarez-Reeves, et al., 2009 [6 month & 12 
month]; Saarto et al., 2012; Winters-Stone et al., 2011) (Table 12). 
Total adherence to the prescribed exercise ranged from 57% to 91% (Table 
12). Adherence to supervised exercise ranged from 63% to 91% and adherence 
to unsupervised exercise ranged from 23% to 107% (Table 12). 
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4.4. BM and BMI outcomes  
The effects of exercise on the BM and BMI of postmenopausal BCSs are presented in Table 13.  
Table 13 
Summary of the main effects of exercise on the BM and BMI of postmenopausal BCSs 
Outcome 
No of 
Studies 
Study 
Mean Change 
Controls  
Mean Change 
Exercisers  
Difference in Mean 
Change between Groups  
P Value 
BM (kg) 6 
Herrero et al., (2006) -0.40 kg -1.10 kg -0.70 kg p = >0.05 
Irwin et al. (2009) 6 month 0.10 kg -0.55 kg -0.65 kg p = 0.39 
Irwin et al. (2009) 12 month 0.65 kg 0.39 kg -0.26 kg p = 0.61 
Rahnama et al. (2009) 1.43 kg -0.99 kg -2.42 kg p = 0.031 
Saarto et al. (2012) 0.15 kg 0.39 kg 0.24 kg p = 0.57 
Winters-Stone et al. (2011) 0.2 kg 0.90 kg 0.70 kg p = 0.55 
BMI (kg/m2) 2 
Irwin et al. (2009) 6 month 0.16 kg/m2 -0.12 kg/m2 -0.28 kg/m2 p = 0.42 
Rahnama et al. (2009) 0.56 kg/m2 -0.3 kg/m2 -0.86 kg/m2 p = 0.022 
Significant findings at the p =<0.05 level are highlighted in red
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There was BM outcome data for all six studies (Herrero et al., 2006; Irwin, 
Alvarez-Reeves, et al., 2009 [6 month & 12 month]; Rahnama et al., 2010; 
Saarto et al., 2012; Winters-Stone et al., 2011) (Table 13; Fig. 6).  
In five out of the six included studies controls experienced mean gains in BM of 
0.10kg (Irwin, Alvarez-Reeves, et al., 2009 [6 month]); 0.65kg (Irwin, Alvarez-
Reeves, et al., 2009 [12 month]); 1.43kg (Rahnama et al., 2010); 0.15kg 
(Saarto et al., 2012) and 0.20kg (Winters-Stone et al., 2011); a mean loss in BM 
of 0.40kg was reported in one study (Herrero et al., 2006) (Table 13).  In three 
studies exercisers experienced mean losses in BM of -1.1kg (Herrero et al., 
2006); -0.55kg (Irwin, Alvarez-Reeves, et al., 2009 [6 month]) and -0.99kg 
(Rahnama et al., 2010).  In the remaining three studies exercisers experienced 
mean gains in BM of 0.39kg (Irwin, Alvarez-Reeves, et al., 2009 [12 month]), 
0.39kg (Saarto et al., 2012) and 0.90kg (Winters-Stone et al., 2011) (Table 13).  
In four out of the six included studies exercisers either lost more BM, or did not 
gain as much BM, as controls with differences in mean change in BM between 
exercisers and controls of -0.70kg (Herrero et al., 2006); -0.65kg (Irwin, Alvarez-
Reeves, et al., 2009 [6 month]); -0.26kg (Irwin, Alvarez-Reeves, et al., 2009 [12 
month]) and -2.42kg (p=0.031) (Rahnama et al., 2010) (Table 13; Fig. 6).  In the 
remaining two studies exercisers experienced greater increases in BM than 
controls, with differences in mean change in BM between exercisers and 
controls of 0.24kg (Saarto et al., 2012) and 0.70kg (Winters-Stone et al., 2011) 
(Table 13; Fig. 6).   In one study exercise had a statistically significant beneficial 
effect on the BM of postmenopausal BCSs (Rahnama et al., 2010). 
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Figure 6 
Difference in the mean change in BM (kg) between postmenopausal BCSs 
assigned to exercise and control conditions 
 
There was BMI outcome data for two studies (Irwin, Alvarez-Reeves, et al., 
2009 [6 month]; Rahnama et al., 2010) (Table 13; Fig. 7).  Irwin, Alvarez-
Reeves, et al. (2009) [6 month] reported that controls increased their BMI by 
0.16kg/m2 whilst exercisers decreased their BMI by 0.12kg/m2.   Rahnama et al. 
(2010) reported that controls increased their BMI by 0.56kg/m2 whilst exercisers 
decreased their BMI by 0.30kg/m2. The differences in mean change in BMI 
between exercisers and controls were -0.28kg/m2  (Irwin, Alvarez-Reeves, et al., 
2009 [6 month]) and -0.86kg/m2 (p=0.022) (Rahnama et al., 2010) (Table 13; 
Fig. 7). 
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Figure 7 
Difference in the mean change in BMI (kg/m2) between postmenopausal 
BCSs  assigned to exercise and control conditions 
 
4.5.  WC, LBM, FM and BF% outcomes  
The main effects of exercise on the WC, LBM, FM and BF% of postmenopausal 
BCSs are presented in Table 14.  
WC outcome data was available for two studies (Irwin, Alvarez-Reeves, et al., 
2009 [6 month]; Rahnama et al., 2010) (Table 14; Fig. 8).  Among controls 
Irwin, Alvarez-Reeves, et al. (2009) [6 month] reported a mean reduction of -
0.84cm and Rahnama et al. (2010) reported no mean change in WC.  Among 
exercisers both Irwin, Alvarez-Reeves, et al. (2009) [6 month] and Rahnama et 
al. (2010) reported mean reductions in WC of -1.38cm and -3.0cm respectively. 
The differences in the mean change in WC between exercisers and controls 
were -0.54cm (Irwin, Alvarez-Reeves, et al., 2009 [6 month]) and -3.0cm 
(Rahnama et al., 2010) (Table 14; Fig 8). None of the WC findings were 
statistically significant. 
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Table 14 
 
Summary of the effects of exercise on the WC, LBM, FM, and BF% of postmenopausal BCSs 
 
Outcome No of Studies Study 
Method of Body 
Composition 
Assessment 
Mean Change 
Controls 
Mean Change 
Exercisers 
Difference in Mean 
Change between 
Groups 
P Value 
WC 
(cm) 2 
Irwin et al. (2009) 6 month Tape Measure -0.84 cm -1.38 cm -0.54 cm p=0.57 
Rahnama et al. (2009) Tape Measure 0.00 cm -3.00 cm -3.00 cm na 
LBM  
(kg) 
Muscle Mass 
5 
Herrero et al., (2006) 3 site SKF* -0.30 kg 0.70 kg 1.00 kg p=<0.05 
LBM Irwin et al. (2009) 6 month DEXA -0.35 kg 0.34 kg 0.69 kg p=0.047 
LBM Irwin et al. (2009) 12 month DEXA -0.09 kg 0.70 kg 0.79 kg p=0.25 
LBM Saarto et al. (2012) DEXA 0.01 kg 0.34 kg 0.33 kg p=0.13 
Bone free 
LBM Winters-Stone et al. (2011) DEXA 0.50 kg 0.60 kg 0.10 kg p = 0.91 
FM 
(kg) 3 
Herrero et al., (2006) 3 site SKF** 0.00 kg -1.70 kg -1.70 kg p = >0.05 
Saarto et al. (2012) DEXA 0.50 kg 0.48 kg -0.02 kg p = 0.95 
Winters-Stone et al. (2011) DEXA 0.00 kg 0.50 kg 0.50 kg p = 0.50 
BF% 
(%) 4 
Herrero et al., (2006) 3 site SKF** 0.00 % -2.00 % -2.00 % p=<0.05 
Irwin et al. (2009) 6 month DEXA 0.42 % -0.79 % -1.21 % p=0.0022 
Irwin et al. (2009) 12 month DEXA -0.03 % -1.19 % -1.16 % p = 0.043 
Winters-Stone et al. (2011) DEXA -0.20 % 0.00 % 0.20 % p = 0.51 
Significant findings at the p = <0.05 level are highlighted in red 
* using anthropometrical data and the equations of Lee et al. (2000); ** using the equations of Jackson and Pollock (1985) 
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Figure 8 
Difference in the mean change in WC (cm) between postmenopausal 
BCSs assigned to exercise and control conditions 
 
LBM outcome data was available for five studies (Table 14; Fig. 9). In three 
studies controls experienced mean losses in LBM of; -0.30 (Herrero et al., 
2006); -0.35kg (Irwin, Alvarez-Reeves, et al., 2009) [6 month] and -0.09 (Irwin, 
Alvarez-Reeves, et al., 2009) [12 month].  In two studies controls experienced 
mean gains in LBM of; 0.01kg (Saarto et al., 2012) and 0.50kg (Winters-Stone 
et al., 2011). In all five studies exercisers experienced mean gains in LBM of; 
0.70kg (Herrero et al., 2006); 0.34kg (Irwin, Alvarez-Reeves, et al., 2009) [6 
month]; 0.70kg (Irwin, Alvarez-Reeves, et al., 2009) [12 month]; 0.34kg (Saarto 
et al., 2012) and 0.60kg (Winters-Stone et al., 2011) (Table 14).  The difference 
in mean change in LBM between exercisers and controls favoured exercisers in 
all five studies; 1.00kg (Herrero et al., 2006); 0.69kg (Irwin, Alvarez-Reeves, et 
al., 2009 [6 month]); 0.79kg (Irwin, Alvarez-Reeves, et al., 2009 [12 month]); 
0.33kg (Saarto et al., 2012) and 0.10kg (Winters-Stone et al., 2011) (Table 14; 
Fig. 9).  In two studies exercise had a statistically significant beneficial effect on 
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the LBM of postmenopausal BCSs of 1.0kg (p=<0.05) and 0.69kg (p=0.047) 
respectively (Herrero et al., 2006; Irwin, Alvarez-Reeves, et al., 2009 [6 month]). 
 
 
Figure 9 
Difference in the mean change in LBM (kg) between postmenopausal 
BCSs assigned to exercise and control conditions 
 
FM outcome data was available for three studies (Herrero et al., 2006; Saarto et 
al., 2012; Winters-Stone et al., 2011) (Table 16; Fig. 10). Controls either 
experienced no mean change in FM, (Herrero et al., 2006; Winters-Stone et al., 
2011) or a mean gain of 0.50kg (Saarto et al., 2012). Among exercisers one 
study reported a mean reduction in FM of -1.70kg (Herrero et al., 2006) and two 
studies reported mean FM gains of 0.48kg (Saarto et al., 2012) and 0.50kg 
(Winters-Stone et al., 2011).  The differences in mean change in FM between 
exercisers and controls were -1.7kg (Herrero et al., 2006); -0.02kg (Saarto et 
al., 2012) and 0.50kg (Winters-Stone et al., 2011) (Table 14; Fig. 10).  None of 
the FM findings were statistically significant.  
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Figure 10 
Difference in the mean change in FM (kg) between postmenopausal BCSs 
assigned to exercise and control conditions 
 
BF% outcome data was available for four studies (Herrero et al., 2006; Irwin, 
Alvarez-Reeves, et al., 2009 [6 & 12 month]; Winters-Stone et al., 2011) (Table 
14; Fig. 11). Among controls; Irwin, Alvarez-Reeves, et al. (2009) [6 month] 
reported a mean increase in BF% of 0.42%; Herrero et al. (2006) reported no 
mean change in BF% and Irwin, Alvarez-Reeves, et al. (2009) [12 month] and 
Winters-Stone et al. (2011) reported small mean reductions in BF% of -0.03% 
and -0.20% respectively.  Among exercisers Herrero et al. (2006) and Irwin, 
Alvarez-Reeves, et al. (2009) [6 & 12 month] reported mean reductions in BF% 
of -2.00%; 0.79% and -1.19% respectively, and Winters-Stone et al. (2011) 
reported no mean change in BF% (Table 16).  The differences in the mean 
change in BF% between exercisers and controls were -2.00% (p=<0.05) 
(Herrero et al., 2006), -1.21% (p=0.0022) (Irwin, Alvarez-Reeves, et al., 2009 [6 
month]); -1.16% (p=0.043) (Irwin, Alvarez-Reeves, et al., 2009 [12 month]) and 
0.20% (Winters-Stone et al., 2011) (Table 14; Fig 11). Three out of four studies 
reported that exercise had a statistically significant beneficial effect on the BF% 
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of postmenopausal BCSs (Herrero et al., 2006; Irwin, Alvarez-Reeves, et al., 
2009 [6 & 12 month]) (Table 14; Fig 11). 
 
Figure 11 
Difference in the mean change in BF% between postmenopausal BCSs 
assigned to exercise and control conditions 
 
4.6. BMC and BMD Outcomes  
The main effects of exercise on the BMC and BMD of postmenopausal BCSs 
are presented in Table 15.  
BMC outcome data was available for three studies (Irwin, Alvarez-Reeves, et 
al., 2009 [6 & 12 month]; Saarto et al., 2012) (Table 15; Fig. 12).  Among 
controls Irwin, Alvarez-Reeves, et al. (2009) [12 month] and Saarto et al. (2012) 
reported mean reductions in BMC of -66g/cm and -49g/cm respectively; whilst 
Irwin, Alvarez-Reeves, et al. (2009) [6 month] reported a mean increase of 
2g/cm. Among exercisers Irwin, Alvarez-Reeves, et al. (2009) [6 month] and 
Saarto et al. (2012) reported mean reductions in BMC of -44g/cm and -60g/cm 
respectively; whilst Irwin, Alvarez-Reeves, et al. (2009) [12 month] reported a 
mean increase of 2g/cm (Table 15).   
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Table 15 
Summary of the main effects of exercise on the BMC and BMD of postmenopausal BCSs 
Outcome Specific Site No of Studies Study 
Method of Body 
Composition 
Assessment 
Mean 
Change 
Controls 
Mean 
Change 
Exercisers 
Difference in 
Mean 
Change 
between 
Groups 
P Value 
BMC 
(g/cm) 
Total 3 
Irwin et al. (2009) 6 month DEXA 2 -44 -46 p = 0.062 
Irwin et al. (2009) 12 month DEXA -66 2 68 p = 0.13 
  Saarto et al. (2012) DEXA -49 -60 -11 p = 0.25 
BMD 
(g/cm2) 
Total 
4 
Irwin et al. (2009) 6 month DEXA -0.008 -0.008 0.000 p = 0.97 
Total Irwin et al. (2009) 12 month DEXA -0.025 0.008 0.033 p = 0.043 
Lumbar Spine Sarrarto et al. (2012) DEXA -0.020 -0.016 0.004 p = 0.30 
Lumbar Spine (L1-L4) Winters-Stone et al. (2011) DEXA -0.022 0.004 0.026 p = <0.01 
Femoral Neck Saarto et al. (2012) DEXA -0.010 -0.010 0.000 p = 0.99 
Femoral Neck Winters-Stone et al. (2011) DEXA -0.015 -0.010 0.005 p = 0.27 
Greater Trochanter  Winters-Stone et al. (2011) DEXA -0.001 -0.003 -0.002 p = 0.15 
 Total Hip  Winters-Stone et al. (2011) DEXA -0.007 -0.003 0.004 p = 0.13 
Significant findings at the p =<0.05 level are highlighted in red
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The differences in the mean change in BMC between exercisers and controls 
were -46g/cm (Irwin, Alvarez-Reeves, et al., 2009 [6 month]), 68g/cm (Irwin, 
Alvarez-Reeves, et al., 2009 [12 month]) and -11g/cm (Saarto et al., 2012) 
(Table 15; Fig. 12). None of the BMC findings were statistically significant. 
 
 
Figure 12 
Difference in the mean change in BMC (g/cm) between postmenopausal 
BCSs assigned to exercise and control conditions 
 
Total BMD outcome data was available in two cases; both outcomes were from 
the same study (Irwin, Alvarez-Reeves, et al., 2009 [6 & 12 month]) (Table 15; 
Fig. 13). Among the 6 month subset, both exercisers and controls experienced 
a mean reduction in total BMD of -0.008g/cm2, therefore there was no mean 
difference in total BMD between exercisers and controls (Irwin, Alvarez-Reeves, 
et al., 2009 [6 month]).  Among the twelve month subset the mean change in 
total BMD of controls was -0.025g/cm2 and was 0.008g/cm2 among exercisers, 
therefore the mean difference in total BMD between exercisers and controls 
was 0.033g/cm2 (p=0.043).  In one study exercise had a statistically significant 
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beneficial effect on the total BMD of postmenopausal BCSs  (Irwin, Alvarez-
Reeves, et al., 2009 [12 month]) (Table 15; Fig. 13). 
 
Figure 13 
Difference in the mean change in BMD (g/cm2) between postmenopausal 
BCSs assigned to exercise and control conditions 
 
Lumbar spine BMD was an outcome in two studies (Saarto et al., 2012; 
Winters-Stone et al., 2011) (Table 15; Fig. 13).  Saarto et al. (2012) reported 
that control and exercise groups both experienced mean reductions in lumbar 
spine BMD of -0.020g/cm2 and -0.016g/cm2 respectively, therefore the 
difference in mean change between exercisers and controls was 0.004g/cm2. 
Among controls Winters-Stone et al. (2011) reported a mean reduction in 
lumbar spine BMD of -0.022g/cm2 and a mean gain of 0.004g/cm2 among 
exercisers; the difference in mean change between exercisers and controls was 
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0.026g/cm2 (p=<0.01) (Table 15; Fig. 13).  In one study exercise had a 
statistically significant beneficial effect on the lumbar spine BMD of 
postmenopausal BCSs (Winters-Stone et al., 2011). 
Femoral neck BMD was an outcome in two studies (Saarto et al., 2012; 
Winters-Stone et al., 2011) (Table 15; Fig. 13).  In both studies controls 
experienced mean reductions in femoral neck BMD of; -0.010g/cm2 (Saarto et 
al., 2012) and -0.015g/cm2 (Winters-Stone et al., 2011). Both exercise groups 
also experienced mean reductions in femoral neck BMD of; -0.010g/cm2 (Saarto 
et al., 2012) and -0.010g/cm2 (Winters-Stone et al., 2011).  Therefore the 
differences in mean change between exercisers and controls were 0.00g/cm2 
(Saarto et al., 2012) and 0.005g/cm2 (Winters-Stone et al., 2011) (Table 15; Fig. 
13). None of the femoral neck BMD findings were statistically significant. 
BMD outcome data was available for two additional sites from one study 
(Winters-Stone et al., 2011). Winters-Stone et al. (2011) reported that both 
controls and exercisers experienced mean reductions in greater trochanter 
BMD of -0.001g/cm2 and -0.003g/cm2 respectively; the loss was less 
pronounced among controls, and the difference in mean change in greater 
trochanter BMD between exercisers and controls was -0.002g/cm2 (Table 15; 
Fig. 13).  Both controls and exercisers also experienced mean reductions in 
total hip BMD of -0.007g/cm2 and -0.003g/cm2 respectively; the loss was less 
pronounced among exercisers and the difference in mean change in total hip 
BMD between exercisers and controls was 0.004g/cm2 (Winters-Stone et al., 
2011) (Table 15; Fig. 13).  The differences in greater trochanter BMD and total 
hip BMD between exercisers and controls were not statistically significant. 
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4.7. Risk of bias within studies 
The results of the assessment of the methodological quality and risk of bias for 
studies included in the review are presented in Table 16. 
 
Table 16 
Downs and Black Checklist (1998) subtotal and total percentage score for 
studies included in the systematic review 
 
Herrero et al., 
(2006) 
Irwin et al. 
(2009) 
Rahnama 
et al., 
(2009) 
Sarrto et 
al.,  
(2012) 
Winters-
Stone et al., 
(2011) 
Reporting 
Subtotal (%) 73% 91% 73% 91% 100% 
External Validity  
Subtotal (%) 33% 67% 67% 67% 33% 
Internal Validity (Bias)  
Subtotal (%) 86% 86% 71% 86% 74% 
Internal Validity 
(Selection Bias) 
Subtotal (%) 
83% 100% 50% 83% 100% 
Power  
Subtotal (%) 100% 100% 100% 100% 100% 
Total Score (%) 78% 91% 72% 88% 88% 
 
Downs and Black Checklist (1998) reporting subtotal percentage scores ranged 
from 73% to 100%; external validity subtotal percentage scores ranged from 
33% to 67%; internal validity (bias) subtotal percentage scores ranged from 
71% to 86% and internal validity (section bias) subtotal percentage scores 
ranged from 50% to 100% (Table 16).  All studies scored the maximum 
available on the Downs and Black Checklist (1998) power subtotal with 
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percentage scores of 100% (Table 16).  The total methodological quality of 
individual studies was high; with Downs and Black Checklist (1998) total 
percentage scores of 78% (Herrero et al., 2006), 91% (Irwin, Alvarez-Reeves, 
et al., 2009); 72% (Rahnama et al., 2010); 88% (Saarto et al., 2012) and 88% 
(Winters-Stone et al., 2011) (Table 16).  
The study of Irwin, Alvarez-Reeves, et al. (2009) obtained the highest overall 
score; and scored highest or equal highest in all of the subtotal areas. The 
study of Rahnama et al. (2010) obtained the lowest overall score; and scored 
lowest or equal lowest in all of the subtotal areas (Table 16). 
 
4.8. Risk of bias across studies: language bias 
The search strategy returned a total of 226 non-English language records, of 
those 14 met the initial eligibility criteria.  Although it was not possible to assess 
non-English language records against the full eligibility criteria, as full text 
articles were not available in the English language, in order to assist future 
researchers a list of non-English language studies meeting the initial eligibility 
criteria is attached in Appendix 20.   
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5.0. Discussion 
5.1. Characteristics of the participants included in the final review 
The total number of postmenopausal BCSs exposed to exercise interventions 
and included in this review was 278; after accounting for attrition this fell to 245. 
The attrition rates of individual studies were generally acceptable, and attrition 
was equally distributed amongst exercisers and controls (Table 11). This 
suggests that postmenopausal BCSs found exercise participation acceptable.  
However Winters-Stone et al. (2011) reported high attrition rates among 
controls and exercisers of 42.6% and 30.8% respectively (Table 11).  Similar 
reasons for attrition were given by controls and exercisers, and the primary 
reason was that participants were “too busy”.  As only four participants stated 
that attrition was due to “poor health” it is unlikely that worsening health 
confounded the results in this study (Winters-Stone et al., 2011). 
Past research that has included older, overweight and obese postmenopausal 
BCSs, has been limited (Visovsky, 2006). The inclusion of older, overweight 
and obese postmenopausal BCSs (mean age range 50 to 62 years; mean BMI 
range 24.0kg/m2 to 30.6kg/m2; Table 11) is a strength this review.  However, 
postmenopausal BCSs with stage 4 breast cancer were not included and 
research amongst postmenopausal BCSs with higher disease stages is lacking 
(Table 11).  Only Irwin, Alvarez-Reeves, et al. (2009)  reported the ethnicity of 
the participants; and 84% of BCSs were Non-Hispanic White. In the future 
researchers should report ethnicity, and include BCSs from more diverse ethnic 
backgrounds and with higher disease stages. 
The relatively low number of participants included in this review means that 
external validity may have been compromised, and the generalisation of 
73 
 
findings to the entire postmenopausal BCS population may be limited. In the 
future researchers should seek to increase the total number of postmenopausal 
BCSs recruited into exercise intervention studies. This would allow results to be 
stratified in relation to key confounders such as age, ethnicity, baseline BMI, 
breast cancer disease stage and type of treatment without statistical power 
being compromised. 
 
5.2. Characteristics of the exercise interventions included in the final 
review 
All of the exercise interventions included in this review were conducted after the 
completion of primary treatment (Table 12).  As Del Rio et al. (2002) and 
Genton et al. (2006) reported that BM gain can occur during treatment, studies 
that examine the effect of exercise during treatment are warranted. 
A variety of different types of exercise were included in this review; including 
aerobic exercise (Irwin, Alvarez-Reeves, et al., 2009 [6 & 12 month]; Saarto et 
al., 2012), resistance exercise (Winters-Stone et al., 2011) and aerobic and 
resistance exercise in combination (Herrero et al., 2006; Rahnama et al., 2010).  
Activities included walking, circuit training, cycling, step aerobics, weight lifting 
with fixed and free weights and impact jumping (Table 12).  Herrero et al. 
(2006); Irwin, Alvarez-Reeves, et al. (2009) [6 & 12 month]; Saarto et al. (2012) 
and Winters-Stone et al. (2011) all specifically reported that that no adverse 
events occurred in response to exercise; Rahnama et al. (2010) did not report 
this information.   It therefore appears that a wide variety of exercises can be 
performed safely by older, overweight and obese postmenopausal BCSs.  This 
review adds to the growing body of evidence which indicates that exercise can 
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be performed safely by cancer survivors  (A. Campbell et al., 2011; Hayes et 
al., 2009; Macmillan Cancer Support, 2012; Schmitz et al., 2010). 
Irwin, Alvarez-Reeves, et al. (2009) [6 &12 month] and Winters-Stone et al. 
(2011) both reported that EI did not change from baseline over the course of the 
exercise interventions, either among controls or exercisers.  This suggests any 
beneficial effects on BM and body composition reported by these studies were 
likely to be due to increased EE from exercise, rather than dietary reductions in 
EI.  However Herrero et al. (2006) Rahnama et al. (2010) and Saarto et al. 
(2012) did not report EI; therefore it was not possible to determine if any 
beneficial BM and body composition changes were due to increased in EE from 
exercise, or due to dietary reductions in EI.  To enable the causes of BM and 
body composition change to be elucidated future researchers should include a 
measure of EI. 
 A strength of this review was the use of a HQTS Tool to determine study 
eligibility (Appendix 13) (Markes, 2010). As a result only exercise interventions 
with frequencies, intensities, times and total durations that were likely to induce 
beneficial BM and body composition adaptations were included in the final 
review (Table 12).  However in order to be effective an exercise intervention 
must be adhered to.    
Total exercise adherence was generally acceptable, and Herrero et al. (2006) 
reported a mean exercise adherence of 91% (Table 12).  However the study of 
Winters-Stone et al. (2011) was a notable exception, and a mean exercise 
adherence of 57% (supervised=76%; unsupervised=26%) was reported (Table 
12). The low adherence in the Winters-Stone et al. (2011) study may have been 
due to; the long total exercise duration, the university setting or the use of free 
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weights and impact jumping; these characteristics may have been off-putting or 
unappealing to postmenopausal BCSs.  In contrast Saarto et al. (2012) reported 
an unsupervised exercise adherence of 107%; the figure of 107% is valid, as 
according to exercise logs BCSs performed an average of 3.2 unsupervised 
exercise sessions a week, this was in excess of the prescribed 3 sessions a 
week, therefore exercise adherence was in excess of 100%.  It is possible that 
these postmenopausal BCSs were highly motivated to exercise, however it is 
more likely that over-estimates of self-reported PA were responsible. Irwin, 
Alvarez-Reeves, et al. (2009) reported a mean exercise adherence of 73%; 
however postmenopausal BCSs with the greatest exercise adherence achieved 
the greatest beneficial body composition changes.   
The importance of exercise adherence cannot be overstated, as in order for the 
potential benefits of exercise to be imparted to postmenopausal BCSs, exercise 
must actually be performed and maintained.  Two recent studies have indicated 
that CBT, and brief regular contact in the form of newsletters and telephone 
counselling, can increase adherence to a healthy lifestyle and result in 
beneficial body composition changes among; older, overweight and obese 
cancer survivors (Demark-Wahnefried et al., 2012); and overweight BCSs 
(Mefferd, Nichols, Pakiz, & Rock, 2007).  A research protocol with the aim of 
improving exercise adherence in cancer survivors has recently been published 
(Rogers et al., 2012).  This is an area of research which demands further study. 
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5.3. Methods of body composition assessment included in the final 
review 
DEXA is considered a valid and reliable method of body composition 
assessment (Heyward & Wagner, 2004, pp. 40-44).  Therefore the fact that 
Irwin, Alvarez-Reeves, et al. (2009)  [6 & 12 month], Saarto et al. (2012) and 
Winters-Stone et al. (2011) used DEXA as the primary method of body 
composition assessment is a strength of this review (Table 14).   Mefferd et al. 
(2007) reported that, among a small sample of 76 BCSs (84% 
postmenopausal), WC and BMI were strongly related to BF% measured by 
DEXA (WC; r=0.579; p=<0.01; BMI; r=0.596; p=<0.01) and to trunk fat 
measured by DEXA (WC; r=0.86, p=<0.01; BMI; r=0.82, p=<0.01).  However 
Irwin, Alvarez-Reeves, et al. (2009) [6 month] reported that significant increases 
in LBM and BF% occurred in postmenopausal BCSs, without any significant 
change in BMI or WC (Tables 13 & 14).  Therefore the use of combined BMI 
and WC measurements may overlook important body composition changes in 
postmenopausal BCSs, who may experience atypical sarcopenic BM gain.  
Battaglini et al. (2011) and Freedman et al. (2004) have reported that common 
methods of body composition assessment may not be valid in BCS populations. 
And due to the expense and lack of accessibility DEXA can only feasibly be 
used for research purposes, and is unsuitable for use with larger sample sizes 
(Heyward & Wagner, 2004, pp. 40-44).  Therefore there is a need to develop 
simple, inexpensive methods of body composition assessment that are 
validated in the specific postmenopausal BCS population. This would enable 
body composition to be monitored in community health and fitness settings, and 
enable larger sample sizes to be used in research. 
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5.4. The effects of exercise on the BM and BMI of postmenopausal 
BCSs 
Both Irwin, Alvarez-Reeves, et al. (2009) [6 month] and Rahnama et al. (2010) 
found that exercise had a favourable effect on the BMI of postmenopausal 
BCSs (Table 13; Fig. 7). The findings from four out of the six included studies 
indicated exercise had a favourable effect on the BM of postmenopausal BCSs 
(Herrero et al., 2006; Irwin, Alvarez-Reeves, et al., 2009 [6 & 12 month]; 
Rahnama et al., 2010); the remaining two studies favoured control conditions 
(Saarto et al., 2012; Winters-Stone et al., 2011) (Table 13; Fig. 6).  However, 
the two studies that favoured control conditions had methodological flaws.  The 
study of Winters-Stone et al. (2011) had poor exercise adherence; therefore the 
stimulus provided by exercise may not have been sufficient to reduce BM.  The 
control group in the Saarto et al. (2012) study spontaneously increased their 
PA, therefore any beneficial effect of exercise may have been obscured.  These 
methodological flaws may have influenced other body composition outcomes 
from these two studies and this should be considered when analysing other 
results.  
Apart from the study of Rahnama et al. (2010), no other included study found 
any statistically significant effect of exercise on the BM or BMI of 
postmenopausal BCSs. In all other studies, the differences in mean change in 
BM between exercisers and controls were less than 1kg, and were therefore 
unlikely to be clinically important (Table 13; Fig. 6).  Rahnama et al. (2010) 
reported statistically significant differences in mean change in BM and BMI 
between exercisers and controls of -2.42kg (p=0.031) and -0.86kg/m2 (p=0.022) 
respectively (Table 13; Figs. 6 & 7).  However, a mean difference of <1.0 BMI 
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point is unlikely to result in a reclassification of BMI status, therefore although 
these differences may be statistically significant they are unlikely to be clinically 
significant.  Especially as of the -0.86kg/m2 difference in mean change in BMI 
between exercisers and controls reported by Rahnama et al. (2010), 0.56kg/m2 
was attributed to a mean gain among controls, and -0.30kg/m2 was attributed to 
a mean loss among exercisers (Table 13).  Herrero et al. (2006) reported that 
exercising postmenopausal BCSs lost a mean BM of -1.1kg, this was the 
greatest mean BM loss among exercisers of any of the included studies; 
however as controls lost a mean of -0.40kg, the difference in mean change in 
BM between exercisers and controls was -0.70kg (Table 13; Fig. 6).   
The two studies that reported the greatest beneficial effects of exercise on BM 
were the only two studies included in this review to prescribe a combination of 
aerobic and resistance exercise (Herrero et al., 2006; Rahnama et al., 2010) 
(Tables 12 & 13; Fig. 6).  These two studies also had the shortest total exercise 
durations; of 8 weeks (Herrero et al., 2006) and 15 weeks (Rahnama et al., 
2010) as opposed to the 26 or 52 week durations of the remaining studies 
(Irwin, Alvarez-Reeves, et al., 2009 [6 & 12 month]; Saarto et al., 2012; Winters-
Stone et al., 2011).  If the BM reductions that occurred in response to combined 
aerobic and resistance exercise continued at the same rate, and if exercise 
adherence could be maintained, increased total exercise durations of this type 
of exercise may have the potential to produce clinically significant reductions in 
the BM and BMI of postmenopausal BCSs. 
Only the study of Rahnama et al. (2010) demonstrated a statistically significant 
effect of exercise on BM and BMI.  However this study had the greatest risk of 
bias of all the studies included in this review; and had the lowest; internal 
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validity-bias (71%), internal validity-selection bias (50%) and total 
methodological quality (72%) scores (Table 16).  Therefore the findings from 
the Rahnama et al. (2010) study were the most likely, out of all the included 
studies, to be subject to an exaggerated treatment effect.  However, the 
statistically significant effect of exercise on BM and BMI reported by Rahnama 
et al. (2010) may have been related to a particular characteristic of the exercise 
intervention used.  For example, Rahnama et al. (2010) required that all 
exercise sessions be supervised; it is possible that this supervision resulted in 
higher adherence and greater effort during exercise among postmenopausal 
BCSs. 
The findings from this review indicate that some exercise prescriptions have the 
potential to attenuate BM gain and induce small reductions in the BM of 
postmenopausal BCSs, during the recovery and survivorship stages of the 
breast cancer experience.  Further research utilising combined aerobic and 
resistance exercise over longer total exercise durations is warranted. 
 
5.5. The effects of exercise on the WC of postmenopausal BCSs 
Both Irwin, Alvarez-Reeves, et al. (2009) [6 month] and Rahnama et al. (2010) 
found that exercise had a favourable effect on the WC of postmenopausal 
BCSs  (Table 14; Fig. 8).  At baseline, the mean WC of the exercise groups 
were  91.13cm  (Irwin, Alvarez-Reeves, et al., 2009 [6 month]) and 99.0cm 
(Rahnama et al., 2010) (Table 14). These mean WC were >88cm, meaning a 
significant number of participants were at a significantly increased risk of 
obesity related diseases (National Institute for Health and Clinical Excellence, 
2006; World Health Organisation, 2004).  After 26 weeks of aerobic exercise 
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Irwin, Alvarez-Reeves, et al. (2009) reported a mean reduction in WC of -
1.38cm to 89.75cm (Table 14).  After 15 weeks of aerobic and resistance 
exercise Rahnama et al. (2010) reported a mean reduction in WC of -3.0cm to 
96.0cm (Table 14). The findings of Rahnama et al. (2010) are in agreement with 
those of Cheema and Gaul (2006) who reported a mean reduction in WC of 
2.8cm among a largely postmenopausal sample of BCSs after eight weeks of 
combined aerobic and resistance exercise.   
From the limited studies available, it appears that if combined aerobic and 
resistance exercise were to be maintained over the longer term, and if 
reductions in WC were maintained at the same rate, this type of exercise has 
the potential to result in the reclassification of the risk of obesity related 
diseases.  For example, if the postmenopausal BCSs in the Rahnama et al. 
(2010) study continued to exercise for a further 45 weeks, mean WC could be 
reduced by a further 9cm to 87cm; thus a significant number of participants 
could significantly reduce their risk of obesity related diseases.  However this is 
only a theoretical assumption, and only further research where the total duration 
of the exercise period was extended, would reveal if this were actually the case.   
 
 5.6. The effects of exercise on the LBM, FM and BF% of 
postmenopausal BCSs 
LBM was an outcome in five studies; all these studies found exercise had a 
favourable effect on the LBM of postmenopausal BCSs (Table 14; Fig. 9). The 
findings from three studies indicated that exercisers gained LBM, whilst controls 
lost LBM (Herrero et al., 2006; Irwin, Alvarez-Reeves, et al., 2009 [6 & 12 
month]). Herrero et al. (2006) and Irwin, Alvarez-Reeves, et al. (2009) reported 
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statistically significant beneficial effects of exercise on the LBM of 
postmenopausal BCSs; with differences in mean change in LBM between 
exercisers and controls of 1.0kg (p=<0.05) and 0.69kg (p=0.047) respectively 
(Table 14; Fig. 9).   
The findings of Herrero et al. (2006) and Irwin, Alvarez-Reeves, et al. (2009) [6 
month] are encouraging; as exercise resulted in mean LBM gains, even in the 
face of mean reductions in BM (Tables 13 & 14; Figs. 6 & 9).  These findings 
suggest that exercise was able to counteract the sarcopenic BM gain that some 
postmenopausal BCSs experience during the treatment and recovery stages of 
the BCS experience.   However, it is important to note that Herrero et al. (2006) 
measured muscle mass (which excludes bone mass) and Irwin, Alvarez-
Reeves, et al. (2009) [6 month] measured LBM (which includes bone mass) 
therefore these findings are not directly comparable (Table 14). 
FM was an outcome in three studies; the findings from two of these studies 
indicated that exercise had a favourable effect on the FM of postmenopausal 
BCSs (Table 14; Fig. 10).  Herrero et al. (2006) reported a mean reduction in 
FM among exercisers of 1.70kg and no change in FM among controls. Saarto 
et al. (2012) reported a minimal difference in mean FM change of 0.02kg in the 
favour of exercisers.  Winters-Stone et al. (2011) reported that control 
conditions were favoured, as exercisers gained 0.50kg of FM whereas controls 
experienced no mean change in FM (Table 14; Fig. 10).   Exercisers in the 
Winters-Stone et al. (2011) study also gained BM and LBM (Tables 13 & 14); 
suggesting that the BM gains of these postmenopausal BCSs were of the type 
typically seen in healthy women, as opposed to the sarcopeinc BM gains that 
have been observed among some BCSs.  
82 
 
BF% was an outcome in four included studies (Table 14; Fig.11). Winters-Stone 
et al. (2011) reported that control conditions were favoured, as the BF% of 
exercisers remained stable, whilst controls lost a mean BF% of 0.20% (Table 
14; Fig. 11). Herrero et al. (2006) and Irwin, Alvarez-Reeves, et al. (2009) [6 & 
12 month] all reported a statistically significant favourable effect of exercise on 
the BF% of postmenopausal BCSs (Table 14; Fig 11).  The greatest reduction 
in BF% was reported by Herrero et al. (2006), who reported that exercisers 
experienced a mean reduction in BF% of -2.0%, whilst no mean change in BF% 
was observed among controls (p=<0.05) (Table 14; Fig 11).   
The findings of Irwin, Alvarez-Reeves, et al. (2009) [6 and 12 month] suggest 
that performing aerobic exercise over a longer total exercise duration may result 
in greater body composition benefits among postmenopausal BCSs.  Compared 
to BCSs who exercised for 6 months, BCSs who exercised for 12 months 
experienced greater mean increases in LBM (0.34kg vs. 0.70kg), and greater 
mean reductions in BF% (-0.79% vs. -1.19%) (Table 14; Figs. 9 & 11). 
Herrero et al. (2006) and Irwin, Alvarez-Reeves, et al. (2009) [6 and 12 month] 
reported a statistically significant beneficial effect of exercise on the LBM and 
BF% of postmenopausal BCSs; despite not reporting any statistically significant 
effect of exercise on BM or BMI (Tables 13 & 14).  These findings are in 
agreement with those of Cheema and Gaul (2006), Courneya et al. (2003) and 
Matthews et al. (2007).  Both Courneya et al. (2003) and Cheema and Gaul 
(2006) reported mean reductions in the sum of SKFs, with no mean change in 
BM or BMI, among exercising postmenopausal BCSs. Matthews et al. (2007) 
reported that after 12 weeks of a counselling intervention, designed to promote 
walking among postmenopausal BCSs, there was no significant change in 
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mean BM; however there was a trend towards increased LBM and reduced FM 
and BF% among exercising postmenopausal BCSs.  
The findings of this review suggest that exercise can induce beneficial changes 
in the LBM, FM and BF% of postmenopausal BCSs, independent of any change 
in BM or BMI.  This is in agreement with previous reviews of BCS populations 
with mixed menopausal statuses (Cheema et al., 2008; Ingram et al., 2006; Kim 
et al., 2009; Stevinson et al., 2004; White et al., 2009). 
 
5.7. The effects of exercise on the BMC and BMD of postmenopausal 
BCSs 
Findings from the studies included in this review show a mixed effect of 
exercise on the BMC and BMD of postmenopausal BCSs.  BMC was an 
outcome in three studies.  One study favoured exercise (Irwin, Alvarez-Reeves, 
et al., 2009 [12 month]) and in two studies exercise had an adverse effect on 
the BMC of postmenopausal BCSs (Irwin, Alvarez-Reeves, et al., 2009 [6 
month]; Saarto et al., 2012) (Table 15; Fig. 12).   
Eight BMD outcomes were reported across four studies.  Five outcomes across 
three studies favoured exercise (Irwin, Alvarez-Reeves, et al., 2009 [6 month]; 
Saarto et al., 2012; Winters-Stone et al., 2011), two outcomes from two studies 
favoured neither exercise or control conditions (Irwin, Alvarez-Reeves, et al., 
2009 [6 month]; Saarto et al., 2012), and one outcome (greater trochanter 
BMD) from the Winters-Stone et al. (2011) study favoured control conditions 
(Table 15; Fig. 13).  
Winters-Stone et al. (2011) reported that 12 months of resistance exercise 
resulted in a statistically significant beneficial effect on the lumbar spine BMD of 
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postmenopausal BCSs; with a mean increase of 0.004g/cm2 among exercisers, 
and a mean reduction of -0.022g/cm2 among controls (mean difference of 
0.005gcm2; p=<0.01) (Table 17; Fig. 12).  Irwin, Alvarez-Reeves, et al. (2009) [6 
month] reported that 6 months of aerobic exercise had no effect on total BMD, 
with both exercisers and controls losing -0.008g/cm2.  However, 12 months of 
aerobic exercise resulted in a statistically significant beneficial effect; exercising 
postmenopausal BCSs gained 0.008g/cm2 of total BMD, whereas controls lost      
-0.025g/cm2 of total BMD (mean difference of 0.033 g/cm2; p=0.043; Table 17; 
Fig. 12) (Irwin, Alvarez-Reeves, et al., 2009 [12 month]). A similar trend was 
observed for BMC (Irwin, Alvarez-Reeves, et al., 2009).  These findings 
demonstrate the importance of the maintenance of weight bearing exercise 
throughout the recovery stage of the breast cancer experience.  
Postmenopausal BCSs who walk five times a week, for 30min, may need to 
maintain this exercise regime for longer than 6 months, in order to achieve 
improvements in total BMC and BMD.  
It has been reported that a 1 to 2% increase in BMD translates to a 7 to 14% 
decrease in fracture risk (Wasnich & Miller, 2000).  Irwin, Alvarez-Reeves, et al. 
(2009) [12 month] reported a mean percentage increase in total BMD of 0.2% 
among exercisers, and a mean percentage reduction of 1.7% among controls. 
Similarly Winters-Stone et al. (2011) reported a mean percentage increase in 
lumbar spine BMD of 0.41% among exercisers, and a mean percentage 
reduction of -1.27% among controls.  Although these exercising 
postmenopausal BCSs did not increase their BMD in a clinically significant way, 
they were able to maintain BMD, whereas controls experienced clinically 
significant reductions in BMD.  It could be speculated that exercising 
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postmenopausal BCSs had a 7 to 14% reduced risk of fracture compared to 
non-exercising postmenopausal BCSs.  However longitudinal studies with long 
term follow-up are required to determine if this is the case. 
No statistically significant effects of exercise were reported by Saarto et al. 
(2012) at the lumbar spine or femoral neck, or by Winters-Stone et al. (2011) at 
the total hip, greater trochanter or femoral neck (Table 15; Fig. 13).  The mixed 
findings between studies may be due to different responses to exercise at the 
different BMD measurement sites.  However it is possible that age acted as a 
significant confounder, as Winters-Stone, Leo, and Schwartz (2012) recently 
reported that age moderated the effect of exercise on BMD; with younger 
postmenopausal BCSs more likely to experience a positive net effect of 
exercise than older postmenopausal BCSs.  
The limited evidence available from this review suggests that exercise has the 
potential to prevent the losses in BMD, which may otherwise occur, in 
postmenopausal BCSs. However it is advisable that exercising postmenopausal 
BCSs have their BMD monitored at regular intervals. 
 
5.8. Moderating effect of bisphosphonates on the BMD of 
postmenopausal BCSs 
Bisphosphonates are often prescribed to increase BMD in postmenopausal 
BCSs; however they can have unpleasant side effects such as gastrointestinal 
disturbance (Irwin, Alvarez-Reeves, et al., 2009). Waltman et al. (2010) 
reported that bisphosphonates resulted in increases in BMD at the total hip 
(1.8%; p=<0.0001), lumbar spine (2.85%; p=<0.0001) and femoral neck (0.63%; 
p=0.14) in postmenopausal BCSs with bone loss.  Additional increases of 
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0.34% at the total hip, 0.23% at the lumbar spine and 0.29% at the femoral 
neck were reported among exercising postmenopausal BCSs who took 
bisphosphonates.  Therefore, it is possible that the use of bisphosphonates may 
be a confounding factor in exercise and BMD research among postmenopausal 
BCSs.  Future studies should seek to control for bisphosphonate use. 
Irwin, Alvarez-Reeves, et al. (2009) reported that 12 months of aerobic exercise 
resulted in statistically and clinically significant increases in total BMD; even 
among a postmenopausal BCS population with low levels of bisphosphonate 
use (13% of the exercise group and 3% of the control group). In this study, 
exercising postmenopausal BCSs were able to maintain BMD whilst reducing 
BM and FM (Irwin, Alvarez-Reeves, et al., 2009 [12 month]). This is significant, 
because the major source of oestrogens in postmenopausal women is from the 
aromatisation of androgens in adipose tissue (Key, Allen, et al., 2001).  
Reductions in FM may result in a greater reduction in oestrogens and, given the 
positive effect of oestrogen on BMD, a greater reduction in BMD.  However in 
the study of Irwin, Alvarez-Reeves, et al. (2009) [12 month]  aerobic exercise, in 
the form of walking, was able to negate this effect and BMD was maintained 
even though BM and FM were lost.  If these results were replicated in larger 
studies, it is possible that walking may prove to be an effective alternative to 
bisphosphonate use, and postmenopausal BCSs may be able to maintain BMD, 
and reduce their fracture risk, without the unpleasant side effects associated 
with bisphosphonates. 
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5.9. Moderating effect of AI use on the body composition of 
postmenopausal BCSs 
AIs are commonly prescribed as part of the treatment regime for oestrogen 
receptor positive postmenopausal breast cancers (Appendix 4).  However, AIs 
can reduce oestrogen to undetectable levels, and AIs have been associated 
with greater reductions in BMD, and an increased risk of fracture compared to 
AOs (Rizzoli et al., 2012).  Saarto et al. (2012) reported that among 
postmenopausal BCSs, mean bone losses at the femoral neck were; -1.8%, -
0.4% and -0.2% for those on AIs, AOs and no hormone therapy respectively.  
van Londen et al. (2011) recently reported that statistically significant greater 
increases in LBM were observed among AI users than non AI users;  whereas 
FM increased significantly among non AI users and remained stable among AI 
users.  It was speculated that these differences may be due to the significantly 
higher free testosterone levels, and significantly lower SHBG levels, that were 
observed among  BCSs who were AI users (van Londen et al., 2011). 
However Winters-Stone et al. (2011) reported that neither AI use, nor AO use 
had any moderating effect on FM or any measure of BMD among 
postmenopausal BCSs. In contrast, Irwin, Alvarez-Reeves, et al. (2009) [6 
month] reported that exercising postmenopausal BCSs who were taking AIs 
(n=10) maintained their BMD and BMC; whereas control postmenopausal BCSs 
who were taking AIs (n=15) experienced reductions in BMD and BMC. In 
addition, reductions in FM and increases in LBM were seen among exercising 
AI users, whereas FM was maintained and LBM was reduced among control AI 
users (Irwin, Alvarez-Reeves, et al., 2009 [6 month]).  These findings suggest 
that exercise can attenuate AI related bone loss, and result in additional 
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beneficial body composition changes among postmenopausal BCSs who are 
prescribed AIs.  However, caution must be taken when interpreting these 
findings, as statistical power may have been compromised, due to the small 
number of participants included in this stratified analysis (Irwin, Alvarez-Reeves, 
et al., 2009). 
Although it is possible that exercise can overcome the detrimental effect of AIs 
on BMD, it is not possible to draw conclusions from the limited studies 
available.  From the limited evidence, it is not possible to determine if AI use 
has a beneficial effect on the LBM and/or FM of postmenopausal BCS.  It is 
also not known if exercise has a synergistic effect, and functions with AIs, to 
induce greater beneficial effects on LBM and/or FM.  This is an area which 
requires further study, and future studies should include sufficient sample sizes 
to enable body composition outcomes to be stratified by type of hormone 
therapy use, without statistical power being compromised.   
 
5.10. Additional benefits of exercise: improvements in quality of life, 
survival and prognostic biomarkers among postmenopausal BCSs 
Aside from the effect of exercise on body composition; exercise may have 
additional health benefits for postmenopausal BSCs.  A recent review has 
confirmed that exercise can improve health related quality of life in BCSs 
(Mishra et al., 2012).  Another recent review has reported that there is fairly 
consistent evidence of an inverse association between post-diagnosis PA, and 
risk of breast-cancer-specific and all-cause mortality (Ballard-Barbash et al., 
2012). This association was not modified by menopausal status; suggesting 
that both premenopausal and postmenopausal BCSs can benefit from post-
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diagnosis exercise (Ballard-Barbash et al., 2012).  However, only one study has 
investigated the effect of exercise on survival among an exclusively 
postmenopausal sample of BCSs (Irwin et al., 2011).  In this longitudinal study, 
postmenopausal BCSs who undertook >150min a week of moderate intensity 
recreational PA, after diagnosis had lower breast-cancer-specific mortality (HR 
= 0.61; [95%CI 0.35-0.99]; p=0.049) and lower all-cause mortality (HR = 0.54; 
[95%CI 0.38-0.79]; p=<0.01).  The effect on all-cause mortality was observed 
even among those who were inactive prior to diagnosis; and BMI did not have 
any moderating effect on survival (Irwin et al., 2011). 
A number of different mechanisms have been proposed to explain the 
relationship between PA and survival following breast cancer (Courneya et al., 
2004). It is possible that PA and exercise exert a beneficial effect, via the 
reduction of circulating oestrogens.  Exercise has been shown to reduce 
circulating oestrogens in healthy postmenopausal women (Friedenreich et al., 
2010; McTiernan et al., 2004).  And some studies have demonstrated a 
stronger inverse relationship between PA and mortality in BCSs with oestrogen 
positive receptive tumours (Holmes, Chen, Feskanich, Kroenke, & Colditz, 
2005; Irwin et al., 2011; Irwin et al., 2008).     
Exercise may also exert its beneficial effect on survival among postmenopausal 
BCSs via reductions in important prognostic biomarkers, related to the insulin 
and inflammatory pathways. Irwin, McTiernan, Bernstein, et al. (2005) reported 
higher PA was associated with beneficial effects on the insulin pathway in both 
premenopausal and postmenopausal women. And Irwin, McTiernan, Bernstein, 
et al. (2005) and Pierce et al. (2009) reported that higher levels of PA were 
statistically significantly associated with lower circulating levels of C-reactive 
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protein (CRP) (a marker of inflammation); and that higher CRP levels were 
associated with higher BMI and greater WC.  In addition several RCTs among 
postmenopausal BCSs have demonstrated that exercise has beneficial effects 
on; the insulin pathway (Fairey et al., 2003; Irwin, Varma, et al., 2009), 
inflammation (Fairey, Courneya, Field, Bell, Jones, Martin, et al., 2005) and 
immune function (Fairey, Courneya, Field, Bell, Jones, & Mackey, 2005). 
Evidence from the limited number of studies available, suggests that higher 
levels of post-diagnosis exercise are associated with improvements in 
prognostic biomarkers and survival among postmenopausal BCSs.  In addition 
higher BMI and WC have been negatively associated with prognostic 
biomarkers.  However, studies investigating the effects of exercise related 
changes in BM or body composition on prognostic biomarkers and survival 
among postmenopausal BCSs have not been conducted. Therefore, it is not 
possible to determine if post-diagnosis exercise exerts its positive effects via a 
direct effect, indirectly via body composition changes, or via a combination of 
the two.  This is an area which warrants further study. 
 
5.11. Limitations: risk of bias associated with individual studies 
The Downs and Black Checklist (1998) reporting subtotal percentage scores of 
individual studies ranged from 73% to 100% (Table 16).  Therefore, it was likely 
that the reporting of studies was of sufficient quality to enable the conduct, 
reliability and validity of studies to be adequately assessed. 
The total methodological quality of individual studies was generally high; with 
total Downs and Black Checklist (1998) methodological quality percentage 
scores of 72%; 78%, 88% 88% and 91% (Table 16). The overall risk of bias 
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associated with individual studies was low, and therefore the findings were 
likely to be true.  However external validity subtotal percentage scores ranged 
from 33% to 67% and none of the included studies scored on question 12 of the 
Downs and Black Checklist (1998) (Table 16; Appendices 15 & 16). Question 
12 related to the representativeness of the sample; therefore it is possible that 
the results of individual studies, and therefore this review, may not reflect the 
entire postmenopausal BCS population and this raises questions about the 
generalisation of results. Internal validity (bias) subtotal percentage scores 
ranged from 71% to 86% (Table 16).  Overall these scores suggest that the 
results were not systematically different from the true effect.  However, none of 
the included studies scored on question 14 of the Downs and Black Checklist 
(1998) (Appendices 15 & 16).  Although this was expected due to the inherent 
difficulties of participant blinding in exercise intervention studies, and although 
unavoidable, the lack of participant blinding may have led to an overestimate of 
the treatment effect. 
 
5.12. Limitations: risk of bias at the review level  
A comprehensive search strategy was conducted, so as to minimise publication 
bias.  However comprehensive searching may not have been sufficient to 
prevent bias, as detecting and correcting potential biases is problematic (Sterne 
et al., 2011). For example Song et al. (2009) reported that publication bias 
occurred early in the research process, before the presentation of findings at 
conferences or submission of manuscripts to journals.  Although the exclusion 
of abstract only publications from this review was necessary for practical 
reasons (see p.42), it is possible that studies with non-significant findings may 
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have been published as abstracts, but may not have reached full publication.  
Therefore the potential for publication bias, and the associated overestimate of 
intervention effects, cannot be excluded from this review. 
The risk of citation bias in this review is minimal, as the reference lists of 
potentially relevant studies were not searched to locate other relevant records. 
Attempts were made to identify duplicate publications (see p.43), however it 
may be difficult or impossible to identify duplicate publications, as they may not 
cross reference each other or share common authors, and they may have 
different numbers of participants and report different outcomes (Centre for 
Reviews and Dissemination, 2009, p. 25; Higgins & Deeks, 2011; von Elm, 
Poglia, Walder, & Tramer, 2004). Substantial biases can be introduced into a 
review if studies are included more than once (Tramer, Reynolds, Moore, & 
McQuay, 1997).  Therefore the potential for duplicate publication bias cannot be 
excluded from this review. 
To minimise the effect of time-lag bias, the search for records was updated 
once during the review process, and studies published up until the End of June 
2012 were included.   However, all of the studies included in this review were 
published within the last decade, indicating that exercise and cancer 
survivorship research is a relatively new and rapidly expanding research area.  
Therefore the risk of time lag bias cannot be excluded from this review. 
Although the search strategy included non-English language records; due to the 
practical and financial issues involved in translation, non-English language 
studies were excluded from the final review (see p.40-42). The imposition of 
English language restrictions may have introduced language bias, and this is a 
limitation of this review. 
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As body composition outcomes have frequently been secondary outcomes in 
exercise and BCS research, it was not possible to determine if insignificant or 
null body composition findings were subject to selective non-reporting. 
Therefore the potential for outcome reporting bias is a limitation of this review.  
Decisions about which studies should be included in a systematic review, and 
which data should be extracted from them, require judgment and are therefore 
subjective (Centre for Reviews and Dissemination, 2009; Higgins & Deeks, 
2011).  
Compared to two reviewers, the use of a single reviewer has been associated 
with a greater number of errors, in relation to the screening of records, and the 
extraction of data (Buscemi, Hartling, Vandermeer, Tjosvold, & Klassen, 2006; 
Edwards et al., 2002).  Therefore, in order to increase objectivity and minimise 
bias it has been recommended that, whenever possible, the systematic review 
process should be conducted by at least two reviewers (Centre for Reviews and 
Dissemination, 2009; Higgins & Deeks, 2011).  
Only one reviewer was available to perform the review process for this MSc 
dissertation.  Although this single reviewer did not receive any rewards from, 
and was not affiliated to any organisations which may have had a vested 
interested in the review outcomes, the use of a single reviewer may have 
introduced subjectivity, selection bias and a greater number of errors.  
Therefore single reviewer bias is a limitation of this systematic review. 
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6.0. Conclusion 
This systematic review found that a wide variety of aerobic and resistance 
exercises could be performed safely by postmenopausal BCSs. Although the 
findings were mixed; exercise appeared to have a small favourable effect on the 
BM, BMI, WC, LBM, FM, BF%, BMC and BMD of postmenopausal BCSs.  
Exercise had a greater beneficial effect on body composition than on BM or 
BMI.  Statistically significant beneficial effects of exercise were reported for BM 
and BMI, LBM, BF%, total BMD and lumbar spine BMD in at least one included 
study.  However, whether these statistically significant benefits result in a 
clinically significant effect remains to be seen. 
The greatest beneficial effects of exercise on the BM, BMI and WC of 
postmenopausal BCSs were reported by Rahnama et al. (2010), and the 
greatest beneficial effects of exercise on the LBM, FM and BF% of 
postmenopausal BCSs were reported by Herrero et al. (2006).  The studies of  
Rahnama et al. (2010) and Herrero et al. (2006) were the only two included 
studies to prescribe a combination of aerobic and resistance exercise, and both 
studies had exercise interventions with short total durations. It is possible 
greater benefits could be achieved if a combination of aerobic and resistance 
exercises were maintained over longer total exercise durations; and further 
studies of this type of exercise are warranted. 
A beneficial effect of aerobic exercise was also noted, and walking five times a 
week, for 30min, for 12 months, resulted in reductions in BM and FM, increases 
in LBM, and the maintenance of BMD, even among postmenopausal BCSs who 
were at high risk of bone loss (Irwin, Alvarez-Reeves, et al., 2009 [12 month]). 
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The major limitation of this systematic review was the lack of generalisation of 
the findings, due to the relatively low total number of included participants.  In 
addition, the risk of single reviewer bias and publication biases remain.  There 
was also the risk that included exercise interventions did not provide an 
adequate training stimulus, due to poor exercise adherence.  Further research 
is required to develop strategies to improve exercise adherence among 
postmenopausal BCSs. 
To the author’s best knowledge this is the first systematic review to determine 
the effects of exercise on body composition in an exclusively postmenopausal 
BCS population; and this was a major strength of this review.  Other strengths 
of this systematic review were; the extensive search strategy which sought to 
minimise bias, the use of a HQTS tool to ensure that exercise provided an 
adequate training stimulus, the high methodological quality and the low risk of 
bias of included studies, and the inclusion of studies which used valid and 
reliable methods of body composition analysis (e.g. DEXA and combined BMI 
and WC).   
At present the evidence from this review is not sufficient to enable specific 
exercise prescriptions, designed to induce beneficial body composition changes 
in postmenopausal BCSs, to be made.  Further research with larger sample 
sizes, to allow for stratification of results by important confounding factors, 
would enable the effects of specific exercise prescriptions on the BM and body 
composition of postmenopausal BCSs to be elucidated.  This would be of 
benefit to health and fitness professionals and to individual postmenopausal 
BCSs. 
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Appendix 1 
Glossary  
 
Glossary definitions that, unless otherwise stated apply throughout this MSc 
dissertation. 
 
Aerobic exercise 
Exercise that is performed in order to induce improvements in cardio-
respiratory fitness, and is of such an intensity and duration that the 
predominate energy source is oxidative phosphorylation (McArdle, Katch, & 
Katch, 2001, p. 459). 
 
Body fat percentage (BF%) 
The amount of FM expressed as a percentage of the total BM (Heyward & 
Wagner, 2004, p. 5). 
 
Body mass (BM) 
A measure of the body’s mass, also commonly referred to as body weight 
(Heyward & Wagner, 2004, p. 5). 
 
Body mass index (BMI) 
A measure of BM relative to height (World Health Organisation, 2004).  
 
Bone mineral content (BMC) 
The absolute amount of BMC (Heyward & Wagner, 2004, p. 5). 
 
Breast cancer 
A cancer that arises from a monoclonal origin in breast (mammary) tissue 
(Pecorino, 2005). 
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Appendix 1: Glossary /cont. 
 
Breast cancer survivor (BCS) 
Anyone diagnosed with breast cancer, from the point of diagnosis up until the 
end of their life, including all people living with a diagnosis of breast cancer 
and  those who have recovered (J. K. Brown et al., 2003). 
 
Cancer 
A group of diseases characterised by unregulated cell growth, invasion of 
surrounding tissue and metastasis to parts of the body distinct from origin 
(King & Robins, 2006).  
 
Cancer survivor 
The American Cancer Association defines a cancer survivor as anyone who 
has been diagnosed with cancer, from the point of diagnosis up until the end 
of their life.  This includes all people living with a diagnosis of cancer and 
those who have recovered (J. K. Brown et al., 2003).  
 
Cluster randomised trial 
A type of RCT in which clusters of people, rather than single individuals, are 
randomised to different interventions. For example, whole clinics or 
geographical locations may be randomised to receive a particular 
intervention (Centre for Reviews and Dissemination, 2009, pp. 11-12). 
 
Exercise 
Exercise is a subset of PA that is planned, structured and performed in order 
to improve one of more of the components of physical fitness (Caspersen et 
al., 1985).  
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Appendix 1: Glossary /cont. 
 
Fat free mass (FFM) 
All residual lipid-free tissues and chemicals in the body that remain after FM 
has been calculated including; water, muscle, bone, connective tissue and 
internal organs (Heyward & Wagner, 2004, p. 5). 
 
Fat mass (FM) 
The absolute amount of body fat; includes all extractable lipids from all 
tissues in the body (Heyward & Wagner, 2004, p. 5).  
 
Healthy weight  
A BMI of 18.5kg/m2 to 24.9kg/m2 (World Health Organisation, 2004). 
 
Lean body mass (LBM) 
Is similar to, but distinct from, FFM; LBM is FFM plus a small amount of 
essential lipids (Heyward & Wagner, 2004, p. 5). 
 
Menopause 
Technically refers to the final menstruation, however the menopause is not 
an abrupt event, but a gradual process which leads to the ceasing of 
menstruation (Key, Verkasalo, et al., 2001). 
 
Overweight 
A BMI of 25.0kg/m2 to 29.9kg/m2 (World Health Organisation, 2004). 
 
Obese/Obesity 
A BMI of >30kg/m2  (World Health Organisation, 2004).  
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Appendix 1: Glossary /cont. 
 
Parallel group trial 
The most common type of RCT.  A parallel group trial randomises 
participants to two or more groups, treats according to assignment, and 
compares the groups with respect to outcomes of interest. Participants are 
allocated to groups using both randomisation (allocation involves the play of 
chance) and concealment (ensures that the intervention that will be allocated 
cannot be known in advance) (Centre for Reviews and Dissemination, 2009, 
pp. 11-12). 
 
Physical activity (PA) 
Any bodily movement, produced by the contraction of skeletal muscle, which 
results in substantially increased EE (Caspersen et al., 1985). 
 
Postmenopausal 
Once menstruation has ceased for twelve months a woman is 
postmenopausal (Key, Verkasalo, et al., 2001). 
 
Premenopausal 
The fertile period of a women's life, when an egg is released from the ovaries 
each month; lasts from puberty to the menopause (Key, Verkasalo, et al., 
2001). 
 
Randomised controlled trial (RCT) 
A RCT allocates participants, or groups of participants, to groups using 
randomisation and concealment (Centre for Reviews and Dissemination, 
2009, pp. 11-12). 
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Appendix 1: Glossary /cont. 
 
Randomised cross-over trial 
A type of RCT in which participants receive all the interventions and the 
sequence of interventions are randomised.  For example in a two arm cross-
over trial, one group receives intervention A before intervention B, and the 
other group receives intervention B before intervention A (Centre for Reviews 
and Dissemination, 2009, pp. 11-12). 
 
Resistance exercise 
Exercise that is performed using BM or other resistance in order to induce 
increases in muscle strength; and is of such an intensity and duration that 
muscles are required to work close to their force-generating capacity 
(McArdle et al., 2001, p. 510). 
 
Sarcoepenic BM gain / Sarcopenic Obesity 
BM gain which is largely composed of FM, and occurs without the associated 
gains, or even losses in LBM  (Heber et al., 1996). 
 
Underweight  
A BMI of <18.5kg/m2 (World Health Organisation, 2004).  
 
Waist Circumference (WC) 
The horizontal measurement of the WC, where the waist is taken to be the 
point halfway between the lowest rib and the top of the hipbone (World 
Health Organisation, 2004). 
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Appendix 2 
Summary of the types of breast cancer 
Type of breast cancer Classification Description 
Ductal carcinoma in situ (DCIS) NST/NOS 
Cancer cells are all contained inside the ducts of the breast and have not spread into the 
surrounding breast tissue. Early breast cancer with very little chance that any of the cells have 
spread to the lymph nodes or elsewhere in the body. About 4650 women are diagnosed with 
DCIS in the UK each year. 
Lobular carcinoma in situ (LCIS) NST/NOS 
Lobular cancer in situ (LCIS) is not cancer; it is a type of lobular neoplasia.  Some cells within 
the inner lining of the breast lobes have started to become abnormal.  Having LCIS increases 
the risk of getting invasive breast cancer About 500 women are diagnosed with LCIS each year 
in the UK. 
Invasive ductal breast cancer  
(ductal carcinoma) NST/NOS 
Cancer cells started in the cells that line the ducts of the breasts and have spread into the 
surrounding breast tissue.  The most common type of breast cancer and accounts for 70-80% 
of all diagnosed breast cancers. 
Invasive lobular breast cancer  
(lobular carcinoma) Special type 
Cancer cells started in the cells that line the lobules or lobes of the breast and have spread into 
the surrounding breast tissue. 10-15% of breast cancers are invasive lobular carcinoma. 
Inflammatory breast cancer Special type Cancer cells block the smallest lymph channels in the breast causing the breast tissue to become inflamed.  A rare type of breast cancer, only 1-4% of breast cancers are inflammatory. 
Paget's disease Special type 
Paget's disease is not cancer.  Begins in the nipple or the areola and is a sign that there is a 
breast cancer in the breast tissues behind the nipple.  A rare disease that is associated with 
breast cancer and is found in 1-2% of women diagnosed breast cancers.  50% of women 
diagnosed with Paget's disease have a lump behind the nipple, In 9 out of 10 cases; this is an 
invasive breast cancer. 
Medullary breast cancer 
 special type 
Medullary breast cancer tumors contain white blood cells, the cancer cells are bigger than 
other types of breast cancer cells, a clear boundary can be seen between the tumour and the 
normal tissue. It is more common in women who have inherited a faulty BRCA 1 gene.  About 
5% of breast cancers are medullary breast cancers. 
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Appendix 2: Summary of the types of breast cancer /cont. 
Type of breast cancer Classification Description 
Rare types of breast cancer 
• Medullary breast cancer 
• Mucinous (mucoid or colloid) breast 
cancer 
• Tubular breast cancer 
• Adenoid cystic carcinoma  
• Metaplastic breast cancer 
• Angiosarcoma of the breast 
• Lymphoma of the breast 
• Basal type breast cancer 
• Phyllodes / cytosarcoma phyllodes 
• Papillary breast cancer 
special type These special type breast cancers have cells with particular features under the microscope.  Each type accounts for fewer than 1% of breast cancers. 
oestrogen receptor positive  
(ER positive) special type 
ER positive breast cancers have a large number of ER on their surface.  Oestrogen attaches to 
these receptors and stimulates the tumour to grow and divide. Hormone therapy may be used 
to treat an ER positive breast cancer so as to reduce oestrogen in the body block its stimulating 
effect on the growth of the this type of breast cancer. 
progesterone receptor positive 
(PR positive)  special type 
PR positive breast cancers have a large number of PR on their surface. Progesterone attaches 
to these receptors and stimulates the tumour to grow and divide.  
Hormone therapy may be used to treat a PR positive breast cancer so as to reduce 
progesterone in the body and block its stimulating effect on the growth of this type of breast 
cancer. 
Human epidermal growth  
factor receptor 2 positive  
(HER2 positive)   
special type 
HER2 positive breast cancers have a large number of HER2 receptors on their surface. Human 
epidermal growth factor attaches to these receptors and stimulates the tumour to grow and 
divide. 
Herceptin by used in the treatment of HER2 positive breast cancer as it attaches to HER2 
receptors on the surface of breast cancer cells stopping the cancer cells from dividing and 
growing.  
Triple receptor negative NST/NOS Triple receptor negative  breast cancers do not have ER, PR or HER2 receptors on their surface. 
NST = no special type; NOS = not otherwise specified;  Adapted from Cancer Research UK (2011d)
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Appendix 3 
 
The Tumour, Node, Metastasis (TNM) system of breast cancer staging 
 
TNM Stage Description 
T stages  T stands for tumour and it denotes of the size of the tumour 
TX  The tumour size cannot be assessed 
T1 
• T1mic 
• T1a 
• T1b 
• T1c 
The tumour is no more than 2 cm across 
• Microscopically the cancer cells spread less than 0.1cm into surrounding tissue (microinvasion) 
• The tumour is more than 0.1 cm but not more than 0.5 cm 
• The tumour is more than 0.5 cm but not more than 1 cm 
• The tumour is more than 1 cm but not more than 2 cm 
T2 The tumour is more than 2 cm, but no more than 5 cm across 
T3 The tumour is bigger than 5 cm across 
T4 
• T4a 
• T4b 
• T4c 
• T4d 
 
• The tumour has spread into the chest wall  
• The tumour has spread into the skin 
• The tumour is fixed to both the skin and the chest wall 
• Inflammatory carcinoma, the overlying skin is red, swollen and painful to the touch 
N stages N stands for node and it denotes whether the cancer has spread to nearby lymph nodes and which nodes are affected 
NX The lymph nodes cannot be assessed (e.g. if they were previously removed) 
NO No cancer cells found in any nearby nodes 
N1 Cancer cells are in the upper levels of lymph nodes in the armpit but the nodes are not stuck to surrounding tissues 
N2 
• N2a 
• N2b 
 
• There are cancer cells in the lymph nodes in the armpit, which are stuck to each other and to other structures 
• There are cancer cells in the lymph nodes behind the breast bone (the internal mammary nodes, which have either been seen on a scan or felt by the doctor. 
There is no evidence of cancer in lymph nodes in the armpit 
N3 
• N3a 
• N3b 
• N3c 
 
• There are cancer cells in lymph nodes below the collarbone 
• There are cancer cells in lymph nodes in the armpit and under the breast bone 
• There are cancer cells in lymph nodes above the collarbone 
M stages M stands for metastasis and denotes whether the cancer has spread to other parts of the body 
M0 There is no sign of cancer spread 
M1 There are signs the cancer has spread to another part of the body, apart from the breast and lymph nodes under the arm 
 
Adapted from Cancer Research UK (2011c) 
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The number system of breast cancer staging  
 
Number Stage Description 
 
Stage 1 breast cancer 
 
The tumour is no more than 2 cm across (T1) 
There are no cancer cells in the lymph nodes in the armpit 
The cancer has not spread anywhere else 
Stage 2A breast cancer The tumour is less than 2 cm, the lymph nodes under the arm contain cancer but are not stuck to each other and the cancer has not 
spread  
or 
The tumour is less than 5 cm, there are no cancer cells in the lymph nodes in the armpit and the cancer has not spread  
or 
Although no tumour is seen in the breast, the lymph nodes under the arm contain cancer cells but are not stuck together or to other 
structures, and there is no sign of spread to other parts of the body 
Stage 2B breast cancer The tumour is less than 5 cm and the lymph nodes under the arm contain cancer cells but are not stuck to each other, and the cancer 
has not spread  
or 
The tumour is bigger than 5 cm across, there are no cancer cells in the lymph nodes in the armpit and the cancer has not spread 
Stage 3A breast cancer Although no tumour is seen in the breast, the lymph nodes under the arm contain cancer cells and are stuck together or to other 
structures, but there is no sign of cancer spread 
or 
The tumour is 5 cm or less, the lymph nodes in the armpit contain cancer cells and are stuck to each other, but the cancer has not 
spread elsewhere 
or 
The tumour is more than 5 cm, the lymph nodes in the armpit contain cancer cells and may be stuck together, but there is no further 
spread 
Stage 3B breast cancer The tumour is fixed to the skin or chest wall, the lymph nodes may or may not contain cancer cells, but there is no further spread 
Stage 3C breast cancer The tumour can be any size and has spread to lymph nodes in the armpit and under the breast bone, or to nodes above or below the 
collarbone, but there is no further spread 
Stage 4 breast cancer The tumour can be any size 
The lymph nodes may or may not contain cancer cells 
The cancer has spread (metastasised) to other parts of the body such as the lungs, liver or bones 
Adapted from Cancer Research UK (2011b) 
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Appendix 5 
Summary of treatments for breast cancer and associated side effects 
 
Type of  treatment Aim / Description Side Effects 
Breast surgery  To remove cancerous tissue from the breast 
 
• Scaring 
• Emotional symptoms; anxiety, depression and low 
confidence associated with coping with a changed 
appearance  
• Pain or stiffness in the breast shoulder or arm 
• Peripheral neuropathy - numbness and tingling in the 
upper arm 
• Cording - an uncomfortable sensation that feels like a 
tight cord running from the armpit to the back of the hand 
- possibly due to hardened lymph vessels 
• Changes in arm/shoulder movement and strength  
• Lymphoedema - a swelling of the arm on the affected 
side. Women who have all or a large number of lymph 
nodes in the armpit removed are more at risk 
 
Breast conserving surgery (wide local 
excision or lumpectomy) 
To remove the breast tumour and a small amount of breast tissue around the tumour, 
called a margin. 
Mastectomy To remove the whole of the breast tissue and possibly the lymph nodes (axillary 
nodes) in the armpit on the same side. 
Indicated for very large tumours, or where the tumour is relatively large in comparison 
to the size of the breast, or where the cancer is in more than one area of the breast. 
 
Axillary surgery 
 
To determine if lymph nodes in the axilla have been affected, and if so to remove 
them. 
Sentinel node biopsy 
 
To remove the first nodes that any cancer cells in the breast would reach if they were 
to spread and perform microscopic examination to check look for the presence of 
cancer cells. 
Axillary node sampling 
 
To remove at least four lymph nodes from the lower level of the axilla and perform 
microscopic examination to check look for the presence of cancer cells. 
Axillary node clearance 
 
To remove all the lymph nodes in the armpit to reduce the risk of cancer spreading 
beyond the breast. 
Indicated when cancer cells are found in the lymph nodes following sentinel node 
biopsy or axillary sampling. Avoids the need for radiotherapy to the axilla. 
Reconstructive breast  surgery 
 
To improve the appearance of the breast either at the same time as mastectomy 
(immediate reconstruction) or at some time after mastectomy (delayed reconstruction) 
Radiotherapy 
 
To reduce the likelihood of cancer returning by using radiation to destroy any cancer 
cells remaining after surgery. 
May be given to the whole breast, just the tumour area of the breast, the chest wall, 
the axilla. 
• Reddening and soreness of the skin 
• Changes in appearance and texture of the breast 
• Telangiectasia – damage to the small blood vessels in 
the skin 
• Fatigue 
• Nausea  
• Lymphoedema - a swelling of the arm on the affected 
side following radiotherapy to the armpit 
• Inflammation of the lung (radiation pneumonitis) causing 
breathlessness, dry cough or chest pain 
• Peripheral neuropathy 
• Rarely causes heart problems  
• Rarely causes a hardening and thickening (fibrosis) of 
the lung tissue  
• Rarely weakens the ribs in the treated area, making them 
more likely to fracture  
External radiotherapy 
 
Delivered from outside the body, through the skin, using high energy x-rays. 
Internal radiotherapy  
(interstitial brachytherapy) 
 
Delivered via radioactive wires or needles inserted into the body for a short time  
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Type of  treatment Aim / Description Side Effects 
 
Chemotherapy 
 
Cyclophosphamide 
Epirubicin 
Fluorouracil (5FU) 
Methotrexate 
Mitomycin 
Mitozantrone 
Doxorubicin 
Docetaxel (Taxotere) 
Gemcitabine (Gemzar) 
 
Chemotherapy Regimes 
 
CMF (cyclophosphamide,methotrexate, 
fluorouracil) 
FEC (epirubicin, cyclophosphamide, 
fluorouracil) 
FEC-T FEC followed by taxotere) 
E-CMF (epirubicin, followed by CMF) 
AC (doxorubicin (adriamycin), 
cyclophosphamide) 
EC (epirubicin, cyclophosphamide) 
MMM  (methotrexate, mitozantrone, 
mitomycin) 
MM (methotrexate, mitozantrone) 
 
 
To reduce the likelihood of cancer returning by using anticancer (cytotoxic) drugs to 
destroy any cancer cells that may have spread beyond the breast and axillary lymph 
nodes, or when surgery to remove the cancer is not possible/appropriate. 
 
Chemotherapy is a systemic treatment; it affects healthy cells as well as cancer cells.  
 
The dose of chemotherapy is calculated to have the most impact on cancer cells and 
the least effect on healthy cells. 
Chemotherapy is given as a course of treatment, lasting several weeks or months. The 
course is divided into smaller units called cycles.  
 
Combination (multi-agent) chemotherapy is generally more effective than being treated 
with just one drug. 
  
The way in which chemotherapy is given (the particular drugs and when they are 
administered) is called a regimen. 
 
Taxanes are a type of chemotherapy drug that are often used in the treatment of 
breast cancer. The most commonly used is docetaxel (Taxotere).  
 
Anthracyclines are a type of chemotherapy drug that are commonly included in 
chemotherapy regimes.  The most commonly used are doxorubicin (Adriamycin) and 
epirubicin. 
 
• Neutropenia (reduced number of white blood cells) 
leading to increased risk of infection. 
• Reduction in platelets, reduced blood clotting ability 
causing bruising or bleeding e.g. nosebleeds, bleeding 
gums, rashes on the skin.  
• Anaemia (reduced number of red blood cells), reduced 
oxygen carrying capacity leading to fatigue and 
breathlessness.   
• Nausea or Vomiting  
• Fatigue 
• Dizziness  
• Pain in joints or muscles  
• Flu-like symptoms  
• Hair loss 
• Taste changes  
• Sore mouth, dry mouth and ulcers 
• Conjunctiva (inflammation of the lining of the eyelids) 
Skin rashes, dry itchy skin 
• Areas of skin previously treated with radiotherapy may 
become red and sore (radiation recall) 
• Extravasation (Leakage into the tissue around the vein) 
causing tissue damage, redness and swelling  
• Palmar plantar (soreness and redness of the palms of the 
hands and soles of the feet  
• Sun sensitivity  
• Nail changes 
• Fluid retention causing gain weight, swelling of ankles 
and legs  
• Peripheral neuropathy  
• Bladder irritation 
• Diarrhoea 
• Changes in liver function 
• Changes in heart function 
• Allergic reaction  
• Increased risk of thrombosis 
• Anxiety, stress and depression 
• Cognitive problems  
• Temporary loss of menstruation 
• Menopause, Menopausal symptoms 
• Weight gain 
• Menopause related osteoporosis 
• Harm to a developing foetus 
 
Neoadjuvant chemotherapy 
 
Given before surgery to shrink a breast tumour to allow breast conserving surgery to 
be carried out rather than a mastectomy, or to make an operation feasible. 
 
 
 
Adjuvant chemotherapy 
 
 
Given after surgery to reduce the likelihood of cancer returning by destroying any 
cancer cells that may have spread beyond the breast and axillary lymph nodes 
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Appendix 5: Summary of treatments for breast cancer and associated side effects /cont. 
Adapted from Breakthrough Breast Cancer (2009) and Macmillan Cancer Support (2012) 
 
Type of  treatment Aim / Description Side Effects 
 
Hormone Therapy  
 
Aromatase inhibitors (AIs) 
anastrozole (Arimidex®) 
letrozole (Femara®) 
exemestane (Aromasin®) 
 
Anti oestrogens (AOs) 
tamoxifen 
 
Pituitary down-regulators 
goserelin (Zoladex®) 
 
 
Surgery 
ovarian ablation 
 
 
To shrink an oestrogen receptor positive (ER positive) tumor before surgery  
To reduce the chance of an ER positive breast cancer coming back 
The type of hormone therapy used depends on; menopausal status, the risk of the 
cancer returning and the likely side effects of the drugs used. 
 
Postmenopausal women may be treated with an aromatase inhibitor e.g. anastrozole 
(Arimidex®), letrozole (Femara®) or exemestane (Aromasin®) and or the anti 
oestrogen drug tamoxifen. 
 
Premenopausal women may be treated with tamoxifen, a pituitary down-regulator drug 
to suppress oestrogen production from the ovaries e.g.  goserelin (Zoladex®), surgery 
to remove the ovaries (ovarian ablation) or a combination of tamoxifen with either 
Zoladex or ovarian ablation 
 
In premenopausal women, some hormonal treatments bring on a temporary or 
permanent menopause 
 
Treatment with hormonal therapy may continue for several years. 
 
• Temporary loss of menstruation 
• Menopause 
• Menopausal symptoms (hot flushes and sweats, joint 
pain, lowered sex drive) 
• Osteoporosis 
• Tumour Flare – a temporary increase in tumour size and 
symptoms during the first few days of Zoladex treatment 
• Skin rashes 
• Joint pain 
• Fatigue 
• Weight gain 
• Vaginal bleeding 
• Harm to developing foetus 
• Slightly increased risk of endometrial cancer 
• Increased risk of thrombosis 
 
Biological Therapy 
 
Monoclonal antibody treatment 
trastuzumab (Herceptin®) 
 
To reduce the risk of human epidermal growth factor receptor 2 (HER2) positive breast 
cancers returning 
 
HER2 positive breast cancers have a large number of HER2 receptors on their surface 
 
Herceptin works by attaching to HER2 receptors on the surface of breast cancer cells 
stopping the cancer cells from dividing and growing. It also works by encouraging the 
body’s own immune cells to destroy the cancer cells.  It is sometimes referred to as a 
targeted therapy as it targets the cancer cells 
 
Treatment with Herceptin usually lasts for 1 year 
 
• Flu-like symptoms (headache, high temperature (fever) 
and chills, feeling sick or being sick) 
• Allergic reaction (a skin rash, itching, wheezing, difficulty 
breathing, and breathlessness) 
• Diarrhoea  
• Headaches  
• Nausea 
• May cause heart problems and it is therefore not  
recommended for women with history of heart disease or 
high blood pressure 
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Appendix 6 
Completed PRISMA checklist 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  ii; 1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, 
and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
ii-iii 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  1-2; 3-26 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
26-28 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
na 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
39-43 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in 
the search and date last searched.  
35-39; XV-XXI 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  XV-XXI 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis).  
39-43 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators.  
49-50; XXX-XXXIII 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
I-V 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study 
or outcome level), and how this information is to be used in any data synthesis.  
43-49 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  49; XXV-XXVIII 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
na 
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Appendix 6: Completed PRISMA checklist /cont. 
Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
40-42 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
na 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
51 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
53-69 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  70-71; XXIX 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
53-69 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  na 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  71 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  na 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
72-90 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
91-93 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  72-92; 94-95 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic 
review.  
na 
Na = not applicable The PRISMA checklist taken from Moher et al. (2009)
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Appendix 7 
Full details of electronic bibliographical database searches  
Database Fields Searched Search 
Limits 
Applied 
No. of 
records 
30/04/2012 
No. of 
records 
04/07/2012 
MEDLINE 
 all 
(Breast AND Cancer OR “Breast Neoplasm” OR “Breast Carcinoma” OR “Breast Tumor” OR “Breast 
Tumour” OR “Mammary Cancer” OR “Mammary Neoplasm”  OR “Mammary Carcinoma” OR “Mammary 
Tumor” OR” Mammary Tumour”  OR” Ductal Carcinoma in Situ” OR “Lobular Carcinoma in Situ” OR 
“Invasive Ductal Breast Cancer” OR “Ductal Carcinoma” OR “Invasive Lobular Breast Cancer” OR “Lobular 
Carcinoma” OR “Invasive Breast Cancer” OR “Breast Cancer Patient” OR “Breast Cancer Survivors” OR 
“Breast Cancer Survivorship” OR “Breast Cancer Recovery” OR “Breast Cancer Treatment”) AND (Exercise 
OR “Exercise Intervention” OR “Exercise Program” OR “Exercise Programme” OR “Exercise Training” OR 
“Exercise Therapy” OR “Rehabilitation” OR “Physical Activity” OR “Physical Activity Intervention” OR 
“Physical Therapy” OR “Physical Fitness”  OR “Aerobic Exercise” OR “Aerobic Training” OR “Aerobics” OR 
“Resistance Exercise” OR “Resistance Training” OR “Weight Training” OR “Weight Lifting” OR “Muscle 
Strengthening” OR “Walking” OR “Running” OR “Jogging” OR “Cycling” OR “Rowing” OR “Racing”) 
Publication 
Date from 
1989/01/01 
Humans 
Female, 
All Adult: 19+ 
yrs 
1914 
 
51 
 
The 
Cochrane 
Library 
all 
(Breast AND Cancer OR “Breast Neoplasm” OR “Breast Carcinoma” OR “Breast Tumor” OR “Breast 
Tumour” OR “Mammary Cancer” OR “Mammary Neoplasm”  OR “Mammary Carcinoma” OR “Mammary 
Tumor” OR” Mammary Tumour”  OR” Ductal Carcinoma in Situ” OR “Lobular Carcinoma in Situ” OR 
“Invasive Ductal Breast Cancer” OR “Ductal Carcinoma” OR “Invasive Lobular Breast Cancer” OR “Lobular 
Carcinoma” OR “Invasive Breast Cancer” OR “Breast Cancer Patient” OR “Breast Cancer Survivors” OR 
“Breast Cancer Survivorship” OR “Breast Cancer Recovery” OR “Breast Cancer Treatment”) AND (Exercise 
OR “Exercise Intervention” OR “Exercise Program” OR “Exercise Programme” OR “Exercise Training” OR 
“Exercise Therapy” OR “Rehabilitation” OR “Physical Activity” OR “Physical Activity Intervention” OR 
“Physical Therapy” OR “Physical Fitness”  OR “Aerobic Exercise” OR “Aerobic Training” OR “Aerobics” OR 
“Resistance Exercise” OR “Resistance Training” OR “Weight Training” OR “Weight Lifting” OR “Muscle 
Strengthening” OR “Walking” OR “Running” OR “Jogging” OR “Cycling” OR “Rowing” OR “Racing”) 
 
Publication 
Date from: 
1989/01/01 
 
914 12 
CINHAL all 
(Breast AND Cancer OR “Breast Neoplasm” OR “Breast Carcinoma” OR “Breast Tumor” OR “Breast 
Tumour” OR “Mammary Cancer” OR “Mammary Neoplasm”  OR “Mammary Carcinoma” OR “Mammary 
Tumor” OR” Mammary Tumour”  OR” Ductal Carcinoma in Situ” OR “Lobular Carcinoma in Situ” OR 
“Invasive Ductal Breast Cancer” OR “Ductal Carcinoma” OR “Invasive Lobular Breast Cancer” OR “Lobular 
Carcinoma” OR “Invasive Breast Cancer” OR “Breast Cancer Patient” OR “Breast Cancer Survivors” OR 
“Breast Cancer Survivorship” OR “Breast Cancer Recovery” OR “Breast Cancer Treatment”) AND (Exercise 
OR “Exercise Intervention” OR “Exercise Program” OR “Exercise Programme” OR “Exercise Training” OR 
“Exercise Therapy” OR “Rehabilitation” OR “Physical Activity” OR “Physical Activity Intervention” OR 
“Physical Therapy” OR “Physical Fitness”  OR “Aerobic Exercise” OR “Aerobic Training” OR “Aerobics” OR 
“Resistance Exercise” OR “Resistance Training” OR “Weight Training” OR “Weight Lifting” OR “Muscle 
Strengthening” OR “Walking” OR “Running” OR “Jogging” OR “Cycling” OR “Rowing” OR “Racing”) 
 
Publication 
Date from: 
1989/01/01 
Female 
All Adult 
 
730 
 
34 
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Appendix 7 
Full details of electronic bibliographical database searches /cont.  
Database Fields Searched Search 
Limits 
Applied 
No. of 
records 
30/04/2012 
No. of 
records 
04/07/2012 
PROQUEST all 
 
 
 
all(“Breast Cancer” OR “Breast Neoplasm” OR “Breast Carcinoma” OR “Breast Tumor” OR “Breast Tumour” 
OR “Mammary Cancer” OR “Mammary Neoplasm” OR “Mammary Carcinoma” OR “Mammary Tumor” OR” 
Mammary Tumour” OR” Ductal Carcinoma in Situ” OR “Lobular Carcinoma in Situ” OR “Invasive Ductal 
Breast Cancer” OR “Ductal Carcinoma” OR “Invasive Lobular Breast Cancer” OR “Lobular Carcinoma” OR 
“Invasive Breast Cancer” OR “Breast Cancer Patient” OR “Breast Cancer Survivors” OR “Breast Cancer 
Survivorship” OR “Breast Cancer Recovery” OR “Breast Cancer Treatment”) AND all((“Exercise”  OR 
“Exercise Intervention” OR “Exercise Program” OR “Exercise Programme” OR “Exercise Training” OR 
“Exercise Therapy” OR “Rehabilitation” OR “Physical Activity” OR “Physical Activity Intervention” OR 
“Physical Therapy” OR “Physical Fitness”  OR “Aerobic Exercise” OR “Aerobic Training” OR “Aerobics” OR 
“Resistance Exercise” OR “Resistance Training” OR “Weight Training” OR “Weight Lifting” OR “Muscle 
Strengthening” OR “Walking” OR “Running” OR “Jogging” OR “Cycling” OR “Rowing” OR “Racing”)) 
Publication 
Date from:1 
989/01/01 
 
Female 
 
Adult (19-44 
yrs; 65+ yrs; 
80+ yrs; 
Middle aged 
45-64 years) 
640 12 
Sports 
Discus all 
 
(Breast AND Cancer OR “Breast Neoplasm” OR “Breast Carcinoma” OR “Breast Tumor” OR “Breast 
Tumour” OR “Mammary Cancer” OR “Mammary Neoplasm”  OR “Mammary Carcinoma” OR “Mammary 
Tumor” OR” Mammary Tumour”  OR” Ductal Carcinoma in Situ” OR “Lobular Carcinoma in Situ” OR 
“Invasive Ductal Breast Cancer” OR “Ductal Carcinoma” OR “Invasive Lobular Breast Cancer” OR “Lobular 
Carcinoma” OR “Invasive Breast Cancer” OR “Breast Cancer Patient” OR “Breast Cancer Survivors” OR 
“Breast Cancer Survivorship” OR “Breast Cancer Recovery” OR “Breast Cancer Treatment”) AND (Exercise 
OR “Exercise Intervention” OR “Exercise Program” OR “Exercise Programme” OR “Exercise Training” OR 
“Exercise Therapy” OR “Rehabilitation” OR “Physical Activity” OR “Physical Activity Intervention” OR 
“Physical Therapy” OR “Physical Fitness”  OR “Aerobic Exercise” OR “Aerobic Training” OR “Aerobics” OR 
“Resistance Exercise” OR “Resistance Training” OR “Weight Training” OR “Weight Lifting” OR “Muscle 
Strengthening” OR “Walking” OR “Running” OR “Jogging” OR “Cycling” OR “Rowing” OR “Racing”) 
 
Publication 
Date from: 
1989/01/01 
 
761 8 
PEDRO (ab/title) 
 
See Appendix 8 Publication 
Date from 
1989/01/01 
1196 43 
Total  6155 160 
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Appendix 8 
Full details of electronic bibliographical PEDro searches 
 
Search 
Number 
Search terms entered into the PEDRO 
database  
Searches limits; ab/title and Publication 
Date  
from 1989/01/01 to 2012/06/30 
No. of 
Records 
01/05/2012 
 
No. of 
Records 
04/07/2012
 
1 Breast AND Cancer AND Exercise 212 6 
2 Breast AND Cancer AND Training 77 3 
3 Breast AND Cancer AND Rehabilitation 41 2 
4 Breast AND Cancer AND Physical Activity 74 3 
5 Breast AND Cancer AND Fitness 30 0 
6 Breast AND Cancer AND Aerobic 81 2 
7 Breast AND Cancer AND Resistance 47 1 
8 Breast AND Cancer AND Weight Training 21 1 
9 Breast AND Cancer AND Weight Lifting 2 0 
10 Breast AND Cancer AND Muscle Strength 19 0 
11 Breast AND Cancer AND Walking 32 1 
12 Breast AND Cancer AND Running 2 1 
13 Breast AND Cancer AND Jogging 1 0 
14 Breast AND Cancer AND Cycling 3 0 
15 Breast AND Cancer AND Rowing 0 0 
16 Breast AND Cancer AND Racing 0 0 
17 Breast Neoplasm  2 0 
18 Breast Carcinoma 6 0 
19 Breast Tumor 14 0 
20 Breast Tumour 3 0 
21 Mammary Cancer 3 0 
22 Mammary Neoplasm 0 0 
23 Mammary Carcinoma 1 0 
24 Mammary Tumor 0 0 
25 Mammary Tumour 0 0 
26 Ductal Carcinoma in Situ 0 0 
27 Lobular Carcinoma in Situ 0 0 
28 Invasive Ductal Breast Cancer 0 0 
29 Ductal Carcinoma 0 0 
30 Invasive Lobular Breast Cancer 0 0 
31 Lobular Carcinoma 0 0 
32 Invasive Breast Cancer 2 0 
33 Breast Cancer Patient 192 7 
34 Breast Cancer Survivors 98 6 
35 Breast Cancer Survivorship 7 0 
36 Breast Cancer Recovery 16 1 
37 Breast Cancer Treatment 210 10 
TOTAL  1196 43 
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Appendix 9 
Full details of the ZETOC database searches 
 
Search 
Number 
Search terms entered into the ZETOC 
database  
Searches limits; Conference only; 
Publication Year from 1989 – 2012 
No. of 
Records 
04/05/2012 
 
No. of 
Records 
04/07/2012
 
1 Breast AND Cancer AND Exercise 15 0 
2 Breast AND Cancer AND Training 25 0 
3 Breast AND Cancer AND Rehabilitation 11 0 
4 Breast AND Cancer AND Physical Activity 15 
0 
5 Breast AND Cancer AND Fitness 1 0 
6 Breast AND Cancer AND Aerobic 4 0 
7 Breast AND Cancer AND Resistance 1 0 
8 Breast AND Cancer AND Weight Training 0 0 
9 Breast AND Cancer AND Weight Lifting 0 0 
10 Breast AND Cancer AND Muscle Strength 1 
0 
11 Breast AND Cancer AND Walking 0 0 
12 Breast AND Cancer AND Running 0 0 
13 Breast AND Cancer AND Jogging 0 0 
14 Breast AND Cancer AND Cycling 0 0 
15 Breast AND Cancer AND Rowing 0 0 
16 Breast AND Cancer AND Racing 0 0 
17 “Breast Neoplasm” 3 0 
18 “Breast Carcinoma” 390 0 
19 “Breast Tumor” 193 0 
20 “Breast Tumour” 23 0 
21 “Mammary Cancer” 58 0 
22 “Mammary Neoplasm” 0 0 
23 “Mammary Carcinoma” 94 0 
24 “Mammary Tumor” 74 0 
25 “Mammary Tumour” 11 0 
26 “Ductal Carcinoma in Situ” 143 0 
27 “Lobular Carcinoma in Situ” 10 0 
28 “Invasive Ductal Breast Cancer” 2 0 
29 “Ductal Carcinoma” 176 0 
30 “Invasive Lobular Breast Cancer” 1 0 
31 “Lobular Carcinoma” 33 0 
32 “Invasive Breast Cancer” 93 0 
33 “Breast Cancer Survivor*” 73 0 
34 “Breast Cancer Recovery” 8 0 
35 “Breast Cancer Treatment” 147 0 
TOTAL  1605 0 
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Appendix 10 
Full details of the SCIRUS database searches 
 
Search 
Number 
Search terms entered into the SCIRUS 
database  
Searches limits; Title; preferred web 
sources; any information type; publication 
year from 1989 – 2012 
No. of 
Records 
04/05/2012 
 
No. of 
Records 
04/07/2012 
 
1 Breast AND Cancer AND Exercise 38 1 
2 Breast AND Cancer AND Training 17 0 
3 Breast AND Cancer AND Rehabilitation 13 2 
4 Breast AND Cancer AND Physical Activity 31 3 
5 Breast AND Cancer AND Fitness 3 0 
6 Breast AND Cancer AND Aerobic 2 0 
7 Breast AND Cancer AND Resistance Training 4 0 
8 Breast AND Cancer AND Weight Training 0 0 
9 Breast AND Cancer AND Weight Lifting 1 0 
10 Breast AND Cancer AND Muscle Strength 0 0 
11 Breast AND Cancer AND Walking 2 0 
12 Breast AND Cancer AND Running 1 0 
13 Breast AND Cancer AND Jogging 0 0 
14 Breast AND Cancer AND Cycling 0 0 
15 Breast AND Cancer AND Rowing 0 0 
16 Breast AND Cancer AND Racing 0 0 
17 Breast Cancer Survivor* 109 1 
18 Breast Cancer Recovery 15 0 
TOTAL 
 
204 25 
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Appendix 11 
Full details of the handsearched book chapters 
Book Chapters searched No. of Records 
Courneya, K. S., & Friedenreich, C. M. (Eds.). (2011). 
Physical Activity and Cancer: Recent Results in 
Cancer Research (Vol. 186). Heidelberg: Springer. 
Schmitz, K. (2011). Physical activity and breast cancer survivorship. In K. Courneya & C. Friedenreich 
(Eds.), Physical Activity and Cancer: Recent Results in Cancer Research (Vol. 186). (pp. 189-209). 
Heidelberg: Springer. 
72 
Irwin, M. L. (Ed.). (2012). ACSM's Guide to Exercise 
and Cancer Survivorship. Champaign; IL: Human 
Kinetics. 
Campbell, K. (2012). Benefits of physical activity after a cancer diagnosis. In M. Irwin (Ed.), ACSM's Guide 
to Exercise and Cancer Survivorship (pp. 49-71). Champaign; IL: Human Kinetics. 
 
42 
McTiernan, A. (Ed.). (2006). Cancer Prevention and 
Management through Exercise and Weight Control. 
Boca Raton; FL: CRC Press. 
 
Harvie, M., & Howell, A. (2006). Incorporating weight control into management of patients with early breast 
cancer in the UK. In A. McTiernan (Ed.), Cancer Prevention and Management through Exercise and 
Weight Control (pp. 535-560). Boca Raton; FL: CRC Press. 
 
7 
Saxton, J., & Daley, A. (Eds.). (2010). Exercise and 
Cancer Survivorship: Impact on Health Outcomes and 
Quality of Life. New York: Springer. 
 
 
 
Markes, M. (2010). Exercise as an intervention during breast cancer treatment. In J. Saxton & A. Daley 
(Eds.), Exercise and Cancer Survivorship: Impact on Health Outcomes and Quality of Life (pp. 37-52). 
New York: Springer. 
Crank, H., & Daley, A. (2010). Exercise after treatment for breast cancer: Effects on quality of life. In J. 
Saxton & A. Daley (Eds.), Exercise and Cancer Survivorship: Impact on Health Outcomes and Quality of 
Life (pp. 53-72). New York: Springer. 
Harvie, M. N. (2010). The importance of controlling body weight after a diagnosis of breast cancer: the role 
of diet and exercise in breast cancer patient management. In J. Saxton & A. Daley (Eds.), Exercise and 
Cancer Survivorship: Impact on Health Outcomes and Quality of Life (pp. 73-96). New York: Springer. 
Irwin, M. (2010). The biological mechanisms by which physical activity might have a impact on 
outcome/prognosis after a breast cancer diagnosis. In J. Saxton & A. Daley (Eds.), Exercise and Cancer 
Survivorship: Impact on Health Outcomes and Quality of Life (pp. 97-112). New York: Springer. 
Stevinson, C. (2010). Ready to change lifestyle? The feasibility of exercise interventions in cancer 
patients. In J. Saxton & A. Daley (Eds.), Exercise and Cancer Survivorship: Impact on Health Outcomes 
and Quality of Life (pp. 211-222). New York: Springer.  
24 
 
43 
 
14 
 
11 
 
31 
Total  237 
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Appendix 12 
Full details of the specific online journals that were handsearched 
Journal Access Method Details of Issues Searched Dates search performed 
No.  
Records 
Retrieved 
 
British Journal of Sports 
Medicine 
 
University of Chester Subscription via 
http://bjsm.bmj.com 
 
 
Full Text - Vol.23(1) Mar 1989 to Vol. 46(8) Jun 2012 
 
 
12/05/2012 
05/07/2012 4 
Journal of Cancer Survivorship University of Chester Subscription via 
ProQuest 
Full Text  - Vol. 1(2) Jun 2007 to Vol.5 (1) Mar 2011 
Title and Abs - Vol.5(2) Jun 2011 to Vol. 6(2) Jun 2012 
 
08/05/2012 
05/07/2012 16  
Journal of Clinical Oncology Freely available content via 
http://jco.ascopubs.org 
 
Title and Abs  - Vol.7(1) Jan 1989 to Vol.30(18) Jun 2012 
 
08-10/05/2012 
05/07/2012 67  
Cancer, Epidemiology, 
Biomarkers &  Prevention 
Freely available content via 
http://cebp.aacrjournals.org 
 
Full text - Vol.1(1) Nov1991 to Vol.20(5) May 2011 
Title and Abs - Vol.20( 6) Jun 2011 to Vol.21(6) Jun 2012 
 
14/05/2012 
05/07/2012 34 
International Journal of Sports 
Medicine 
Freely available content via 
https://www.thieme-connect.de 
 
Title and Abs- Vol.10(1) Feb 1989 to Vol.33(6) Jun 2012 
 
15/05/2012 
05/07/2012 7 
Medicine & Science in Sport & 
Exercise 
University of Chester Subscription via 
OvidSP 
Title and Abs- Vol. 21(1) Feb 1989 to Vol.27(12) Dec 1995 
Full Text- Vol.28(10) Jan 1996 to Vol.44(6) Jun 2012 
 
06-12/05/2012 
05/07/2012 192  
Oncology Nursing Forum University of Chester Subscription via  
EBSCO host 
Title - Vol.16(1) Jan 1989 to Vol.26(10) Dec 1999 
Full text-  Vol.27(1) Jan 2000 to Vol.38(3) May 2011  
Title- Vol.38(4) Jul 2011 to Vol.39(4) June 2012 
 
05-09/05/2012 
05/07/2012 
 
77 
 
Psycho-Oncology University of Chester Subscription via 
EBSCO host 
 
 
Full text - Vol. 1(1) Apr 1992 to Vol. 20(4) Apr 2011  
Title and Abs - Vol. 20(5) May 2011 to Vol. 21(6) Jun 2012 
 
13-14/05/2012 
05/07/2012 74 
Total 471 
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Appendix 13 
Assessment of high quality training studies (HQTS) for studies meeting all other inclusion criteria 
  Studies considered for inclusion into the review 
 Herrero et al., 
(2006) 
Irwin et al. 
(2009) Rahnama et al., (2009) 
Saarto et al. 
(2012) 
Winters-Stone et 
al., (2011) 
Aerobic exercise criteria      
• Frequency 
at least three days per week 1 1 0 1 n/a 
• Intensity 
55-85% of max heart rate 
40-75% of max heart rate reserve 
40-75% of max oxygen uptake reserve 
1 1 1 
 
 
1 
n/a 
• Time 
20-60min (min 2 x 10 min contin bouts) 1 1 1 
 
1 n/a 
• Duration of Exercise Intervention 
at least six weeks 1 1 1 
 
1 n/a 
Aerobic exercise criteria score 4 4 3 4 n/a 
Resistance exercise criteria      
• Frequency 
At least two days per week 1 n/a 1 n/a 1 
• Intensity 
to near fatigue 
at least 60% of one repetition max 
1 n/a 1 n/a 1 
• Time  
at least 1 set of 10-15 repetitions 1 n/a 1 n/a 1 
• Duration of Exercise Intervention 
at least six weeks 1 n/a 1 n/a 1 
Resistance exercise criteria score 4 n/a 4 n/a 4 
Overall score / Pass or Fail 4 (Pass) 4 (Pass) 3.75  (Pass) 4 (Pass) 4 (Pass) 
 
Each exercise intervention was assessed against the four criteria outline in the table above. If the exercise intervention met the criteria 1 point was awarded, 
if the exercise intervention did not meet the criteria 0 points were awarded.  The scores were summed to give an overall HQTS score.  For combined aerobic 
and resistance exercise interventions the training stimulus was assessed for both aerobic and resistance exercise, the scores were summed and the 
corresponding mean was used to determine HQTS. Studies were classified as HQTS if they scored at three out of four.
XXIII 
 
Appendix 14 
The 25 item CONSORT statement checklist of items that should be reported 
for a RCT 
Item No. Checklist Item 
1a • Identification as a randomised trial in the title 
1b • Structured summary of trial design, methods, results, and conclusions  
2a • Scientific background and explanation of rationale 
2b • Specific objectives or hypotheses 
3a • Description of trial design (such as parallel, factorial) including allocation ratio 
3b • Important changes to methods after trial commencement (such as eligibility 
criteria), with reasons
4a • Eligibility criteria for participants 
4b • Settings and locations where the data were collected 
5 • The interventions for each group with sufficient details to allow replication, including 
how and when they were actually administered
6a • Completely defined pre-specified primary and secondary outcome measures, 
including how and when they were assessed
6b • Any changes to trial outcomes after the trial commenced, with reasons 
7a • How sample size was determined 
7b • When applicable, explanation of any interim analyses and stopping guidelines 
8a • Method used to generate the random allocation sequence 
8b • Type of randomisation; details of any restriction (such as blocking and block size) 
9 • Mechanism used to implement the random allocation sequence (such as 
sequentially numbered containers), describing any steps taken to conceal the 
sequence until interventions were assigned 
 
10 • Who generated the random allocation sequence, who enrolled participants, and 
who assigned participants to interventions 
 
11a • If done, who was blinded after assignment to interventions (for example, 
participants, care providers, those assessing outcomes) and how 
11b • If relevant, description of the similarity of interventions 
12a • Statistical methods used to compare groups for primary and secondary outcomes 
12b • Methods for additional analyses, such as subgroup analyses and adjusted 
analyses 
 
13a • For each group, the numbers of participants who were randomly assigned, 
received intended treatment, and were analysed for the primary outcome 
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Appendix 14: The 25 item CONSORT statement checklist of items that should be 
reported for RCT /cont. 
 
13b • For each group, losses and exclusions after randomisation, together with reasons 
14a • Dates defining the periods of recruitment and follow-up 
14b • Why the trial ended or was stopped 
15 • A table showing baseline demographic and clinical characteristics for each group 
16 • For each group, number of participants (denominator) included in each analysis 
and whether the analysis was by original assigned groups 
 
17a • For each primary and secondary outcome, results for each group, and the 
estimated effect size and its precision (such as 95% confidence interval) 
 
17b • For binary outcomes, presentation of both absolute and relative effect sizes is 
recommended 
 
18 • Results of any other analyses performed, including subgroup analyses and 
adjusted analyses, distinguishing pre-specified from exploratory 
 
19 • All important harms or unintended effects in each group 
20 • Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, 
multiplicity of analyses 
 
21 • Generalisability (external validity, applicability) of the trial findings 
22 • Interpretation consistent with results, balancing benefits and harms, and 
considering other relevant evidence 
 
23 • Registration number and name of trial registry 
24 • Where the full trial protocol can be accessed, if available 
25 • Sources of funding and other support (such as supply of drugs), role of funders 
Schulz et al. (2010) 
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Appendix 15 
 
The Downs and Black Checklist of (1998) methodological quality 
 
Question 
No. Reporting Scoring
1 Is the hypothesis/aim/objective of the study clearly described? Yes = 1 No = 0 
2 
Are the main outcomes to be measured clearly described in the 
Introduction or Methods section? 
If the main outcomes are first mentioned in the Results section, the question should 
be answered no. 
Yes = 1 
No = 0 
 
3 
Are the characteristics of the patients included in the study clearly 
described? 
In cohort studies and trials, inclusion and/or exclusion criteria should be given. In 
case-control studies, a case-definition and the source for controls should be given. 
Yes = 1 
No = 0 
 
4 
Are the interventions of interest clearly described? 
Treatments and placebo (where relevant) that are to be compared should be clearly 
described. 
Yes = 1 
No = 0 
 
5 
Are the distributions of principal confounders in each group of 
subjects to be compared clearly described? 
A list of principal confounders is provided. 
Yes = 2 
Partially = 
1 
No =0 
6 
Are the main findings of the study clearly described? 
Simple outcome data (including denominators and numerators) should be reported 
for all major findings so that the reader can check the major analyses and 
conclusions. (This question does not cover statistical tests which are considered 
below). 
Yes = 1 
No = 0 
 
7 
Does the study provide estimates of the random variability in the data 
for the main outcomes? 
In non normally distributed data the inter-quartile range of results should be reported. 
In normally distributed data the standard error, standard deviation or confidence 
intervals should be reported. If the distribution of the data is not described, it must be 
assumed that the estimates used were appropriate and the question should be 
answered yes. 
Yes = 1 
No = 0 
 
8 
Have all important adverse events that may be a consequence of the 
intervention been reported?  
This should be answered yes if the study demonstrates that there was a 
comprehensive attempt to measure adverse events. (A list of possible adverse events 
is provided). 
Yes = 1 
No = 0 
 
9 
Have the characteristics of patients lost to follow-up been described? 
This should be answered yes where there were no losses to follow-up or where 
losses to follow-up were so small that findings would be unaffected by their inclusion. 
This should be answered no where a study does not report the number of patients 
lost to follow-up. 
Yes = 1 
No = 0 
 
10 
Have actual probability values been reported (e.g. 0.035 rather than 
<0.05) for the main outcomes except where the probability value is less 
than 0.001? 
Yes = 1 
No = 0 
 
Reporting Subtotal  (11) 
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Appendix 15: The Downs and Black Checklist of (1998) methodological quality 
 /cont. 
 
Question 
No. External validity Scoring
11 
Were the subjects asked to participate in the study representative of 
the entire population from which they were recruited? 
The study must identify the source population for patients and describe how the 
patients were selected. Patients would be representative if they comprised the entire 
source population, an unselected sample of consecutive patients, or a random 
sample. Random sampling is only feasible where a list of all members of the relevant 
population exists. Where a study does not report the proportion of the source 
population from which the patients are derived, the question should be answered as 
unable to determine. 
Yes = 1 
No = 0 
UTD = 0 
12 
Were those subjects who were prepared to participate representative of 
the entire population from which they were recruited? 
The proportion of those asked who agreed should be stated. Validation that the 
sample was representative would include demonstrating that the distribution of the 
main confounding factors was the same in the study sample and the source 
population. 
Yes = 1 
No = 0 
UTD = 0 
13 
Were the staff, places, and facilities where the patients were treated, 
representative of the treatment the majority of patients receive? 
For the question to be answered yes the study should demonstrate that the 
intervention was representative of that in use in the source population. The question 
should be answered no if, for example, the intervention was undertaken in a specialist 
centre unrepresentative of the hospitals most of the source population would attend. 
Yes = 1 
No = 0 
UTD = 0 
External validity Subtotal  (3) 
 Internal validity – bias  
14 
Was an attempt made to blind study subjects to the intervention they 
have received? 
For studies where the patients would have no way of knowing which intervention they 
received, this should be answered yes. 
Yes = 1 
No = 0 
UTD = 0 
15 Was an attempt made to blind those measuring the main outcomes of the intervention? 
Yes = 1 
No = 0 
UTD = 0 
16 
If any of the results of the study were based on “data dredging”, was 
this made clear? 
Any analyses that had not been planned at the outset of the study should be clearly 
indicated. If no retrospective unplanned subgroup analyses were reported, then 
answer yes. 
Yes = 1 
No = 0 
UTD = 0 
17 
In trials and cohort studies, do the analyses adjust for different lengths 
of follow-up of patients, or in case-control studies, is the time period 
between the intervention and outcome the same for cases and 
controls? 
Where follow-up was the same for all study patients the answer should yes. If 
different lengths of follow-up were adjusted for by, for example, survival analysis the 
answer should be yes. Studies where differences in follow-up are ignored should be 
answered no. 
Yes = 1 
No = 0 
UTD = 0 
18 Were the statistical tests used to assess the main outcomes 
appropriate? 
The statistical techniques used must be appropriate to the data. For example 
nonparametric methods should be used for small sample sizes. Where little statistical 
analysis has been undertaken but where 
there is no evidence of bias, the question should be answered yes. If the distribution 
of the data (normal or not) is not described it must be assumed that the estimates 
used were appropriate and the question should be answered yes. 
Yes = 1 
No = 0 
UTD = 0 
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Appendix 15: The Downs and Black Checklist of (1998) methodological quality 
/cont. 
 
Question 
No. Internal validity – bias \ cont. Scoring
19 
Was compliance with the intervention/s reliable? 
Where there was non compliance with the allocated treatment or where there was 
contamination of one group, the question should be answered no. For studies where 
the effect of any misclassification was likely to bias any association to the null, the 
question should be answered yes. 
Yes = 1 
No = 0 
UTD = 0 
20 
Were the main outcome measures used accurate (valid and reliable)?  
For studies where the outcome measures are clearly described, the question should 
be answered yes. For studies which refer to other work or that demonstrates the 
outcome measures are accurate, the question should be answered as yes. 
Yes = 1 
No = 0 
UTD = 0 
Internal validity – bias subtotal  (6) 
 Internal validity - confounding (selection bias)   
21 
Were the patients in different intervention groups (trials and cohort 
studies) or were the cases and controls (case-control studies) recruited 
from the same population? 
For example, patients for all comparison groups should be selected from the same 
hospital. The question should be answered unable to determine for cohort and case-
control studies where there is no information concerning the source of patients 
included in the study. 
Yes = 1 
No = 0 
UTD = 0 
22 
Were study subjects in different intervention groups (trials and cohort 
studies) or were the cases and controls (case-control studies) recruited 
over the same period of time? 
For a study which does not specify the time period over which patients were 
recruited, the question should be answered as unable to determine. 
Yes = 1 
No = 0 
UTD = 0 
23 
Were study subjects randomised to intervention groups? 
Studies which state that subjects were randomised should be answered yes except 
where method of randomisation would not ensure random allocation. For example 
alternate allocation would score no because it is predictable. 
Yes = 1 
No = 0 
UTD = 0 
24 
Was the randomised intervention assignment concealed from both 
patients and health care staff until recruitment was complete and 
irrevocable? 
All non-randomised studies should be answered no. If assignment was 
concealed from patients but not from staff, it should be answered no. 
Yes = 1 
No = 0 
UTD = 0 
25 
Was there adequate adjustment for confounding in the analyses from 
which the main findings were drawn? 
This question should be answered no for trials if: the main conclusions of the study 
were based on analyses of treatment rather than intention to treat; the distribution of 
known confounders in the different treatment groups was not described; or the 
distribution of known confounders differed between the treatment groups but was not 
taken into account in the analyses. In nonrandomised studies if the effect of the main 
confounders was not investigated or confounding was demonstrated but no 
adjustment was made in the final analyses the question should be answered as no. 
Yes = 1 
No = 0 
UTD = 0 
26 
Were losses of patients to follow-up taken into account? 
If the numbers of patients lost to follow-up are not reported, the question should be 
answered as unable to determine. If the proportion lost to follow up was too small to 
affect the main findings, the question should be answered yes. 
Yes = 1 
No = 0 
UTD = 0 
Internal validity - confounding subtotal  (6) 
   
XXVIII 
 
Appendix 15: The Downs and Black Checklist of (1998) methodological quality 
/cont. 
 
Question 
No. Power Scoring 
27 
Did the study have sufficient power to detect a clinically important 
effect where the probability value for a difference being due to chance 
is less than 5%? 
Sample sizes have been calculated to detect a difference of x% and y%. 
<n1 =0 
n1-n2 = 1 
n3-n4 = 2 
n5-n6 =3 
n7-n8 =4 
n9+ = 5 
Power subtotal  (5) 
Total  (32) 
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Appendix 16 
Downs and Black Checklist (1998) quality scoring for studies included in 
the review 
 
  
 Studies included in the review 
Item number 
Downs and Black 
(1998) checklist of 
methodological 
quality 
Maximum 
score for 
each item 
Herrero et 
al., 
(2006) 
Irwin et 
al. (2009) 
Rahnama 
et al., 
(2009) 
Sarrto et 
al.,  
(2012) 
Winters-
Stone et al., 
(2011) 
1 1 1 1 1 1 1 
2 1 1 1 1 1 1 
3 1 1 1 1 1 1 
4 1 1 1 1 1 1 
5 2 1 2 0 1 2 
6 1 1 1 1 1 1 
7 1 1 1 1 1 1 
8 1 1 0 0 0 1 
9 1 0 1 1 1 1 
10 1 0 1 1 1 1 
Reporting 
Subtotal 11 8 10 8 10 11 
11 1 0 1 1 1 1 
12 1 0 0 0 0 0 
13 1 1 1 1 1 0 
External 
Validity 
Subtotal 
3 1 2 2 2 1 
14 1 0 0 0 0 0 
15 1 1 1 1 1 1 
16 1 1 1 1 1 1 
17 1 1 1 1 1 1 
18 1 1 1 1 1 1 
19 1 1 1 0 1 0 
20 1 1 1 1 1 1 
Internal 
Validity (Bias) 
Subtotal 
7 6 6 5 6 5 
21 1 1 1 1 1 1 
22 1 1 1 1 1 1 
23 1 1 1 1 1 1 
24 1 1 1 0 0 1 
25 1 1 1 0 1 1 
26 1 0 1 0 1 1 
Internal 
Validity 
(Selection 
Bias) Subtotal 
6 5 6 3 5 6 
27 5 5 5 5 5 5 
Power 
Subtotal 5 5 5 5 5 5 
Total Score 32 25 29 23 28 28 
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Appendix 17 
Blank data extraction tool 
 
Date of data extraction  
Study Details 
Author  
Year  
Title  
Journal  
Located via  
Accessed from  
Confirm RCT 
Yes No 
  
Downs and Black Score 
(32)  
Study characteristics  
Country:  
Sample size: 
Controls Exercisers 
  
Attrition rate: 
Controls Exercisers 
  
Population  
Confirm postmenopausal 
status 
Yes No 
  
Mean Age (yrs) 
Controls Exercisers 
  
Body Mass (kg) Controls Exercisers   
BMI (kg/m2) 
Controls Exercisers 
  
Stage of cancer  
Type of treatment  
Type of hormone therapy   
Comparators  
Description  
Intervention   
Confirm HQTS 
Yes No 
  
Timing in relation to 
treatment 
During Treatment After Treatment 
  
Type  
Aerobic Resistance Mixed 
   
Specific type  
Frequency (times/wk)  
Time  
Intensity  
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Appendix 17 
Blank data extraction tool /cont. 
 
Intervention 
Duration (wks)  
Setting   
Supervision  
Supervised Unsupervised 
  
Adherence rate  
Adverse effects  
Outcomes  
Body composition 
assessment method 
 
BM (kg) Pre Post Change Difference P Value 
Controls     
  
Exercisers    
BMI (kg/m2) Pre Post Change Difference P Value 
Controls       
Exercisers    
FM (kg) Pre Post Change Difference P Value 
Controls     
  
Exercisers    
LBM (kg) Pre Post Change Difference P Value 
Controls     
  
Exercisers    
BF% (%) Pre Post Change Difference P Value 
Controls     
  
Exercisers    
WC (cm) Pre Post Change Difference P Value 
Controls       
Exercisers    
BMD (g/cm2) Pre Post Change Difference P Value 
Controls       
Exercisers    
BMC (g/cm) Pre Post Change Difference P Value 
Controls       
Exercisers    
Notes   
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Appendix 18 
Example of completed data extraction tool; Herrero et al., (2006) 
 
Date of data extraction 18/06/2012 
Study details 
Author Herrero, F., San Juan, A. F., Fleck, S. J., Balmer, J., Perez, M., Canete, S. et al. 
Year 2006 
Title Combined aerobic and resistance training in breast cancer survivors: a randomized, controlled pilot trial 
Journal International Journal of Sports Medicine 
Located via MEDLINE, CINHAL, Sports Discus, PEDRO, HS Journal, HS Book 
Accessed from University of Chester Subscription in Print 
Confirm RCT 
Yes No 
3  
Downs and Black Score (32) 25 
Study characteristics 
Country: Spain 
Sample size (n) 
Controls Exercisers 
10 10 
Attrition rate (%) 
Controls Exercisers 
20 20 
Population 
Confirm postmenopausal 
status 
Yes No 
3  
Mean Age (yrs) 
Controls Exercisers 
51 ± 10 50 ± 5 
Body Mass (kg) 
Controls Exercisers 
67.7 ± 8.9 66.7 ± 10.5 
BMI (kg/m2) Controls Exercisers 24 ± 3.2 25.1 ± 3.5 
Stage of cancer I-II 
Type of treatment SUR + CT + RT 
Type of hormone therapy  na 
Comparators 
Description Followed usual sedentary lifestyle (< a total of 30-60min walking, 3x/wk) and no strenuous exercise 
Intervention  
Confirm HQTS 
Yes No 
3  
Timing in relation to 
treatment 
During Treatment After Treatment 
 3 
Type  
Aerobic Resistance Mixed 
  3 
Specific type Cycle egometer and weight lifting 
Frequency (times/wk) 3 combined cycling and weight lifting sessions 
Time Cycling = 20-30 min; weight lifting = 11 ex; 1-2 sets; 8-15 reps 
Intensity Cycling = 70-80% max HR; weight lifting = 8-15 rep max 
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Appendix 18 
Example of completed data extraction tool; Herrero et al. (2006) /cont. 
 
Duration (wks) 8 
Setting  Recreational Fitness – community fitness club 
Supervision  
Supervised Unsupervised 
3  
Adherence rate 91% ± 7% 
Adverse effects No major adverse effects and no major health problems  
Outcomes 
Body composition 
assessment method 
FM and BF% = 3 site skinfold measurement (triceps, abdominal 
and suprailiac)* 
Muscle mass = from anthropometrical data** 
BM (kg) Pre Post Change Difference P Value 
Controls  67.7 67.3 -0.4 
-0.7 p=>0.05 
Exercisers 66.7 65.6 -1.1 
BMI (kg/m2) Pre Post Change Difference P Value 
Controls       
Exercisers    
FM (kg) Pre Post Change Difference P Value 
Controls  15.3 15.3 0 
-1.7 p=>0.05 
Exercisers 16.4 14.7 1.7 
LBM (kg) (muscle mass) Pre Post Change Difference P Value 
Controls  28.6 28.3 -0.3 
1.0 p=<0.05 
Exercisers 27.3 28 0.7 
BF% (%) Pre Post Change Difference P Value 
Controls  22 22 0 
-2.0 p=<0.05 
Exercisers 24 22 2 
WC (cm) Pre Post Change Difference P Value 
Controls       
Exercisers    
BMD (g/cm2) Pre Post Change Difference  
Controls       
Exercisers    
BMC (g/cm) Pre Post Change Difference  
Controls       
Exercisers    
Notes  
 
* using the equations of Jackson and Pollock (1985) 
** using the equations of Lee et al. (2000) 
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Appendix 19 
Search location and retrieval of method of studies included in the final review 
 
 
Studies included in the review 
Search Location Herrero et al., (2006) 
Irwin et al. 
(2009) 
Rahnama et al., 
(2009) 
Saarto et al., 
(2012) 
Winters-Stone et 
al., (2011) 
MEDLINE 
 3 3 x x 3 
CINHAL 
 3 3 3 3 x 
Cochrane Lib 
 x 3 x x 3 
ProQuest 
 x x x x x 
Sports Discus 
 3 3 x x x 
Pedro 
 3 3 3 3 3 
ZETOC 
 x x x x x 
SCIRUS 
 x x x x x 
Hand searched Journals 
 3 x x x x 
Hand searched Book Chapters 
 3 3 x x x 
Retrieval method 
University of 
Chester 
Subscription in Print 
Freely Available Via 
Pubmed Central 
Freely Available Via 
Pubmed Central 
British Library via 
University of Chester 
Inter-Library Loans 
Freely Available Via 
Pubmed Central 
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Appendix 20 
List of non-English language studies meeting initial eligibility criteria but 
subsequently excluded from final review on the basis of language 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chae, Y. R., & Choe, M. A. (2001). Effects of exercise on cardiopulmonary 
functions and shoulder joint functioning in breast cancer patients undergoing 
radiation therapy after breast cancer [Korean]. Taehan Kanho Hakhoe Chi 
[Journal of Korean Academy of Nursing], 31(3), 454-466.  
 
Cho, O. H. (2004). Effects of a comprehensive rehabilitation program for 
mastectomy patients [Korean]. Taehan Kanho Hakhoe Chi [Journal of 
Korean Academy of Nursing], 34(5), 809-819.  
 
Damm, F. (1996). Sports and breast cancer - exercise, games and sports in 
breast cancer /  Sport and breast cancer: motor activity, leisure time physical 
activity and playing sports after breast cancer. (Sport und Brustkrebs - 
Bewegung, Spiel und Sport bei Brustkrebs / Sport et cancer du sein: activite 
motrice, activite physique de loisir et pratique d'un sport apres un cancer du 
sein) [German]. Deutsche Zeitschrift fuer Sportmedizin [International Journal 
of Sports Medicine - German], 47(7/8), 440-441.  
 
de Rezende, L. F., Beletti, P. O., Franco, R. L., Moraes, S. S., & Gurgel, M. 
S. (2006). Random clinical comparative trial between free and directed 
exercise in post-operative complications of breast cancer. (Exercicios livres 
versus direcionados nas complicacoes pos-operatorias de cancer de mama)  
[Portuguese]. Revista da Associacao Medica Brasileira [Journal of the 
Medical Association], 52(1), 37-42.  doi:10.1590/S010442302006000100020 
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Appendix 20: List of non-English language studies meeting initial 
eligibility criteria but subsequently excluded from final review on the 
basis of language /cont. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dincer, U., Kaya, E., Cakar, E., Kiralp, M. Z., & Dursun, H. (2007). 
Effectiveness of comprehensive rehabilitation program and home-based 
exercise in middle and long term mastectomy related disability (Mastektomiye 
bagl orta ve gec donem dizabilite tedavisinde kapsaml rehabilitasyon ve ev 
egzersiz programlar n etkinligi ) [Turkish]. Turkiye Fiziksel Tip ve 
Rehabilitasyon Dergisi [Turkish Journal of Physical Medicine and 
Rehabilitation] 53(4), 138-143.  
 
He, X., Li, H., & Xiang, M. (2006). The effects of comprehensive intervention 
on quality of life of breast cancer patients [Chinese]. Chinese Journal of 
Rehabilitation Medicine, (11), 1012-1015.  
 
Latikka, P., Pukkala, E., & Vihko, V. (1997). Exercise and breast cancer 
(Liikunta ja rintasyöpä) [Finnish]. Duodecim, 113(4), 317-322.  
Malicka, I., Pawłowska, K., & Woźniewski, M. (2008). The effect of physical 
exercises on effort tolerance and work of the trunk muscles in women after 
breast cancer treatment (Wplyw ćwiczeń fizycznych na zdolność wysiJkową 
pracę mięśni tulowia kobiet po leczeniu raka piersi) [Polish]. Fizjoterapia 
[Physiotherapy], 16(3), 48-56.  
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Appendix 20: List of non-English language studies meeting initial 
eligibility criteria but subsequently excluded from final review on the 
basis of language /cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Malicka, I., Pawłowska, K., & Woźniewski, M. (2008). The effect of physical 
exercises on effort tolerance and work of the trunk muscles in women after 
breast cancer treatment (Wplyw ćwiczeń fizycznych na zdolność wysiJkową i 
pracę mięśni tulowia kobiet po leczeniu raka piersi) [Polish]. Fizjoterapia 
[Physiotherapy], 16(3), 48-56.  
 
Moros, M. T., Ruidiaz, M., Caballero, A., Serrano, E., Martnez, V., & Tres, A. 
(2010). Effects of an exercise training program on the quality of life of women 
with breast cancer on chemotherapy (Efectos de un programa de 
entrenamiento físico sobre la calidad de vida de las mujeres con cáncer de 
mama en la quimioterapi)  [Spanish]. Revista Medica de Chile [Chile Medical 
Journal], 138(6), 715-722.  
Park, H. S., Cho, G. Y., & Park, K. Y. (2006). The effects of a rehabilitation 
program on physical health, physiological indicator and quality of life in breast 
cancer mastectomy patients [Korean]. Taehan Kanho Hakhoe Chi [Journal of 
Korean Academy of Nursing], 36(2), 310-320.  
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Appendix 20: List of non-English language studies meeting initial 
eligibility criteria but subsequently excluded from final review on the 
basis of language /cont. 
 
Rezende, L. F., Beletti, P. O., Franco, R. L., Moraes, S. S., & Gurgel, M. S. 
(2006). Random clinical comparative trial between free and directed exercise 
in post-operative complications of breast cancer (Ensaio clínico aleatório 
comparativo entre o exercício livre e dirigido em complicações pós-
operatórias de significância de mama) [Portuguese]. Revista da Associação 
Médica Brasileira [Journal of the Brazilian Medical Association], (1), 37-42. 
 
So, H. S., Kim, I. S., Yoon, J. H., & Park, O. J. (2006). Effects of aerobic 
exercise using a flex-band on physical functions & body image in women 
undergoing radiation therapy after a mastectomy [Korean]. Taehan Kanho 
Hakhoe Chi [Journal of Korean Academy of Nursing], 36(7), 1111-1122.  
 
The Norwegian Knowledge Centre for the Health, S. (2009). Rehabilitation of 
breast cancer patients (Rehabilitering av brystkreftpasienter) [Norwegian]. 
Oslo: Den norske kunnskapssenter for helsetjenesten [Oslo: The Norwegian 
Knowledge Centre for the Health Services]. 
 
Wang, B. G., Yuan, X. Y., Wang, Q. T., Luan, X. D., Wang, C. P., Jia, A. L., . 
. . Sun, Y. (2005). Functional rehabilitation gymnastics for the edema of 
upper limbs and the activity of shoulder joint in postoperative patients with 
breast cancer [Chinese]. Zhongguo Linchuang Kangfu [Chinese Journal of 
Clinical Rehabilitation], 9(30), 16-19.  
 
